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Abstract 
 
Introduction: Elevated cyclic strain often leads to vein graft rejection, which is correlated to 
increased thrombomodulin release. Limited in vitro and in vivo studies document this release 
but the pathway involved is still unclear. In this study, we examine thrombomodulin (TM) 
expression and release after elevated cyclic strain. We also look at how physiological levels of 
shear stress impact TM expression and release. We assess the effect that various inflammatory 
mediators (i.e., ox-LDL) have on this cyclic strain-induced TM response. We investigate a 
range of signalling components (i.e., eNOS) in the cyclic strain-mediated TM expression and 
release pathway. We finish on the possible microvesicle (MV) involvement in cyclic strain-
induced TM release.   
Hypothesis: Thrombomodulin (TM), an integral membrane protein involved in coagulation, 
is regulated by cyclic strain and plays a pivotal role in endothelial dysfunction.  
Results: (i) Following cyclic strain (7.5%), TM expression was down-regulated in both 
protein and RNA but up-regulated release into the cell culture media. (ii) Physiological levels 
of shear stress (10 dynes/cm2) acted as a more potent stimulus for TM release (when 
compared to cyclic strain) and also increased TM mRNA expression. (iii) Both TNF-α and 
ox-LDL had a down-regulatory effect on TM expression in static HAECs whereas glucose has 
no effect. In addition, TNF-α or ox-LDL caused an additive increase in cyclic strain-induced 
TM release. By contrast, glucose was found to “attenuate” cyclic strain-mediated TM release. 
(iv) We established that inhibition of PTK and p38 MAPK increased cyclic strain-mediated 
TM expression (i.e., reverses the typical strain-dependent response), thus play are role in the 
cyclic strain-decrease TM pathway. (v) We showed that MMPs and ROS decreased cyclic 
strain-induced TM release (i.e., reverses the typical strain-dependent response), thus they are 
involved in the cyclic strain-induced TM release pathway. (vi) We also observed that 
inhibition of integrin ανβ3 causes an additional increase in TM release in both static and 
strained HAECs, suggesting that integrins serve as a cellular “brake” for the release of TM.  
(vii) We noted that cyclic strain-induced TM release has some microvesicle involvement with 
one third of the release on exosomes.    
Conclusions: Cyclic strain regulates the release and expression of thrombomodulin in 
endothelial cells. TM release is regulated by MMPs and ROS, although a portion of release is 
due to microvesicle involvement.   
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Chapter 1: 
Introduction 
 
 
 
 
 
 
 2 
  This chapter is an overview of the cardiovascular system, specifically concentrating on 
endothelial cells where we discuss their function in maintaining vascular haemostasis, and the 
after effects if they become dysfunctional. Endothelial cells have the capacity to sense and 
respond to alterations in shear and pulsatile blood flow, which is crucial for both arterial wall 
remodeling and vasoregulation. However, the deviation of endothelial cells from normal 
physiology plays a central role in the initiation of vascular disease. Mechanosensors, present 
in the vascular wall, have the ability to convert physical forces into biochemical signals. This 
mechanoregulation influences signalling pathways which are imperative for endothelial 
homeostasis as these pathways control the expression and function of many bioactive 
molecules including an endothelial cell membrane protein, thrombomodulin (TM), the main 
focus of this project.  
 
1.1 The vascular tree 
 
The rhythmic beat of the human heart keeps blood flowing through the body. It is one 
of the most important organs in the entire body as it is responsible for the circulation of blood 
for the cellular exchange of nutrients and gases in place of wastes and metabolic by-products 
(Fig 1.1). It is basically a pump the size of your fist, composed of muscle which beats 
approximately 72 times per minute of our lives keeping the blood flowing through it’s 60,000 
miles of blood vessels. The endothelium lines the entire vasculature, having first point of 
contact with the blood and thus, is crucial to the homeostasis of the circulatory system.   
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Figure 1.1: The entire human vascular tree (http://nl.dreamstime.com/royalty-vrije-stock-
foto-s-vasculair-systeem-image6730718).  
 
 The circulatory system is composed of both the microvasculature and the 
macrovasculature. The microvasculature is that portion of the vasculature made up of small 
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vessels including capillaries, arterioles and venules. The macrovasculature is that portion of 
the circulatory system containing large vessels such as arteries and veins (diameters measuring 
greater then 100 microns) (Fig 1.2).  
 
 
 
Figure 1.2: The aortic vasculature with a cross-section exposing the multi-layer structure 
(http://www.hearts.vcu.edu/clinical/aortic/index2.html).  
 
Every one of these blood vessels in the vasculature, apart from capillaries, shares a 
common three layered structure (Fig 1.3). These three layers are known as: (i) tunica 
adventitia; (ii) tunica media and (iii) tunica intima;   
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(i) Tunica adventitia 
The tunica adventitia is the outermost layer of the blood vessel that links it to the adjacent 
tissue and is made up of elastic and collagen fibres. It also provides larger blood vessels with 
nerves and collateral vessels to aid blood supply for the surrounding tissues (Corselli et al., 
2012).  
(ii) Tunica media 
The tunica media or middle coat is composed principally of smooth muscle cells and large 
amounts of elastic fibres organised in roughly spiral layers. It is responsible for controlling 
vascular tone and function via smooth muscle cell circular orientation around the vessel, 
perpendicular to the direction of blood flow (Liddy et al., 2011).  
 
 
 
Figure 1.3: Three-layer structure of the blood vessel (McKinley and O'Loughlin, 2006).  
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(i) Tunica intima 
The tunica intima is the innermost layer consisting of a simple, squamous layer surrounded by 
a connective tissue basement membrane with elastic fibres. The whole lumenal surface itself, 
collectively known as the endothelium, is essentially a monolayer of endothelial cells. The 
endothelium is in direct contact with the blood as it flows through the lumen of the blood 
vessel and acts as the main focus of this thesis (Vanhoutte et al., 2007). 
 
1.1.1 The vascular endothelium 
 
  The vascular endothelium, a continuous monolayer of flattened endothelial cells that 
forms the lumenal lining of all blood vessels, separates circulating blood from the vascular 
wall and surrounding tissues and is vital to the health and homeostatic responsiveness of the 
mammalian circulatory system (for review see Michiels, 2003). Within the adult human, it 
comprises up to 6x1013 cells (or an exchange surface area of up to 350 m2), and it exhibits 
considerable phenotypic heterogeneity across different vascular beds (Pries et al., 2000; Aird, 
2007).  
  As the central theme of several thousand publications over the last few decades, the 
highly dynamic nature and functional complexity of the endothelium have been well 
documented. Under normal physiological conditions, its prime function is to regulate 
systemic blood flow and tissue perfusion rates through adjustment of vessel diameter and 
vascular tone (closely interacting with the underlying smooth muscle cells and pericytes), 
with a vasodilatory phenotype predominating in healthy vessels (Furchgott and Zawadzki, 
1980). The endothelium also acts as a highly selective barrier controlling the paracellular 
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(and transcellular) exchange of fluids, ions and diverse nutrient macromolecules between 
circulating blood and tissues (Balda and Matter, 1998), a homeostatic function maintained by 
the coordinated interaction of inter-endothelial adherens and tight junction complexes 
(Taddei et al., 2008).  
  In a further dimension to this barrier role, endothelial cells (which normally maintain 
an anti-inflammatory phenotype) can mediate the recruitment and extravasation of pro-
inflammatory leukocytes to areas of tissue damage and infection via the lumenal 
expression/release of cell adhesion molecules (selectins, integrins, platelet & endothelial cell 
adhesion molecule type-1/PECAM-1) and cytokines (tumor necrosis factor-α/TNF-α, IL-1, 
IL-6, monocyte chemoattractant protein type-1/MCP-1) (Cotran and Pober 1990; Ebnet and 
Vestweber, 1999). Finally, the lumenal surface of the healthy endothelium expresses a wide 
variety of molecules that serve to down-regulate platelet and thrombotic mechanisms, thereby 
creating an anti-coagulant surface for blood flow and preventing thrombus formation (Cines 
et al., 1998; Pearson, 1999). One of these anti-coagulant molecular targets, thrombomodulin 
(TM), represents the focus of this thesis and will be discussed in more detail below. 
 
1.1.2 Endothelial dysfunction 
 
  As discussed already, the vascular endothelium is essential for maintaining the 
homeostatic integrity of the blood vessel via its ability to monitor and respond to 
acute/chronic changes in circulatory parameters. During pathological conditions, endothelial 
cells become “activated” due to a combination of one or more stimuli such as altered flow 
hemodynamics, injury, hypoxia, or the action of blood-borne constituents, eliciting 
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dysfunction of the endothelium with consequences for vessel remodeling. Importantly, 
endothelial dysfunction only transpires if the activation of endothelial cells is long-term. So 
short-term activation of endothelial cells that may occur (e.g., during exercise) does not 
irreparably impair endothelial function. Impairment in endothelial function not only changes 
endothelial cell morphology and phenotype, but also causes initiation and progression of 
cardiovascular diseases (Aird, 2007; Cines et al., 1998; Deanfield et al., 2007).  
  Due to the architecture of the vasculature tree, certain areas, such as arterial 
bifurcations or curvatures are characterised by attenuated levels and patterns of shear stress 
and cyclic strain (e.g., atherosclerosis). Moreover, certain vascular conditions lead to locally 
and globally elevated levels of shear and strain (e.g., hypertension, vein graft bypass) with 
supraphysiological shear near lesions. These haemodynamic alterations can lead to 
endothelial dysfunction and enhance the progression of vascular dysfunction and diseases 
(Han et al., 2010; Matsushita et al., 2001). These forces will be discussed in more detail 
below in Section 1.1.4.  
    
1.1.3 Cardiovascular disease 
 
It is evident that when endothelial cells become dysregulated it can lead to cardiovascular 
disease (CVD). CVD is an umbrella term for any disease of the heart or circulatory system 
encompassing atherosclerosis, congenital heart disease, heart failure, coronary artery disease, 
peripheral vascular disease, cerebrovascular disease and hypertension. Atherosclerosis is a 
common inflammatory response affecting arterial blood vessels. It is characterised by plaque 
deposition and thrombosis at atheroprone sites. Endothelial dysfunction is a hallmark of 
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atherosclerosis and can initiate an inflammatory cascade and endothelial barrier break down. 
This can lead to plaque build-up which if ruptured can cause a myocardial infarction (Tineli et 
al., 2007; Hahn and Schwartz, 2009). 
According to the World Health Organisation (WHO) 17.3 million people died from 
CVDs in 2008 with over 80% of these deaths occurring in low and middle-income countries. 
They predict that by 2030 more than 23 million people will die annually from CVDs. In 
Ireland, about 10,000 people die each year from CVD which is 36% of all deaths (Irish Heart 
Foundation).  
Dysfunction of the circulatory system stems from both fixed and modifiable risk 
factors. The fixed risk factors that may make you susceptible to CVD include;  
! Gender (higher risk in males) 
! Age (risk increases as you age)  
! Genetic make-up (family history of heart disease)  
! Race (African Americans, American Indians and Mexican Americans are more 
likely to develop heart disease then Caucasians).  
However, there are numerous lifestyle changes you could make to lower the risk of 
developing CVD. These modifiable risk factors include; 
! Smoking 
! Stress 
! Physical inactivity 
! Hypertension (high blood pressure) 
! Obesity (more then 20% over one’s ideal body weight) 
! Unhealthy diet and high cholesterol 
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! Type-2 diabetes 
The risk factors listed above play a crucial role in initiating or worsening the outcomes 
of CVD shown by an array of studies on stroke, atherosclerosis or the mediation of blood 
flow-associated hemodynamic forces and blood pressure.  
 
1.1.4 Hemodynamic forces 
 
 
 
Figure 1.4: Mechanical forces; frictional shear stress (τ) and cyclic circumferential stretch (ρ), 
acting on the vessel wall (Hahn and Schwartz, 2009). 
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 The endothelium exists within a pressurized fluid environment in direct contact with 
the circulating blood and blood-borne components. Blood flow-associated hemodynamic 
forces, namely pulsatile shear stress and cyclic circumferential strain (Fig 1.4), exert a 
profound influence on endothelial cell fates, gene expression and signaling (Ando and 
Yamamoto, 2011). The latter force, cyclic strain, will be the chief focus of this PhD thesis.  
 Shear stress is the tangential frictional force exerted by blood flow as it drags across 
the endothelial surface, causing cells to ‘flatten’ and morphologically align in the direction of 
flow (Ando and Yamamoto, 2011; Ensley et al., 2012; Malek and Izumo, 1994). Laminar 
shear stress (LSS), as used throughout this thesis, is well known to have an “atheroprotective” 
effect on endothelial cells (Traub and Berk, 1998).  
 Shear stress is expressed in units of force / unit area  (Newton per meter squared 
[N/m2] or Pascal [Pa] or dynes/cm2; 1 N/m2 = 1 Pa = 10 dynes/cm2). In normal physiological 
circumstances, the endothelium is subjected to shear ranges of 10-70 dyne/cm2. For laminar 
flow, vessel shear can be expressed as follows; 
 
 
 
Where τ = shear stress, µ = blood viscosity, Q = flow rate and r = vessel radius.  
Physiologically, flow rate is highest at the centre of the vessel lumen and reduces 
towards the endothelium. 
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Cyclic strain, the principal emphasis of this work, describes the repetitive 
circumferential stretching of the vessel wall in synchronization with the cardiac cycle (Fig 
1.5) (Awolesi et al., 1995; Cummins et al., 2007; Chen et al., 2008; Chien, 2007). This 
mechanical force, generated by the periodic contraction of the heart, impacts both the 
endothelial and underlying smooth muscle cells in macrovessels (Fig 1.4 above). The measure 
of cyclic strain is proportionally related to vessel diameter and blood pressure as large arteries 
such as the aorta enlarge at the peak of this blood pressure cycle (systole) and then slowly 
collapse as pressure from the heart drops (diastole) to pump blood downstream. Cyclic strain 
studies carried out in vitro, including the work in this thesis, replicate the effects of cyclic 
strain on cellular signal transduction in endothelial cells using vacuum based technologies to 
deform flexible-bottom culture plates (Awolesi et al., 1995; Chen et al., 2008; Collins et al., 
2006; Han et al., 2010). In response to cyclic strain, the blood vessel wall thickens or thins so 
that force per unit of wall is constant (Schiffrin, 1992), which is portrayed by Laplace’s Law 
(Laplace, 1899), as shown below; 
 
 
 
Where T = wall tension (or force per unit length of the vessel), P = blood pressure, r = radius 
and h = the thickness of the vessel wall.  
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Figure 1.5: How biomechanical forces affect endothelial cells. (A) Cyclic strain, which is felt 
principally in larger arterial vessels. (B) Laminar shear stress, which is sensed predominantly 
in straight sections of the vasculature. (C) Disturbed shear, which is found in areas of high 
curvature or downstream of bifurcations (http://www.qiagen.com/Knowledge-and-
Support/Resource-Center/Resource-Search/Lab-and-Scientific-Knowledge/Newsletters-and-
Magazines/Articles/Reviews-online-mechanotransduction/). 
Under physiological conditions, arterial diameters can remodel according to changes 
in fluid flow (Schaper, 2009). Conversely, vessels with high blood pressure need denser walls 
to be mechanically stable. If this pressure remains high, which may happen in pathological 
conditions such as hypertension, the vessel walls ability to remodel will be compromised. 
This eventually affects vessel elasticity and reduces the capacity of the artery to modulate 
blood flow in response to unexpected changes in blood pressure (Hahn and Schwartz, 2009).    
According to the literature, there is a strong link between endothelial dysfunction and 
pathological levels of cyclic strain, which will be main focus of this thesis (Cummins et al., 
2007; Chen et al., 2008; Collins et al., 2006; Han et al., 2010; Matsushita et al., 2001; Von 
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Offenberg et al., 2004). The focus of this thesis is to understand how the hemodynamic 
environment, and specifically cyclic strain, impacts thrombomodulin dynamics within human 
vascular cells in vitro. The rationale for this will be outlined towards the end of this chapter. 
The ability of the endothelial cell to convert these biomechanical forces into molecular 
responses is known as mechanotransduction and will be discussed in more detail in the next 
section. 
 
1.1.5 Mechanotransduction 
  
 Endothelial cells possess diverse mechanoreceptor mechanisms (Fig 1.6) that allow 
them to sense their hemodynamic environment and transduce mechanical signals into 
appropriate cellular responses (e.g., nitric oxide release, gene expression), thus enabling blood 
vessels to structurally adapt their architecture (i.e., diameter, wall thickness, barrier function) 
to suit circulatory parameters (Wang and Thampatty, 2006). This process is known as 
mechanotransduction. Within this context, physiological ranges of laminar shear stress and 
cyclic strain of endothelial cells promote anti-proliferative, anti-coagulant and anti-thrombotic 
characteristics consistent with an atheroprotective phenotype (i.e., manifesting healthy 
endothelial function and atherosclerotic resistance) (Wu et al., 1995; Traub and Berk, 1998; 
Akimoto et al., 2000). Moreover, chronic dysregulation of endothelial responsiveness to 
hemodynamic stimuli (e.g., in arterial oscillatory flow zones or in vein graft regions of 
impaired endothelial function) has very serious clinical implications ranging from endothelial 
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dysfunction to atherosclerosis, intimal hyperplasia, thrombosis and stroke (Tineli et al., 2007; 
Hahn and Schwartz, 2009). 
 
 
 
Figure 1.6: Mechanotransduction mechanisms used by endothelial cells (Chien, 2007).  
  
 It is clear from the many publications that hemodynamic forces influence the 
expression and/or activation of various signaling pathways (Fig 1.7) (Chen et al., 2008; Cheng 
et al., 2001; Takada et al., 1994). For instance, shear stress effects the gene expression of 
endothelial nitric oxide synthase (eNOS), endothelin-1, and thrombomodulin in human retinal 
microvascular endothelial cells (Ishibaza et al., 2011). Also, cyclic strain was shown to induce 
reactive oxygen species production through an endothelial NAD(P)H oxidase (Matsushita et 
al., 2001). An understanding of which signalling pathways putatively mediate the cyclic 
strain-dependent regulation of TM will therefore undertaken in this thesis.  
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Figure 1.7: The mechanotransduction pathways activated inside endothelial cells in response 
to shear stress (El-Hamamsy et al., 2010). Key: Akt, protein kinase B; AP-1, activator protein-
1; eNOS, endothelial nitric oxide synthase; ERK-5, extracellular signal-regulated kinase-5; 
ICAM-1, intercellular adhesion molecule-1; IKK, IĸB Kinase; KLF-2, krüppel-like factor-2; 
NFĸB, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K, phosphoinositide 
3-kinase; VCAM-1, vascular adhesion molecule-1; VE-cadherin, vascular endothelial 
cadherin. 
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1.2 Thrombomodulin (TM) 
 
1.2.1 TM structure 
 
 Thrombomodulin (THBD, CD141, BDCA3, fetomodulin), discovered and first named 
in 1982 by Esmon et al. (for review see Esmon and Owen, 2004), is a multi-domain integral 
membrane protein constitutively expressed on the lumenal surface of vascular endothelial cells 
at a density of 50,000-100,000 molecules per cell (Suzuki et al., 1988). In addition to coating 
the endothelium throughout all vascular beds, TM expression has been widely detected in 
several other tissues suggesting multi-functionality beyond its widely established anti-
coagulation and anti-inflammatory roles (Van de Wouwer et al., 2004). It has also been 
identified in human gestational tissues such as placenta and myometrium (Uszyński et al., 
2000), the gingival epithelium (Matsuyama et al., 2000), keratinocytes (Senet et al., 1997), 
polymorphonuclear neutrophils (Conway et al., 1992), monocytes (Tsai et al., 2010), dendritic 
cells (Yerkovich et al., 2009), osteoblasts (Maillard et al., 1993), and even platelets (Suzuki et 
al., 1988). Furthermore, TM has also been detected in a variety of cultured cells including 
smooth muscle cells (Soff et al., 1991), A549 small cell lung cancer cells (Fujiwara et al., 
2002) and NIH 3T3 cells (Dittman et al., 1988), whilst soluble variants have been detected in 
human urine (Nakano et al., 1998) and serum (Zycinska et al., 2009). 
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Table 1.1: The functions of each of the five domains of TM. 
 
 The human TM gene, separately cloned by Wen et al. (Wen et al., 1987) and Suzuki et 
al. (Suzuki et al., 1988) from a human cDNA library, is an intronless gene localized to 
chromosome 20p12-cen (Espinosa et al., 1989). It codes for a protein of 575 amino acids 
(processed to 557 amino acids following removal of the N-terminal signal peptide) and has 
been widely reported as having a MW ranging from 70-100 kDa. TM is structurally organized 
into five domains (Table 1.1): (D1) an N-terminal C-type lectin domain (CTLD); (D2) a chain 
of six extracellular EGF-like repeats; (D3) an extracellular serine/threonine (ser/thr) rich 
region; (D4) a transmembrane spanning region; and (D5) a short cytoplasmic tail (Fig 1.8). 
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Over the last two decades, a multitude of studies have uncovered the complex functional 
heterogeneity of these domains (Table 1.1), ranging from mediating TM interaction with anti-
coagulant cofactors such as thrombin, protein C and thrombin-activatable fibrinolysis inhibitor 
(D2.D3) (Ito and Maruyama, 2011; Kokame et al., 1998), to TM internalization and regulation 
of inflammatory responses (D1) (Conway et al., 1994; Kokame et al., 1998). For a highly 
comprehensive overview of the structural properties of TM, the reader is directed to a recent 
review by Conway (Conway, 2011). 
  
 
 
Figure 1.8: Structure of TM consisting of five domains; N-terminal lectin-like domain, 
epidermal growth factor-like domain, ser/thr-rich domain, transmembrane domain and 
cytoplasmic domain. Key: COOH, carboxyl group; CS, chondroitin sulphate; EGF, epidermal 
growth factor-like domain; O, oxygen; NH2, amine group.   
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1.2.2 Functions of TM 
 
 TM exerts a vasculoprotective function in endothelial cells by inhibiting both 
coagulation (Weiler and Isermann, 2003) and fibrinolysis (Bajzar, 2000), whilst suppressing 
inflammation (Esmon and Owen, 2004). These roles substantively overlap and compliment 
each other and will be described below: 
 
1.2.2.1 Anti-coagulant 
 
 The first characterized function of TM revolved around its role in the coagulation 
cascade (Fig 1.9). The ability to bind the serine protease thrombin and potentiate its role 
within the protein C (PC) activation cascade is often viewed as the archetypal function of TM. 
Numerous knock-out studies have shown that TM is essential for life. Indeed, mouse models 
of TM gene mutation (TMpro/pro mouse) and endothelial cell-specific gene deletion (TMLox- 
mouse) both exhibit greatly reduced ability to generate activated protein C (APC) within the 
circulation, leading to thrombosis and a hypercoagulable state (Isermann et al., 2001; 
Rijneveld et al., 2004). Coagulation is regulated by two main mechanisms; (i) the heparin-
antithrombin mechanism, which inhibits coagulation proteases and (ii) the anti-coagulant 
pathway of protein C (PC) which will be discussed in slightly more detail (Califano et al., 
2000). TM has a high affinity for binding to thrombin (Kd ~0.5 nmol L-1), with bound 
thrombin subsequently going on to generate activated protein C (APC) (Weiler and Isermann, 
2003).  
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 Thrombin, known to regulate thrombosis and homeostasis, is a pro-coagulant 
disulphide-bonded protease dimer (Freedman, 2001). Thrombin binds to the TM EGF5-6 
repeat domains and also, with lower affinity, to the TM CS moiety within the ser/thr-rich 
domain via the thrombin anion binding exosite I and II regions, respectively (Light et al., 
1999; Ye et al., 1993). Upon binding to TM, this ultimately induces endocytosis and 
degradation of the TM-thrombin complex in lysosomes, a mechanism inhibited by PC but not 
by APC (Okamoto et al., 2012). The TM binding also alters thrombin’s conformation allowing 
it to activate PC (Freedman, 2001). The action of TM binding therefore converts thrombin 
from a pro-coagulant protease to an anti-coagulant enzyme by shielding the pro-coagulant 
exosite I of thrombin (Esmon, 2003).   
 
 
 
Figure 1.9: The binding of TM with thrombin to convert endogenous Protein C into activated 
Protein C (APC) (Mann HJ et al., 2009). 
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 The binding of thrombin with TM has the effect of blocking the interaction of 
thrombin with circulating pro-coagulant substrates (e.g., fibrinogen) and enhancing its 
specificity for PC, leading to a substantially elevated rate of PC activation (over 1000-fold 
relative to unbound thrombin) (Adams and Huntington, 2006). Thrombin cleaves PC to cause 
the release of a dodecapeptide activation sequence and yield activated PC (APC), a disulphide-
linked heterodimer, an event that is significantly enhanced if PC is bound to endothelial 
protein C receptor (EPCR) (Stearns-Kurosawa et al., 1996). Once dissociated from EPCR, 
APC elicits potent anti-coagulant effects primarily through the proteolytic inactivation of 
factor Va and factor VIIIa (Dahlbäck and Villoutreix, 2005).  This is a fundamental anti-
coagulant mechanism that inhibits the amplification of thrombin generation and catalyzes the 
proteolytic activation of PC.  
 
1.2.2.2 Anti-fibrinolytic 
 
 In conjunction with its anti-coagulant function, TM also has an anti-fibrinolytic role. 
Thrombin biding to TM enhances the substrate specificity of the latter towards thrombin-
activable fibrinolysis inhibitor (TAFI), a plasminogen-bound zymogen, to yield TAFIa 
(Adams and Huntington, 2006; Nesheim et al., 1997). TAFIa - also known as 
procarboxypeptidase B2 (CPB2), carboxypeptidase U (CPU), and plasma carboxypeptidase 
(pCPB) - exhibits carboxypeptidase-like activity towards C-terminal lysine residues from 
partially degraded fibrin (Leung et al., 2008; Zhao et al., 2003), thereby serving as a negative 
regulator of fibrinolysis (Fig 1.10). This enhances the stabilization of fibrin clots ensuring 
greater injury localization during vascular inflammatory events. Interestingly, selective 
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blockade of the TM/thrombin-mediated generation of TAFIa (e.g., using monoclonal 
antibodies) represents a valid approach to the development of pro-fibrinolytic therapies to 
reduce clot lysis time (Mishra et al., 2011). 
 
 
 
Figure 1.10: Thrombin/TM or plasmin can activate TAFI (60 kDa) yielding TAFIa (35kDa). 
Consequently, TAFIa is heat inactivated (triangle) to form TAFIai (shaded). All TAFI 
isoforms are found in plasma. TAFIa/ai-specific ELISA measured only TAFIa and TAFIai, 
not TAFI (Park et al., 2010). 
 
1.2.2.3 Anti-inflammatory 
 
 The anti-inflammatory properties of TM have also been well documented (Van de 
Wouver et al., 2004). The N-terminal C-type lectin-like domain (LLD) of TM was found to 
have a direct role in regulating inflammation. A relatively recent study by Nara et al. (Nara et 
al., 2006) for example describes how treatment of human endothelial cells with an anti-TM 
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monoclonal antibody elicits inflammatory signalling mechanisms (e.g., NF-κB stimulation, 
IL-6 secretion) leading to endothelial activation, whilst Takagi and co-workers report that the 
C-type lectin domain of TM is a modulator of dendritic cell-mediated immunostimulatory 
events (Takagi et al., 2011). Whilst bound to EPCR for example, thrombin-generated APC 
can suppress monocyte-dependent cytokine production (Grey et al., 1994) and induce a 
cytoprotective endothelial gene expression profile (Joyce et al., 2001). EPCR-bound APC can 
also switch the signalling specificity of protease-activated receptor 1 (PAR1), which serves to 
orchestrate cellular responses to coagulation proteases such as thrombin from a pro-
inflammatory to an anti-inflammatory response (Cheng et al., 2003; Rezaie, 2001; Riewald et 
al., 2003). Similarly, both in vitro (Leung et al., 2008) and in vivo (Beppu et al., 2010; Mao et 
al., 2005) studies have shown that thrombin-generated TAFIa can proteolytically inactivate a 
number of endogenous pro-inflammatory mediators such as bradykinin, osteopontin, and the 
complement-derived anaphylotoxins C3a and C5a via cleavage of their C-terminal arginine 
residues (Fig 1.10). TM can also negatively regulate the complement system by accelerating 
factor I-mediated inactivation of C3b. In this respect, missense mutations in TM can lead to a 
diminished ability to protect against activated complement – a feature of ~5% of potentially 
fatal atypical hemolytic-uremic syndrome (HUS) cases (Delvaeye et al., 2009). It should also 
be noted that circulating thrombin itself has several potent pro-inflammatory properties within 
the vascular endothelium - from induction of pro-inflammatory molecule expression (e.g., IL-
6, IL-8, E-selectin, and MCP-1) (Anrather et al., 1997; Stanková et al., 1995) and nitric oxide 
production (Motley et al., 2007), to activation of NF-κB signalling and monocyte/endothelial 
adhesion (Delekta et al., 2010). Thrombin is also known to potentiate endothelial activation 
by TNF-α (Anrather et al., 1997). Thus, by reducing circulating levels of thrombin as well as 
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switching its substrate specificity towards PC and TAFI (to yield anti-inflammatory APC and 
TAFIa), TM functions as an anti-inflammatory molecule, rendering it both a pivotal player in 
the progression of inflammatory diseases and a viable target for therapeutic intervention. 
Evidently, TM plays a pivotal role in endothelial homeostasis by accelerating APC 
production, inhibiting coagulation and fibrinolysis (Nesheim, 2003) and mediating 
inflammation via its lectin-like domain (LLD) (Conway, 2011). This gives the endothelium 
protection against apoptosis, inflammation, fibrinolysis and thrombosis (Morser et al., 2010). 
 
1.2.3 Transcriptional regulation of TM 
 
The 5’-untranslated promoter region of the TM gene displays numerous response 
elements conferring transcriptional sensitivity to various stimuli (Fig 1.11) (Tazawa et al., 
1993; Yao et al., 1999). Oxidative stress (Kumar et al., 2009), hypoxia (Ogawa et al., 1990), 
oxidized LDL (Ishii et al., 2003), C-reactive protein (Nan et al., 2005), phorbolesters (PMA) 
(Grey et al., 1994), cyclic adenosine monophosphate (cAMP) (Grey et al., 1998) and TNF-α 
(Grey et al., 1998) tend to down-regulate endothelial TM expression, whilst an up-regulatory 
effect has been attributed to thrombin (Séguin et al., 2008), VEGF (Calnek and Grinnell, 
1998), retinoic acid (Marchetti et al., 2003) and heat shock (Fu et al., 2008).  
In view of so many competing influences, basal endothelial TM levels typically reflect 
a balance between up- and down-regulatory forces. For example, p66Shc-mediated cellular 
oxidative stress leading to transcriptional repression of Krüppel-like factor 2 (KLF2), a 
transcription factor positively regulating the TM promoter, can lead to down-regulation of TM 
expression (Kumar et al., 2009), whilst up-regulation of KLF2 by antioxidant laminar shear 
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stress has the opposite effect (Dekker et al., 2002; Ishibazawa et al., 2011) – a particular 
aspect of TM regulation discussed in greater detail in the next section (post-transcriptional 
regulation). 
Similarly, TNF-α dependent suppression of endothelial TM levels via NF-κB 
activation has been well documented (Lin et al., 2010, Sohn et al., 2005), an effect that can be 
counter-balanced by all-trans retinoic acid treatment (Marchetti et al., 2003), laminar shear 
stress (Jun et al., 2009), and statins (Bergh et al., 2012).  Interestingly, the TM promoter does 
not actually contain a classic NF-κB consensus motif, but NF-κB can mediate cytokine-
induced repression of TM expression by competing for binding to p300, a transcriptional 
coactivator essential for TM expression (Sohn et al., 2005). An intriguing study by Takeda et 
al. (Takeda et al., 2007) also reports that endothelial TM levels are subject to circadian 
variation (an important variable in CVD event occurrence) via TM promoter transactivation 
involving CLOCK/BMAL-2 heterodimer binding to the promoter E-box region (-CANNTG-). 
Endothelial TM expression also displays sensitivity to blood flow-associated laminar 
shear stress, a hemodynamic force known to impart an atheroprotective phenotype to the 
endothelium (Traub and Berk, 1998). In view of the anti-coagulant and anti-inflammatory 
characteristics of this phenotype, the observation that shear stress is a positive regulator of 
TM expression in most studies is therefore unsurprising. Shear-dependent up-regulation of 
TM expression under both acute and chronic treatment paradigms has been reported in human 
retinal microvascular endothelial cells (Ishibazawa et al., 2011), primate peripheral blood-
derived endothelial outgrowth cells (Ensley et al., 2012), HUVECs (Bergh et al., 2009; 
Takada et al., 1994; Wu et al., 2011), human abdominal aortic endothelial cells (HAAECs) 
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(Rossi et al., 2010), and even in a mouse transverse aortic constriction model of flow-
dependent remodeling (Li et al., 2007).  
 
 
 
Figure 1.11: Promoter region of the TM gene with predicted response elements. Consensus 
motifs and corresponding response element are highlighted. Key: KLF-1, Krüppel-like factor-
2; HIF-1, hypoxia inducible factor-1; ETS-1, v-Ets E26 erythoblastosis; AP-1, activating 
protein-1; CRE, cAMP response element; SP-1, specificity protein-1, GRE, glucocorticoid 
response element; N, any base. Sequence shown is for rat thrombomodulin promoter 
(GenBank AF022742.1) Promoter 1-708; ATG start site, 900-902. 
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The ability of shear stress to offset the down-regulatory impact of TNF-α treatment on 
TM expression in HUVECs has also been reported (Jun et al., 2009). In stark contrast to these 
studies, an early publication by Malek et al. (Malek et al., 1994) has reported that endothelial 
TM expression exhibits a mild transient increase followed by a (reversible) decrease to just 
16% of baseline levels within 9 hrs of flow onset in bovine aortic endothelial cells (BAECs). 
One should probably regard this early observation as somewhat atypical however, in light of 
the volume of recent studies reporting the opposite effect. The use of BAECs for this study (as 
opposed to human/primate/mouse models) may serve as a possible explanation. Interestingly, 
the same authors also report that TM is similarly regulated in BAECs by both laminar and 
turbulent shear, although they suggest that this unusual observation should be interpreted with 
caution due to the arbitrary nature of the chosen shearing conditions (i.e., may not reflect the 
true in vivo situation). 
Whilst studied to a lesser extent, contrasting observations also accompany reports on 
the regulation of TM expression by cyclic strain, the repetitive mechanical deformation of the 
vessel wall as it rhythmically distends and relaxes with the cardiac cycle. Using a rabbit 
autologous vein graft model, Sperry et al. (2003) have demonstrated that the substantially 
reduced TM expression in vein grafts (observed both acutely and chronically) occurs as a 
direct consequence of outward vessel wall distension and, interestingly, not elevated vessel 
shear rates or local inflammatory response - leading them to conclude that strain-mediated 
elevation of endothelial thrombogenicity is a principal cause of occlusive thrombosis 
preceding autologous vein graft failure. In an apparent contrast to this observation, slightly 
earlier paired studies by Golledge et al. (1999) and Gosling et al. (1999) employing ex vivo 
human saphenous vein segments within a validated in vitro flow circuit, report that exposure 
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of vein grafts to arterial flow significantly reduces endothelial TM expression in a cyclic 
strain-independent manner (although stretch-activated calcium ion channels appear to be 
involved). One explanation for this difference may possibly be attributed to ineffective 
external stenting used in the earlier studies to block out cyclic strain influences, with up to 
7±2% pulsatile expansion still possible with external polytetrafluoroethylene (PTFE) stents. 
Another explanation may stem from the fact that the later (Sperry et al., 2003) and earlier 
(Gosling et al., 1999; Golledge et al., 1999) studies reflect chronic (weeks) versus acute (45-
90 mins) observations, respectively. 
Using both vein graft and in vitro vascular cell culture models, recent studies by Kapur 
and co-workers into the mechanism of endothelial thromboresistance in vein grafts 
convincingly demonstrate that cyclic strain-dependent induction and release of transforming 
growth factor-β1 (TGF-β1) within the medial smooth muscle cell layer could decrease 
endothelial TM expression in a paracrine manner (Kapur et al., 2011), albeit via an unknown 
signaling mechanism. Using a pan-neutralizing TGF-β1 antibody (1D11), these authors were 
able to block TM down-regulation, preserve levels of activated protein C, and reduce 
thrombus formation in a rabbit vein graft model. In stark contrast to these observations 
however (and indeed to those above), a recent paper by Chen et al. (2008) demonstrates a 
sustained increase in TM protein expression in HUVEC cultures following 21% (but not 15%) 
cyclic strain, with a nitric oxide (NO) signaling mechanism strongly implicated in these 
events. The authors of this study suggest that as TM promoter activity was not induced by 
cyclic strain of HUVECs, the observed increase in protein expression may putatively be 
attributed to NO-mediated stabilization of TM protein via S-nitrosylation. In the absence of 
further data however, and considering the supra-physiological levels of strain applied, the 
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relevance of this study remains questionable and possibly highlights a limitation of cell 
culture models in addressing the regulatory impact of cyclic strain on TM expression. Finally, 
a study by Feng and co-workers report a 2.6 fold down-regulation of TM expression in human 
aortic smooth muscle cells (HASMCs) following 4% equibiaxial cyclic strain for 24 hrs 
(1999), however the physiological relevance of this result is questionable in view of the fact 
that vascular SMCs do not appear to express TM protein or mRNA in vessel walls (Soff et al., 
1991) (again highlighting a limitation of cell culture models). The focus of this thesis will try 
to address the limitation in cell culture models in relation to cyclic strain and TM. 
 
1.2.4 Post-transcriptional regulation of TM 
 
MicroRNAs (miRNAs) are endogenously expressed non-coding RNA molecules (18-
24 bases) that post-transcriptionally regulate gene expression within eukaryotic genomes, a 
mechanism that involves miRNA hybridization with the 3’-untranslated mRNA region of 
target genes leading to gene silencing and translational repression of protein synthesis 
(Bonauer et al., 2010;  Hussain, 2012). The vascular endothelium is now a confirmed source 
of several dozen miRNAs that collectively facilitate regulation of endothelial gene expression 
and cell fate (Staszel et al., 2011; Suarez et al., 2007). 
Recent findings on the flow-dependent regulation of Krüppel-like factor 2 (KLF2), a 
vasoprotective transcription factor known to positively regulate endothelial genes including 
TM (Fig 1.12) (Gracia-Sancho et al., 2011), provide the most compelling evidence thus far 
that endothelial TM expression is influenced albeit indirectly by miRNA. Inhibition of miR-
92a, a member of the miR-17-92 cluster predicted to bind the 3’-UTR of the KLF2 transcript 
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(Bonauer and Dimmeler, 2009), was found to increase protein and mRNA levels for both 
KLF2 and TM in HUVECs (Irani, 2011; Wu et al., 2011). The same study also demonstrates 
that miR-92a is down-regulated by atheroprotective laminar shear to induce KLF2 and TM 
levels, consistent with earlier shear studies (Dekker et al., 2002; Ishibazawa et al., 2011). 
Thus, shear-dependent suppression of miR-92a in endothelial cells likely enhances expression 
of KLF2 leading to transactivation of the TM promoter. Consistent with these observations, 
atheroprone endothelial sites (e.g., aortic arch) that exhibit non-laminar shear flow pattern, 
manifest elevated miR-92a leading to decreased levels of KLF2 (and, one would assume, TM) 
(Fang and Davies, 2012). 
 
 
 
Figure 1.12: Shear stress regulation of Krüppel-like factor 2 (KLF2). Key: EC, endothelial 
cell; eNOS, endothelial nitric oxide synthase; ITGA5, integrin alpha-5; miR, microRNA; 
SIRT1, sirtuin 1; Spred1, sprout-related ECH1 domain-containing protein 1; TF, transcription 
factor; TM, thrombomodulin (Wu et al., 2011).  
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MicroRNAs are now established therapeutically viable targets in the regulation of 
vascular inflammation and senescence (e.g., miR-146a, miR-217, miR-34a, miR-126, miR-21, 
miR-210, miR-181b) (Qin et al., 2012; Sun et al., 2012; Vasa-Nicotera et al., 2011; 
Voellenkle et al., 2012), tumour angiogenesis (miR-19b-1) (Yin et al., 2012), and in vascular 
diseases such as hypertension (miR-125a/b-5p) (Li et al., 2010) and atherosclerosis (miR-92a, 
miR-27, miR-10a) (Chen et al., 2012; Fang and Davies, 2012; Fang et al., 2010). In view of 
the established roles for TM in the regulation of inflammatory and thrombotic processes 
within the vascular wall, in conjunction with its indirect regulation by miR-92a via KLF2 
(Fang and Davies, 2012, Wu et al., 2011), one can anticipate future studies detailing 
approaches to modulating TM levels in vivo using miRNA-targeting strategies. 
 
1.2.5 Post-translational regulation of TM 
 
As with many regulatory proteins, TM can undergo an assortment of post-translational 
modifications that can lead to alterations in its size, structural orientation, amino acid side 
chain chemistry, and localization, ultimately modulating its vascular homeostatic properties to 
reflect the tissue environment. 
 
1.2.5.1 Oxidation 
 
Early work by Glaser et al. (1992) demonstrated that endothelial TM could be almost 
completely inactivated by oxidation of methionine-388 located within the fifth EGF-like 
repeat domain (which mediates thrombin binding and anti-coagulant function). These authors 
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present evidence pointing to polymorphonucleur neutrophil-derived NADPH oxidase as a 
probable source of the biological oxidants that cause the TM inactivation typically observed 
in inflamed tissues. Oxidation of met-388 (Fig 1.13) leads to lessening of TM functions 
(Wang et a., 2000; Wood et al., 2003; Wood et al., 2005), whilst ROS-dependent inactivation 
of TM has been reported in a mouse model of vascular dysfunction and thrombosis (Adams et 
al., 2011). Furthermore, a relatively recent article by Stites and Froude (2007) proposes that 
the elevated oxidative stress associated with smoking and diabetes is responsible for the pro-
thrombotic state of these conditions by virtue of increased TM met-388 oxidation and the 
subsequent decrease in circulating activated protein C levels. Also noteworthy, cellular 
reducing agents have been shown to modify TM disulphide bonds, rendering the molecule 
more susceptible to serine protease-mediated cleavage and its subsequent shedding 
(Menschikowski et al., 2010). 
 
 
 
Figure 1.13: The smallest active fragment of TM. Key: amino acids, single letter code; Met 
388, in bold; disulphide bonding pattern between cysteine residues, solid lines; two N-linked 
glycosylation sites, flags (Wood et al., 2005). 
 34 
1.2.5.2 Glycosylation 
 
As with many transmembrane proteins boasting an ecto-domain, TM is a glycoprotein 
likely displaying tissue-, organ- and species-specific glycosylation phenotypes, thus enabling 
regulatory flexibility with respect to TM:thrombin function in different vascular beds. N-
linked glycosylation at asparagine residues has been reported for urinary TM (Edano et al., 
1998; Wakabayashi et al., 2001). Early studies also report the presence of a TM-associated O-
linked glycosaminoglycan (GAG) chain, showing cell-dependent modification of TM at Ser-
474 (Lin et al., 1994). Interestingly, both Edano et al. and Lin et al. also report GAG 
modification at Ser-472 in C127 mammary tumour cells and CHL-1 melanoma cells, 
respectively (Edano et al., 1998; Lin et al., 1994). This O-linked GAG modification mediates 
TM interactions with exogenous GAGs and modulates its thrombin-binding and anti-
coagulant activities (Koyama et al., 1991). Indeed, treatment of rabbit TM with chondroitin 
ABC lyase to remove O-linked GAGs substantially reduced its thrombin-binding capacity 
(Koyama et al., 1991), whilst Ye et al. (1993) report that the chondroitin sulphate (CS) moiety 
of TM allows it to bind a second molecule of thrombin. The relevance of the O-linked GAG 
chain in TM is further clarified in a relatively recent study by Bouton and co-workers (2007), 
who demonstrate in HAECs that the TM CS moiety facilitates complexation with protease 
nexin-1 (PN-1), a thrombin-inhibiting serpin secreted by endothelial cells. The resultant 
TM/PN-1 complex has markedly increased inhibitory capacity towards thrombin activity and 
thrombin-induced fibrinogen clotting in comparison to either unbound TM or PN-1. 
Importantly, this study is consistent with an earlier paper by Koyama et al. (1991) 
demonstrating how TM can modulate thrombin inactivation by other heparin-activated serpins 
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(i.e., heparin cofactor II and antithrombin III) as a function of its O-linked CS phenotype in 
conjunction with the presence or absence of exogenous GAGs (e.g., heparin or dermatan 
sulphate). 
 
1.2.5.3 Proteolysis 
 
 
 
Figure 1.14: Soluble TM is shed and/or proteolysed from the membrane as a result of 
endothelial injury (Spanier et al., 1996). 
 
Much attention has been devoted to the subject of endothelial TM as a cellular 
substrate for proteolytic cleavage, frequently leading to its shedding as a soluble variant 
(sTM) (Fig 1.14). In this respect, sTM has been observed in biological fluids ranging from 
serum (Oida et al., 1990) and urine (Jackson et al., 1994) to synovial fluid (Conway and 
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Nowakowski, 1993). A study by Abe et al. (1994) demonstrated that following incubation of 
HUVECs with either granulocyte elastase or cathepsin G, both leukocyte-derived lysosomal 
proteases, cellular TM activity was respectively decreased by 90% and 80%, with a 
concomitant increase in soluble TM variants within the media fraction. Other early studies 
further confirm likely roles for neutrophil-derived elastase and cathepsin G in the reduction of 
endothelial cell surface TM activity and elevated TM shedding as causative elements of 
vascular injury in models of E.coli-induced sepsis, TNFα-induced endothelial activation, and 
adult respiratory distress syndrome (ARDS) (Boehme et al., 1996; Kobayashi et al., 1998; 
MacGregor et al., 1997; Redl et al., 1995). Moreover, a recent study by Matsuyama et al. 
(2008) has implicated neutrophil-derived enzymes in the proteolytic release of TM from 
gingival epithelial cells during periodontitis. Other enzymes have also been implicated in TM 
proteolysis and subsequent shedding. Wu et al. (2008) report that LPA-induced shedding of 
the TM lectin-like domain in HUVECs is MMP-dependent. Moreover, P.gingivalis-derived 
cysteine proteases (arginine- and lysine-specific gingipains) have been shown to elicit TM 
degradation and release from the microvascular endothelium in patients with periodontitis, 
leading to vascular coagulation and inflammation (Inomata et al., 2009). Studies have also 
confirmed TM cleavage by rhomboids, a family of evolutionarily conserved intramembrane 
serine proteases originally characterized based on their proteolytic specificity towards 
Drosophila “Spitz-like” substrates. The TM transmembrane domain can be cleaved by 
RHBDL2-like rhomboids to release soluble TM, a process mediated through the TM 
cytoplasmic domain (Lohi et al., 2004). Whilst intriguing however, the relationship between 
rhomboids and TM has thus far only been studied in non-vascular cells and dermal wound 
models (Fig 1.15) (Cheng et al., 2011; Lohi et al., 2004; Bergbold and Lemberg, 2013). 
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Figure 1.15: Putative role of rhomboids (RHBDL2) in the release of bioactive molecules 
(e.g., TM) (A) and remodeling of cell-cell contact points (B) (Bergbold and Lemberg, 2013).  
 
Non-proteolytic mechanisms causing loss of TM from the cell surface are also worth 
mentioning. Early studies using A549 and hemangioma cells demonstrated how 
TM/Thrombin binding could lead to internalization of surface TM with evidence for partial 
TM degradation and recycling (Maruyama and Majerus, 1985; Dittman et al., 1988). Later 
studies go on to demonstrate that TM cell surface levels can be regulated by endocytosis via 
non-clathrin coated pits, an internalization process directed by TM’s extracellular lectin-like 
domain (Conway et al., 1994; Conway et al., 1997). TM shedding from activated endothelium 
via endothelial microparticles (and exosomes) has also been suggested. These heterogeneous 
microvesicles facilitate the inter-cellular exchange of signalling components such as miRNAs, 
coagulant molecules, and receptors (Andriantsitohaina et al., 2012). Early work by Satta and 
co-workers for example has demonstrated that LPS treatment increases TM activity on 
monocyte-derived MPs by up to 80% (Satta et al., 1997). Co-elevated TM and MP levels in 
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serum have also been observed during systemic inflammatory response syndrome (SIRS) in 
humans and during heatstroke in baboons (Bouchama et al., 2008; Ogura et al., 2004), whilst 
recent work by Duchemin points to an influence of circulating MPs on the “TM-resistance” of 
patients suffering from myeloproliferative neoplasm (Duchemin et al., 2010). Importantly, the 
putative role of MPs/exosomes as vehicles for TM release from HAECs will be further 
investigated in this thesis. 
Circulating levels of TM are typically in the low ng/ml range in healthy human 
subjects, with pathology frequently causing a moderate, but significant, 1.5-2.0 fold increase 
in patient plasma TM levels (Dharmasaroja et al., 2012; Lin et al., 2008; Mok et al., 2010; 
Rousseau et al., 2009; Welters et al., 1998). Whilst these TM levels are probably too low to 
have a significant impact on coagulation processes, the consistent elevation in circulating TM 
levels during pathologies is now widely regarded as an important circulatory biomarker for 
endothelial dysfunction and vascular risk assessment (Boehme et al., 1996). Consistent with 
this notion, elevated plasma TM levels have been found to correlate with atherosclerosis 
(Pawlak et al., 2010; Taylan et al., 2012), cardioembolic stroke (Dharmasaroja et al., 2012), 
obesity (Urban et al., 2005), Lupus erythomatosus-associated metabolic syndrome (Mok et al., 
2010), pre-eclampsia (Rousseau et al., 2009), sepsis-associated disseminated intravascular 
coagulation (DIC) (Lin et al., 2008), and severe acute respiratory syndrome (SARS) (Liu et 
al., 2005). Significantly elevated plasma TM levels have also been observed in patients 
following coronary artery bypass graft (CABG) surgery (Arazi et al., 1998; Kokame et al., 
1998). By contrast, several clinical studies report on vascular pathologies manifesting reduced 
sTM levels. For example, an inverse relationship between sTM and disease risk has been 
reported for type-2 diabetes (Thorand et al., 2007) and coronary heart disease (Salomaa et al., 
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1999; Wu et al., 2003), whilst lower levels of sTM have been reported in the serum of patients 
suffering from acute cerebral infarction (Nomura et al., 2004). Indeed, the more recent 
MONICA/KORA study demonstrates a lack of any association between sTM levels and CHD 
risk (Karakas et al., 2011). The incongruity within these collective observations therefore 
illustrates the need for greater understanding of the precise functional relevance and action of 
sTM in serum and reinforces the importance of co-analysing sTM levels with other 
thrombotic/coagulation markers (e.g., factor VIII, PAI-1) during vascular risk assessment and 
cohort stratification (Aleksic et al., 2008). 
 
1.2.6 Therapeutic considerations for TM 
 
1.2.6.1 Soluble recombinant TM (sTM) 
 
An improved understanding of the regulation and functions of TM within the vascular 
endothelium has enabled researchers to better exploit its therapeutic potential. The 
vasculoprotective properties of various soluble TM preparations (which have been shown to 
effectively bind circulating thrombin and generate activated protein C) have received 
particular attention, with studies ranging from animal models to human clinical trials (for 
review see Morser et al., 2012). An early study by Li et al. (Li et al., 2004) for example 
demonstrates how recombinant sTM infusion could reduce neointimal hyperplasia following 
ballon injury in a rabbit femoral artery model - a therapeutic mechanism that likely 
encapsulates the anti-coagulant and anti-inflammatory properties of the recombinant sTM 
domains. The ability of sTM to effectively reverse the inflammatory phenotype of the renal 
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microvascular endothelium in rat and murine models of acute ischemic kidney injury and 
chronic kidney disease, respectively, has also been reported (Rajashekhar et al., 2012; 
Sharfuddin et al., 2009). As further testament to its vasculoprotective properties, the 
therapeutic benefits of recombinant sTM administration towards recovery from severe 
inflammatory disorders such as heatstroke and radiation toxicity have again been 
demonstrated in rat and murine models, respectively (Geiger et al., 2012; Hagiwara et al., 
2010), the former study highlighting an sTM mechanism involving a decrease in high-
mobility group box 1 (HMGB1) serum levels in conjunction with blockade of NO over-
production. A human recombinant TM comprising the six EGF-like repeats (domain 2) and 
ser/thr-rich section (domain 3), subsequently referred to as TMD23, has also been reported to 
have vasculoprotective properties in animal models. Shi et al. (2005) illustrate the pro-
angiogenic potential of TMD23 in rat corneal implants, whilst Wei et al. (2011) demonstrate 
the ability of TMD23 to reduce both neointimal formation (C57BL/6 mouse carotid ligation 
model) and atherosclerotic lesion formation (ApoE-/- mouse model). 
The beneficial effects of soluble TM have also been reported in human clinical trials 
(Saito et al., 2007). Approved in 2008 for human therapy in Japan, ART-123 
(thrombomodulin alpha, RecomodulinTM) is a recombinant human soluble TM comprising 
extracellular domains 1-3, which are essential for the anti-inflammatory and anti-coagulant 
actions of the molecule. ART-123 has been reported to be extremely effective in the rapid 
resolution of DIC (Fig 1.16) (Ito and Maruyama, 2011; Kawano et al., 2011; Ogawa et al., 
2012), proving safer and more effective as an inhibitor of the propagation of coagulation than 
traditional low-dose heparin therapy (Nakashima et al., 1998). ART-123 has also been used to 
successfully treat microangiopathies stemming from transplantation-associated sepsis (Sakai 
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et al., 2010) and Lupus-induced thrombosis (Suarez et al., 2007), as well as reversing the 
capillary leakage that accompanies ‘inflammatory engraftment syndrome’ in individuals 
undergoing hematopoietic stem cell therapy (Ikezoe et al., 2010).  
 
 
 
Figure 1.16: Mechanism of action of RecomodulinTM (ART-123). It activated protein C by 
binding to thrombin (http://www.recomodulin.com/en/recomodulin/mechanism.html).  
 
Solulin® (sothrombomodulin alpha) is another human recombinant sTM analogue that 
has recently undergone a Phase 1 human clinical trial (Van Iersel et al., 2011). Solulin 
comprises the same soluble extracellular structure as ART-123, but with specific 
modifications to further enhance the pharmacokinetic and pharmacodynamic properties of the 
molecule. These include a series of N-/C-terminal amino acid deletions and up to four single 
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amino acid exchanges to enhance resistance to oxidation, improve cellular export, and prevent 
attachment of chondroitin sulphate - collectively improving the stability, homogeneity, and 
plasma elimination half-life of sTM (Van Iersel et al., 2011). The efficacy of Solulin in 
reducing infarct volume during acute ishemic stroke in rats has been attributed to its thrombin 
binding anti-coagulant properties (Su et al., 2011), as well as its ability to down-regulate 
inflammatory cytokine gene expression (Ryang et al., 2011), whilst its anti-fibrinolytic 
properties are evident in clot stability assays performed on whole blood drawn from 
hemophilic human and canine subjects (Foley et al., 2012). 
 
 
 
Figure 1.17: The PECAM-1 (CD31) protein domain structure and sites of molecular binding 
interactions (Chacko et al., 2012).  
 
Finally, strategies to improve sTM targeting and therapeutic efficacy offer a means of 
enhancing the clinical value of recombinant soluble TM. Early work by Wang and co-workers 
for example demonstrated that fusing a tissue factor (TF) single chain antibody to an active 
TM fragment generated a novel fusion protein, Ab(TF)-TM, with a dual mechanism of action 
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- namely, anti-coagulant TM-mediated enhancement of protein C activation in conjunction 
with blockade of pro-thrombotic TF/factor VIIa-mediated activation of factor IX/X. The 
fusion protein subsequently demonstrated significantly higher fold efficacy in the resolution 
of DIC in rats than either sTM or Ab(TF) alone (Wang et al., 2006). Similarly, linking a 
PECAM-1-directed antibody single chain fragment (scFv) to TM recently yielded a fusion 
protein, scFv (PECAM-1)-TM, for enhanced vascular immunotargeting of TM in mice (Fig 
1.17) (Chacko et al., 2012). Moreover, fusion of TM to a red blood cell-directed scFv was 
recently shown to prolong the circulation time and bioavailability of soluble TM (Zaitsev et 
al., 2012). 
 
1.2.6.2 Biomaterial coating and TM 
 
The use of recombinant human TM to modulate the surface thromboresistance of 
blood-contacting biomaterials represents another important therapeutic application. Workers 
have recently demonstrated for example that coating of ART-123 onto dialyzer membranes 
can effectively prevent clot formation during dialysis, thereby providing a safe alternative to 
the drawbacks of heparin administration (Matsusaki et al., 2008; Omichi et al., 2010). 
Moreover, recent evidence demonstrating incomplete endothelialization and low TM 
expression levels among existing FDA-approved drug eluting stents (DES) has prompted 
scientists to re-consider the influence of DES agents on endothelial thromboresistance leading 
to stent thrombosis (Joner et al., 2008). Paclitaxel, an anti-proliferative DES agent used to 
prevent neointimal hyperplasia, has been shown to cause TNF-α-induced release of tissue 
factor leading to endothelial TM down-regulation and thereby contributing to a pro-
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thrombotic intimal stent surface (Wang et al., 2011; Wood et al., 2010). Re-engineering of 
stents to avoid such thrombogenic complications is now being undertaken. Wong et al. have 
demonstrated for example that stenting with recombinant human TM-coated PTFE stents (Fig 
1.18) could significantly reduce balloon angioplasty-induced neointimal hyperplasia in a pig 
carotid artery model (Wong et al., 2008). Long term studies however need to be conducted to 
ascertain the resilience of this and other related stent coating improvements for the prevention 
of arterial thrombosis and graft stenosis following balloon angioplasty and CABG, 
respectively. 
 
 
 
Figure 1.18: Photographs of the luminal surface of expanded polytetrafluoroethylene 
(ePTFE) covered stent grafts explanted at 4 weeks. (A) The recombinant TM-coated ePTFE 
stent graft is covered with a smooth, gleaming white thin layer with minimum surface 
deposition. (B) The uncoated ePTFE stent graft is covered with an uneven thick yellow-brown 
layer with scattered blood clots (Wong et al., 2008). 
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1.2.6.3 Statins and TM 
 
Statins reduce endogenous cholesterol biosynthesis through selective inhibition of 3-
hydroxy-3-methylglutaryl co-enzyme A reductase (Krukemyer and Talbert, 1987), and so are 
widely prescribed for the treatment of dyslipidemias associated with cardiovascular disease 
and diabetes. Statins also exhibit a multitude of beneficial pleiotropic (non-lipid) effects, of 
which the vascular endothelium is a key target. Statin-mediated up-regulation of eNOS for 
example has well known anti-inflammatory and anti-coagulant effects (Takemoto and Liao, 
2001). Induction of endogenous TM production leading to anti-inflammatory effects 
constitutes a further pleiotropic benefit of statins, albeit originally unforseen for this class of 
drug (and quite distinct from the pre-designed therapeutic modality of recombinant soluble 
TM). Various studies have documented the up-regulation of TM expression in endothelial 
cells in response to either atorvastatin or simvastatin treatment and demonstrate the anti-
inflammatory ability of statins to counteract the suppressive effects of TNF-α (and thus, NF-
κB) on TM expression (Bergh et al., 2012; Lin et al., 2009; Shi et al., 2003). The induction of 
TM expression and protein C activation in irradiated HUVECs has also recently been reported 
to be a protective effect of atorvastatin (Ran et al., 2010). The statin-mediated induction of 
TM expression has been attributed to transcriptional mechanisms involving both the up-
regulation of KLF2 expression and the NO-dependent dissociation of HSF1 from heat shock 
protein 90, with subsequent nuclear translocation of both factors to Kruppel-like factor and 
heat shock elements within the TM promoter, respectively (Fu et al., 2008; Sen-Banerjee et 
al., 2005). With respect to KLF2, researchers have also reported that atheroprotective laminar 
shear stress, through suppression of miR-92a, can up-regulate endothelial TM via KLF2-
 46 
dependent transactivation of the TM promoter (Dekker et al., 2002; Wu et al., 2011). 
Interestingly, the pleiotropic up-regulation of endothelial TM by statins was only observed 
under atheroprotective shearing conditions (consistent with miR-92a suppression and KLF2 
induction), and not under conditions of atherogenic oscillatory shear (Rossi et al., 2011). 
These collective observations suggest that statin-mediated pleiotropic effects on TM are 
restricted to shear-protected regions of the endothelium and putatively involve suppression of 
miR-92a. They also lead one to speculate that anti-miR-92a-driven TM up-regulation, used in 
conjunction with statins, may be a potentially viable future therapeutic approach for the 
improved treatment of vascular pathologies manifesting elevated endothelial thrombogenicity. 
 
1.3 Rationale for project 
 
 Circumferential cyclic strain is an important moderator of the biochemical and 
physical properties of the endothelium and the entire vasculature in general (Cheng et al., 
2001; Howard et al., 1997; Matsushita et al., 2001). Dysregulation of cyclic strain (e.g., 
attenuated, elevated, altered pulsatility) can affect vessel wall health and normal remodeling 
processes (Chen et al., 2008). It can also lead to endothelial dysfunction and cardiovascular 
diseases including hypertension (Li et al., 2010), atherosclerosis (Hahn and Schwartz, 2009), 
coronary heart disease (Tineli et al., 2007) and vein graft rejection (Sperry et al., 2003). 
Thrombomodulin is clearly critical to endothelial function (Adams and Huntington, 2006; 
Conway, 2011; Esmon, 2003).  Interestingly, elevated levels of cyclic strain have been 
correlated to increased thrombomodulin release (Kim et al., 2002). However, extremely 
limited in vitro and in vivo studies document this release (Chen et al., 2008; Feng et al., 1999; 
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Golledge et al., 1999; Gosling et al., 1999; Kapur et al., 2011; Sperry et al., 2003), whilst the 
pathway involved still remains unclear. Furthermore, there are limited studies on the effect of 
cyclic strain on TM expression.  
 
Biomechanical force TM expression TM release 
Shear stress 
 
↑ (Takada 1994; Bergh 
2009; Wu 2011) 
? 
Cyclic strain ↑ in vitro (Chen et al., 
2008) 
 
↓ in vivo vein grafts 
(Sperry et al., 2003) 
? 
Soluble TM (sTM) NA ↑ in DIC, 
hypertension (Lin 
et al., 2008; 
Lopes et al., 
2002) 
 
↓ in type-2 
diabetes, 
coronary heart 
disease (Thorand 
et al., 2007; Wu 
et al., 2003) 
 
Table 1.2: Current literature documenting the effect of hemodynamic forces on TM 
expression and release. The symbols used represent the following; ↑, increased; ↓, decreased; 
+/-CS, in the absence or presence of cyclic strain; NA, not applicable. 
 
 
 
 48 
1.4 Objectives  
 
With this in mind, a clearer understanding of how cyclic strain modulates TM production and 
release within the vascular endothelium is warranted. Our basic objectives are:  
  
1. To understand how cyclic strain regulates thrombomodulin release and expression 
 
2. To identify the signalling components mediating strain-dependent regulation of 
thrombomodulin  
 
3. To understand how inflammatory mediators (e.g., TNF-α) influence strain-induced 
regulation of thrombomodulin  
 
4. To investigate microvesicle involvement in cyclic strain-mediated thrombomodulin 
release whilst more clearly clarifying whether thrombomodulin is released from the 
membrane via exosomes or microparticles  
 
 The data presented in the subsequent chapters investigates; (i) the regulatory effect of 
equibiaxial cyclic strain on TM in cultured HAECs; (ii) the role played by inflammatory 
mediators (e.g., TNF-α and ox-LDL) on the strain-mediated regulation of TM expression and 
release; a range of signalling mechanisms were also studied to determine their involvement in 
both cyclic strain-mediated regulation of TM expression and release; and (iii) the putative role 
of both MPs and exosomes as microvesicular vehicles for TM release in response to strain. 
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Chapter 2: 
Materials & Methods 
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2.1 Materials 
 
Abcam (MA, USA): Mouse anti-thrombomodulin monoclonal IgG antibody, human 
thrombomodulin ELISA kit  
 
Acris antibodies (Herford, Germany): Rabbit anti-human CD141/THBD 
 
Aktiengeselischaft and Company (Numbrecht, Germany): T25/75/175 tissue culture 
flasks, 1.5 ml micro tube with safety cap, 6-well and 96-well tissue culture plates, 2 ml 
blowout pipette, 2 ml, 5 ml, 10 ml and 25 ml serological pipettes, 10, 20 and 1000 µl pipette 
tips, 15 ml and 50 ml falcons, 50 ml flat-bottom falcons, cryovials, cell scrapers, P100 tissue 
culture dishes. 
 
Applied Biosystems (CA, USA): Fast optical 96-well reaction plates (with adhesive covers), 
high capacity cDNA reverse transcription kit 
 
BioRad (CA, USA): Coomassie stain, Precision Plus protein marker, thick mini trans-blot 
filter paper 
 
Bio-Sciences Ltd (Dun Laoghaire, Ireland): F96 immuno plate II maxisorp 
 
Biotrend Chemikalien Gmbh (Köln, Germany): Oxidized low-density lipoprotein 
 
Calbiochem (San Diego, CA): Apocynin 
 
Corriell Cell Repository (NJ, USA): Bovine aortic endothelial cells (BAECs) 
 
Dunn Labortechnik GmBH (Germany): Bioflex® plates (Pronectin® -coated) 
 
eBioscience (CA, USA): Il-6 ELISA kit 
 
Enzo Life Sciences (NY, USA): GM6001 
 
Eurofins MWG Operon (Ebersburg, Germany): Human primer sets: eNOS, GAPDH, 
KLF2, S18, Thrombomodulin 
 
Fermentas (York, UK): Green Taq, DNA ladder 100 bp and 1 Kb, dNTPs, 10X Buffer, 
MgCl2 
 
GE-Healthcare (Bucks, UK): ECL secondary antibodies; donkey anti-rabbit, sheep anti-
mouse 
 
Gibco (Scotland, UK): UltraPUR™ Distilled water DNAse-/RNAse-free  
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Invitrogen (Bio-Sciences) (Groningen, The Netherlands): Propidium iodide (PI), 
SyberSafe®, Total exosomes isolation reagent, Trizol® reagent, Vybrant™ FACs apoptosis 
assay kit #2, ultra pure water 
 
Labtech (East Sussex, UK): ADAM™ counter kit 
 
Merck Millipore (MA, USA): Rabbit anti-sheep IgG HRP-conjugated secondary antibody  
 
Meso Scale Discorvery (MD, USA): K15009C-1 MS2400 Human Pro-inflammatory panel 1, 
Ultrasensitive ELISA kit, K15135C-1 MS2400 Human vascular injury panel I, Ultrasensitive 
ELISA kit 
 
Millipore (MA, USA): Amicon Ultra 2ml 30K 24PK, Luminata™ Crescendo Western HRP 
Substrate, tumour necrosis factor-α (TNF-α) 
 
PALL Corporation (Dun Laoghaire, Ireland): Acrodisc 32 mm syringe filter with 0.2 µM 
super membrane, biotrace nitrocellulose membrane 
 
Promocell (Heidelberg, Germany): Cryo-SFM, Endothelial cell growth media MV, Human 
aortic endothelial cells (HAECs) 
 
R&D Systems (MN, USA): Human thrombomodulin/BCDA-3 Duoset ELISA, sheep anti-
human thrombomodulin antibody 
 
Roche Diagnostics (Basel, Switzerland): FastStart universal SYBR green (ROX), protein 
and phosphatase inhibitor cocktail 
 
Sigma-Aldrich (Dorset, UK): Autoradiography Kodak developing and fixer solutions, 
acetone, agarose, ammonium persulfate, β-mercaptoethanol, bisacrylamide, bromophenol 
blue, chloroform, CL-Xposure film 125 mm X 175 mm, dimethyl sulfoxide, DNAse 
amplification kit, EDTA, glucose, glycerol, glycine, HEPES, hydrochloric acid, Lauryl sulfate 
(i.e., SDS), magnesium sulphate, methanol, PBS tablets, penicillin-streptomycin (100X), 
Ponceau S, potassium chloride, potassium phosphate, potassium phosphate-dibasic trihydrate, 
potassium hydroxide, sodium chloride, sodium deoxicholate, sodium fluoride, sodium 
orthovanadate, sodium phosphate, sucrose, superoxide dismutase, tetramethylethylenediamine 
(TEMED), 3,3',5,5'-tetramethylbenzidine liquid substrate, trypsin-EDTA solution (10X), 
Triton® X-100, trizma base, tryptone, Tween® 20. 
 
Qiagen (West Sussex, UK): SYBR Green® PCR kit 
 
Technoclone GmbH (Vienna, Austria): Technozym® von Willebrand factor:Ag ELISA kit 
 
Thermo Fisher Scientific (Leicestershire, UK): BCA protein assay kit, bovine serum 
albumin (BSA), Taq DNA Polymerase, isopropanol, trizma base, weigh boats, Supersignal 
West Pico chemiluminescent substrate, restore Western blot stripping buffer, RNase Away 
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2.2 Cell culture methods 
  
All cell culture procedures were carried out in a clean and sterile environment using a 
Holten Lamin-Air laminar flow cabinet. Cells were examined daily for growth and 
morphology characteristics using a Nikon Eclipse TS100 phase-contrast microscope.  
 
2.2.1 Endothelial cells 
 
2.2.1.1 Culture of human aortic endothelial cells (HAECs) 
 
Differentiated human aortic endothelial cells (HAECs) were obtained from PromoCell 
GmbH (Heidelberg, Germany). The cells were isolated from a 22 year old female donor. Cells 
were cultured in Endothelial cell growth medium MV supplemented with antibiotics (100 
U/ml penicillin and 100 µg/ml streptomycin) and a separate Supplement Mix® of growth 
factors containing fetal calf serum (FCS) (0.05 ml/ml), endothelial cell growth supplement 
(0.004 ml/ml), epidermal growth factor (10 ng/ml), heparin (90 µg/ml), and hydrocortisone (1 
µg/ml). Cells between passages 5-11 were used for experimental purposes and were stored in 
a humidified atmosphere of 5% CO2/95% air at 37oC (Fig 2.1). 
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2.2.2 Trypsinisation of HAECs 
 
HAECs are an adherent cell line so trypsinisation is necessary for their sub-culture. 
Growth media was removed from the flasks and the cells were washed X3 sterile PBS to 
remove α-macroglobulin, a trypsin inhibitor present in FCS. An appropriate volume of 
trypsin/EDTA (10% volume in sterile PBS) was subsequently added to the cells and incubated 
at 37oC for 1-2 mins until the cells begin to detach from the flask surface. Trypsin was 
inactivated by the addition of complete growth media containing FCS and the cells were 
removed from suspension by centrifugation at 0.1 rcf for 5 min. Cells were resuspended in 
growth medium (or freeze medium) and counted using either a Neubauer chamber 
haemocytometer or ADAM™ Counter. HAECs were routinely split at a 1:3 or 1:4 ratios for 
either further sub-culturing or to be cryopreserved. 
 
 
 
Figure 2.1: HAECs are isolated from the human ascending (thoracic) and descending 
(abdominal) aorta. They have a “cobblestone” morphology when static, as shown above.   
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2.2.3 Cryopreservation and recovery of cells 
 
For long-term storage, cells were maintained in a liquid nitrogen cryo-freezer unit 
(Taylor-Wharton, USA). Following trypsinisation, cells to be stored were centrifuged at 0.1 
rcf for 5 min at room temperature and the resultant pellet was resuspended in HAEC media 
containing 20% (v/v) FBS, 10% (v/v) dimethylsulphoxide (DMSO) and 1% (v/v) 
penicillin/streptomycin. 1.5 ml aliquots were transferred to sterile cryovials and frozen in a –
80°C freezer at a rate of –1°C/minute using a Mr Freeze® cryo-freezing container. Following 
overnight freezing at –80°C, the cryovials were transferred to the cryo-freezer unit. 
For recovery of cells, cryovials were thawed rapidly in a 37°C water bath and added to 
a cell culture dish containing pre-warmed (37°C) growth medium to dilute the DMSO. After 
24 hrs the medium was removed, the cells were washed in PBS and fresh growth medium 
added. 
 
2.2.4 Cell counting 
 
2.2.4.1 Haemocytometer 
 
To aid in reproducibility of experiments, cells were seeded at precise numbers and 
densities. This was done using a Neubauer chamber haemocytometer following trypan blue 
staining for cell viability (Fig 2.2). 20 ml of trypan blue was added to 100 ml of cell 
suspension and the mixture left to incubate for 2 min. 20 ml of this mixture was loaded into 
the counting chamber of the haemocytometer and cells visualized by light microscopy (Fig 
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2.1). Viable cells excluded the dye, whilst dead cells stained blue due to compromise of the 
cell membrane. Cells that touch the top and right lines of a square were not counted, while 
cells on the bottom and left side were counted. The number of cells was calculated using the 
following equation: 
 
Average Cell No. x Dilution Factor x 1x104 (area under cover slip mm3) = Viable cells/ml 
 
 
Figure 2.2: The haemocytometer, indicating the counting grid. 
 
2.2.4.2 ADAM™ cell counter  
 
Cell counts were also made using an Advanced Detection and Accurate Measurement 
(ADAM™) cell counter (Digital Bio, Korea) that utilises fluorescent cell staining to determine 
total and viable cell count in a given sample (Fig 2.3). Cells are mixed with two solutions; 
Solution N, containing propidium iodide (PI), a fluorescent dye that will intercalate with 
DNA, but which cannot enter cells with intact membranes. Therefore, only non-viable cells 
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will fluoresce with PI alone. The second, Solution T, contains PI and a detergent that will 
disrupt viable cell membranes allowing PI to stain both viable and non-viable cells. ADAM™ 
contains both laser optics and image analysis software that allows parallel determination of 
both total and viable cell numbers in a sample from these two staining methods.  
Two 12 µl aliquots of a cell sample were taken; one aliquot was mixed with 12 µl of 
Solution N accustain and the second with 12 µl Solution T accustain. 20 µl of each cell 
mixture was then loaded into the appropriate labelled chamber in an AccuChip. The AccuChip 
was then loaded into the ADAM™ counter where 40-60 images were taken of the cell 
chambers and average cell number and viability calculated using the integrated image analysis 
software (Fig 2.3). 
 
 
      
 
Figure 2.3: The ADAM™ counter (A) and loading of an AccuChip and reading (B). 
 
 
 
 
A B 
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2.2.5 Hemodynamic force studies  
 
2.2.5.1 Cyclic strain: Flexercell® Tension Plus™ FX-4000T™ System 
 
 
 
 
Figure 2.4: Flexercell® Tension Plus™ FX-4000T™ system. 
 
For cyclic strain studies, HAECs were seeded onto 6-well Bioflex® plates at the 
appropriate seeding density (300,000 – 500,000 cells/well). Bioflex® plates have a flexible 
Pronectin®-coated silicon membrane bottom which can be deformed by microprocessor-
controlled vacuum (Fig 2.4) (Dunn Labortechnik GmbH, Germany). Before the experiment, 
media is replenished and cells are then exposed to equibiaxial cyclic strain. A Flexercell® 
Tension Plus™ FX-4000T™ system (Flexercell International Corp., Hillsborough, NC) was 
used to apply physiological equibiaxial cyclic strain to each plate (0-12.5% strain, 60 
cycles/min, 0-48 hr, cardiac waveform) as previously described (Collins et al., 2006; von 
Offenberg Sweeney et al., 2004). Post-strain, media supernatants, cell lysates, and mRNA 
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samples were harvested for analysis. Media supernatants were harvested per each individual 
well whereas 2-3 wells were frequently pooled for each cell lysate or mRNA sample.     
Both dose-response and time-course studies were carried out. Control plates 
containing “unstrained” endothelial cells were also seeded into Bioflex® plates in the same 
manner and kept in the same incubator as the strained cells. Following cyclic strain 
experiments, cells were either; (i) harvested for Real-Time PCR measurement of mRNA; (ii) 
harvested for ELISA measurement of secreted protein concentration in the supernatant or; (iii) 
harvested for Western blotting to determine protein expression levels. 
 
2.2.5.2 Laminar shear stress: Orbital Rotation 
 
For laminar shear stress studies, orbital rotation was applied as described in other 
publications (Fitzpatrick et al., 2009; Colgan et al., 2007). HAECs were seeded at 300,000 
cells/well onto 6-well plates and grown to confluency. Culture medium was removed and 
replenished with 4 ml of fresh medium. Cells were then exposed to laminar shear stress (0-10 
dynes/cm2, 0-24 hr) using an orbital rotator (Stuart Scientific Mini Orbital Shaker, 
Staffordshire, UK), with shear determined by the following equation (Hendrickson et al., 
1999);  
Control plates containing un-sheared “static” endothelial cells were cultured in the 
same incubator but on a different shelf to avoid vibrations caused by the orbital rotator. 
Studies were carried out for differing periods of time (0-48 hrs, 0–10 dynes/cm2). Following 
shearing experiments, cells were either; (i) harvested for Real-Time PCR measurement of 
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mRNA expression levels or; (ii) harvested for ELISA measurement of secreted protein 
concentration in the supernatants.  
 
 
 
Where        α = radius of rotation in cm 
                   ρ = density of liquid in g/l  
                   f = rotation per second 
                   n = liquid viscosity 7.5 x 10-3 dynes/cm2 @ 37°C 
 
2.2.6 Transendothelial permeability assay 
 
To measure permeability, HAECs were trypsinised and re-plated at high density 
(500,000 cells/well) into Millicell hanging cell culture inserts (6-well format, 0.4 µm pore 
size, 24 mm filter diameter). After 24 hrs, cells were attached to the surface of the membrane 
and transendothelial permeability was analysed as previously described (Collins et al., 2006). 
Fluorophore media was prepared with 1 ml of media and 5 mg (0.0050 g) of FITC-Dextran. A 
working solution of FITC-Dextran was prepared as follows; 
250 µg/ml/5000 µg/ml = 0.05 ml = 50 µl 
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Figure 2.5: Transendothelial permeability assay. (A) Shows FITC-labelled dextran in the 
upper (abluminal) compartment at t=0, which diffuses through the HAEC monolayer and 
semi-permeable membrane, into the lower (subluminal) compartment (B), from which 
samples are collected every 30 min over 3 hrs.  
 
The final volume is per ml of solution that you are working with, so you need to 
multiply by 2 (for each insert) and then by the numbers of wells you intend to use (i.e., 2 
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mls*number of wells + 1). The FITC-Dextran solution was sterilized before application to 
cells using a syringe fitted with a sterile filter. Fresh culture media was added to the upper 
(abluminal) and lower (subluminal) chambers of the Millicell insert within the 6- well dish 
(e.g., 2 ml: upper, 4ml: lower). For the purpose of testing for functional sTM, the upper 
(abluminal) chambers were “spiked” with 250 µg/ml of concentrated media (described in 
more detail in Section 5.2.1.5) in the presence or absence of thrombin (1 unit) for 30 mins at 
37oC. Subsequently, the media is aspirated and replaced with 4 mls of fresh media in the 
subluminal chamber and 2 mls of fluorophore media in the abluminal chamber. Transwell 
diffusion was allowed to advance (Fig 2.5).  
Medium samples (28 µl) were collected every 30 min from the subluminal 
compartment (for up to 3 hrs), diluted to a final volume of 400 µl with complete medium, and 
examined for FITC-dextran fluorescence (as 3x100 µl replicates in a 96-well fluorescence 
microplate). Using a TECAN Safire 2 fluorospectrometer (Tecan Group, Switzerland), 
excitation and emission wavelengths of 490 and 520 nm, respectively, were chosen. % 
Transendothelial exchange (%TE) of FITC-dextran 40 kDa is expressed as the total 
subluminal fluorescence at a given time point (from 0-180 min) expressed as a percentage of 
total abluminal fluorescence at t=0 min.     
 
2.2.7 Inhibitors and inflammatory mediators 
 
In order to probe the signaling pathway putatively mediating the effects of cyclic 
strain on TM expression and release, inhibitor studies were performed on HAECs in the 
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absence or presence of cyclic strain. We also investigated the effect of inflammatory 
mediators on cyclic strain mediated TM expression and release. Prior to treatment with 
pharmacological inhibitors or inflammatory mediators, HAECs were grown to 80% 
confluency on Bioflex® plates for cyclic strain studies or 6-well dishes for static cell studies, 
after which growth medium was removed and cells were washed twice in sterile PBS. 
Inflammatory mediators (Table 2.1) or inhibitors (Table 2.2) were re-constituted in a suitable 
diluent. Working concentrations were made up in Endothelial Cell Growth Medium MV with 
addition of antibiotics and Supplement Mix®. Cells were then exposed to inhibitors for 1 hr 
prior to, and for the duration of, hemodynamic challenge. Inhibitor concentrations used in 
experiments were taken from recent literature and manufacturer’s recommendations.  
For inflammatory mediator studies (Table 2.1), cells were incubated in culture media 
containing; 
 
Inflammatory component Type Conc. Used 
TNF-α Pro-inflammatory cytokine 0-100 ng/ml 
Ox-LDL Atherogenic lipid 0-145.7 µg/ml 
Glucose Hyperglycemia 5-30 mM 
 
Table 2.1: Inflammatory mediator and concentrations used in HAECs. 
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For inhibitor studies (Table 2.2), cells were incubated in culture media containing; 
 
Target Inhibitor Conc. 
MMPs GM6001 10 µM 
Integrin ανβ3 Cyclic RGD integrin inhibitor 130 µM 
Rhomboids DCI 10 µM 
eNOS L-NAME 1mM 
Rac1 NSC23766 50 µM 
NADPH oxidase Apocynin 
SOD 
10 µM 
100 U/ml 
Erk 1/2 PD98059 10 µM 
p38 PD169316 10 µM 
PI3K PI3K-α In. 2 µM 
Protein Tyr Kinase Genistein 2 µM 
 
Table 2.2: Pharmacological inhibitors blocking specific cellular targets and concentrations 
used in HAECs.   
 
2.2.8 Fluorescence Activated Cell Sorting (FACs) analysis 
 
Flow cytometry is a process used to characterize the properties of fluorescently 
labelled cells. It gives information about cell size, granularity, and the phenotypic expression 
of protein markers on or in a particular cell, as well as the proliferative, apoptotic and necrotic 
state of cells in response to different experimental treatments. 
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2.2.8.1 Vybrant™ Apoptosis Assay Kit 
 
A Vybrant™ Apoptosis Kit #2 was used to monitor apoptosis in HAECs following 
cyclic strain experiments. The kit contains an Alexfluor488-conjugated recombinant Annexin 
V and a red-fluorescent Propidium Iodide (PI) nucleic acid-binding dye. The Alexafluor488 
dye is an almost perfect match to Fluorescein IsoThioCyanate (FITC), but it creates brighter 
and more photostable conjugates. PI stains necrotic cells (but not live apoptotic cells) with red 
fluorescence, binding tightly to the nucleic acids in the cell. After staining a cell population 
with Alexafluor488-conjugated Annexin V and PI in the provided binding buffer, apoptotic 
cells show green fluorescence, dead cells show red and green fluorescence, and live cells 
show little or no fluorescence. These populations can easily be distinguished using a flow 
cytometry with the spectral line of an argon-ion laser set for 488 nm excitation. 
HAECs were seeded onto Bioflex® plates and allowed to grow for 24 h. Cyclic strain 
was applied to cells as described above for 24 h. After the treatment, HAECs were washed in 
PBS three times and harvested by trypsinisation. Cell counts were carried out on each well 
using both the haemocytometer and Adam™ Cell counter. Afterwards, cell suspensions were 
pelleted by centrifugation (700 rcf for 5 min) and washed again in 1 ml PBS (containing 0.1% 
BSA) and re-suspended by gentle pipetting. Cells were subsequently pelleted by 
centrifugation and re-suspended in 200 µl of 1X Annexin-binding buffer. Propidium Iodide 
(0.4 µl from 100 µg/ml working solution) and 1 µl Alexafluor488 Annexin V were added to 
the cell suspension and incubated at room temperature for 15 min. Cells were then placed on 
ice pending flow cytometry analysis using a Becton Dickinson FACSCAN flow cytometer 
(NJ, USA).     
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2.2.9 Membrane vesicle analysis 
 
Cells are known to secrete or shed a large variety of vesicles such as microparticles 
and exosomes into the extracellular space in normal physiology as well as in activated or 
disease states (Izumi, 2012).  These microvesicles are now emerging as new diagnostic 
biomarkers with possible roles in mediating inflammation and immunological processes. They 
have the unique ability to allow the horizontal transfer of bioactive molecules such as proteins, 
RNAs and microRNAs, to neighbouring cells via outward budding and fission of the plasma 
membrane of the host cell (Cocucci et al., 2009).  
Microparticles (MPs), also referred to as microvesicles, particles, shedding vesicles or 
ectosomes, are small complex membrane-enclosed structures (measuring 100 nm to 1 mm) 
that can be “shed” from the plasma membrane of activated or apoptotic endothelial cells. In 
contrast, exosomes are small intracellularly derived vesicles (30-120 nm) containing RNA and 
protein that are “secreted” by a wide variety of cell types and detected in body fluids including 
blood, saliva, urine and breast milk. Both the type of stimulus and the originating cell 
determine the vesicle composition (Fleissner et al., 2012). Levels of these vesicles were 
measured in response to cyclic strain using a combination of centrifugation and isolation 
techniques described below.  
 
2.2.9.1 Centrifugation techniques 
 
Post-cyclic strain, media supernatants were harvested per well as before. All media 
samples were spun at 98 rcf for 5 mins at 4oC to remove cellular debris. 110 µl of each sample 
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was transferred to a fresh eppendorf for ELISA analysis. The media samples were then spun at 
700 rcf for 15 mins at 4oC to further eliminate cellular debris, then at centrifugation speeds 
ranging from 14,400-20,000 rcf for 20 and 40 minutes, respectively. The supernatants were 
collected for analysis and the pellets (containing microparticle fractions) were re-suspended in 
1 ml or 110 µl of 1X PBS for downstream analysis. All samples were monitored for 
thrombomodulin using a Human Thrombomodulin/BDCA-3 DuoSet® ELISA kit (R&D 
Systems, MN USA). The steps used to process microvesicles are illustrated by a flow-chart in 
Fig 5.2. 
 
2.2.9.2 Exosome isolation   
 
Culture media Reagent 
1 mL 500 µl 
10 mL 5 mL 
 
Table 2.3: 0.5 volumes of Total Exosome Isolation reagent (Invitrogen, The Netherlands) was 
added to the appropriate volume of cell culture media. 
 
Post cyclic strain, media supernatants were harvested per well as before. Samples were 
initially spun at 98 rcf for 5 mins at 4oC, followed by a further spin at 2000 rcf for 30 mins to 
remove cells and debris. The clear cell-free supernatant was transferred to a new eppendorf. 
Total Exosome Isolation (Invitrogen, The Netherlands) reagent was then added in 0.5 volumes 
to the cell culture media (Table 2.3). This reagent forces less-soluble components (i.e., 
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exosomes) out of solution, allowing them to be collected after brief, low-speed centrifugation. 
After this, the eppendorfs were vortexed several times and incubated overnight with Total 
Exosome Isolation reagent at 2 oC to 8 oC. After incubation, 120 µl of media, now known as 
“pre-spin” media, was transferred to a fresh eppendorf. The remaining media was centrifuged 
at 10,000 rcf for 1 hour at 2oC to 8oC. Following this spin, the supernatant, now known as 
“post-spin” media, was transferred to a new eppendorf for further analysis. Exosomes were 
contained in the pellet (not visible) at the bottom of the tube and then re-suspended in 25 – 
100 µl 1X PBS. TM concentration was measured in the re-suspended pellet, the post- and pre- 
spin media using the Human Thrombomodulin/BDCA-3 DuoSet® ELISA kit (R&D Systems, 
MN USA). The steps used to process microvesicles are illustrated by a flow-chart in Fig 5.4. 
 
2.2.9.3 Media concentration 
 
 
 
 
Figure 2.4: Amicon® Ultra-2 centrifugal filter device (Millipore, MA, USA). 
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In order to further investigate TM release, we concentrated serum-free cell culture 
media for analysis via Western blotting. Post-cyclic strain, serum-free cell culture media was 
harvested as before and then concentrated using Amicon® Ultra-2 30K Centrifugal Filter 
Devices (Millipore, MA USA) according to the manufacturer’s instructions (Fig 2.6). This 
device processed volumes up to 2 mls with a 30K (30,000 NMWL) cutoff point, thus not 
allowing biomolecules with molecular weights lower then 30 kDa to pass through.  Firstly, the 
empty filter device, filtrate collection tube and concentrate collection tube are separately 
weighed before use. After addition of approximately 2 mls cell culture media, the assembled 
unit is re-weighed. The filter device is centrifuged for 20 mins in a swinging bucket rotor at 
3220 rcf. The filter device is then removed from the centrifuge and the Amicon® Ultra filter 
unit is separated from the filtrate collection tube. To recover the concentrated solute, invert the 
filter unit and concentrate collection tube, and spin for 2 mins at 1000 rcf to transfer the 
concentrated sample from the filter device to the tube. After the spin, the filter unit is removed 
from the concentration collection tube and the filtrate and collection tube are weighed again. 
The weight of the empty device/tubes is subtracted from this new value in order to calculate 
weights of the starting material, filtrate and concentrate. This direct weighing procedure 
allowed us to quantify recoveries. This concentrated media (approximately 30-40 µl) was also 
analysed for protein concentration via a Bicinchoninic acid (BCA) assay, and subsequently 
employed for Western blotting.  
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2.3 mRNA Preparation and Analysis 
 
2.3.1 An RNase-free environment 
 
As RNA is susceptible to degradation by ubiquitous RNases, standard procedures 
were utilised to avoid this potential hazard (Sambrook et al., 1989). Before working with 
RNA, any apparatus or surfaces to be used were treated with RNase AWAY spray (Thermo 
Fisher, Leicestershire, UK) to remove RNases. As hands are a major source of RNase 
contamination, gloves were used at all times and changed regularly. Pipette tips, eppendorfs, 
PBS and buffers were also autoclaved to avoid RNase contamination. 
 
2.3.2 RNA preparation 
 
Following cyclic strain or shear stress experiments, mRNA is harvested. Trizol® is a 
ready-to-use reagent for the isolation of total RNA, DNA and/or protein from cells and tissues 
based on the technique developed by Chomczynski and Sacchi in 1987. Trizol® maintains the 
integrity of the RNA whilst disrupting cells and dissolving subcellular components.   
Following the treatment, cells are lysed directly in Bioflex® culture plates by the 
addition of 1 ml of Trizol® per 10 cm2. A volume less than this can result in contamination of 
the RNA with DNA. To ensure complete homogenization, cells were lysed by scraping the 
plate with a cell scraper and samples were then incubated for 5 min at room temperature to 
allow complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added per 
1 ml of Trizol® reagent used, then mixed for 15 sec before being incubated for 15 min at room 
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temperature. Samples were then centrifuged at 7969 rcf for 15 min at 4oC. The mixture 
separated into a lower red phenol-chloroform phase, an interphase and an upper colourless 
aqueous phase, which is entirely RNA.  The aqueous phase was carefully removed and 
transferred into a fresh, sterile eppendorf. The RNA was then precipitated out of solution by 
the addition of 0.5 ml of isopropanol per 1 ml of Trizol® used. Samples were inverted 5-8 
times and incubated for 10 min at room temperature and then centrifuged at 7969 rcf for 10 
min at 4°C. The RNA precipitate forms a gel-like pellet on the side of the tube. The 
supernatant was removed and the pellet washed in 1 ml of 75% ethanol per ml of Trizol® used 
followed by centrifugation at 7969 rcf for 5 min at 4°C. The resultant pellet was air-dried for 
5-10 min before being re-suspended in DEPC-treated water. This was then incubated for 10 
min at 60°C, to homogenize the sample prior to quantification. The concentration of total 
RNA was determined using a NanoDrop®, as outlined below. The sample was then stored at –
80°C until used. 
 
2.3.3 The NanoDrop® ND-1000 Spectrophotometer 
 
The NanoDrop® ND-1000 Spectrophotometer was used to measure nucleic acid 
sample concentrations. An undiluted 1.2 µl sample was pipetted onto the end of a fibre optic 
cable (the receiving fibre). A second fibre optic cable (the source fibre) was then brought into 
contact with the liquid sample causing the liquid to bridge the gap between the fibre optic 
ends. (The gap is controlled to both 1 mm and 0.2 mm paths by the computer). A pulsed 
xenon flash lamp generated the light source and a spectrometer was used to analyse the light 
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after passing through the sample. The instrument was controlled by special software run from 
a PC, and the data were logged in an archive file on the PC. 
 
 
 
 
Figure 2.7:  The NanoDrop® machine (A) and typical graph readouts for (B) RNA and (C) 
DNA are shown. 
 
The NanoDrop® automatically calculates the purity of the nucleic acid samples by 
reading the absorbance at 260 nm and the absorbance at 280 nm and then determining the 
ratio between the two (A260/A280) (Fig 2.7). Pure DNA which has no protein impurities has a 
ratio of 1.8 whereas pure RNA has a ratio of 2.0. Lower ratios signify the presence of proteins, 
higher ratios imply the presence of organic reagents. Purification of RNA samples was 
achieved using a DNase treatment kit (Sigma-Aldrich, Dorset, UK) as described below. 
A 
B C 
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2.3.4 DNase treatment of mRNA 
 
The RNA sample for analysis was digested with 1 µl RNase-free DNase I along with 1 
µl 10X DNase Buffer and incubated for 15 min at 37°C. 1 µl DNase stop solution was added 
to the reaction mixture and was incubated for a further 10 min at 70°C to denature the DNase 
enzyme. The sample is then incubated for 5 mins on ice and the RNA could then be 
synthesised to cDNA. 
 
2.3.5 Reverse transcription  
 
In this procedure, mRNA was transcribed into cDNA by the enzyme reverse 
transcriptase. A high capacity cDNA reverse transcription kit (Applied Biosystems, CA, USA) 
was used as described below:  
Reactions were made up as follows;  
 
RT Buffer (10X)                                   2 µl 
dNTP mix (100 mM)                         0.8 µl 
Random primers (10X)                          2µl 
MultiScribe Reverse Transcriptase       1 µl 
Nuclease-free H2O                             4.2 µl 
Final volume                                       10 µl  
 
This mixture was added to a 0.2 ml PCR tube containing 1000 ng RNA diluted in 
nuclease-free water to 10 µl to give a final volume of 20 µl. Samples were spun down briefly 
in a centrifuge and then placed into a PCR machine and run at 25°C for 10 min, 37°C for 120 
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min, and finally 85°C for 5 min. cDNA products were then quantified on a NanoDrop® 
(Section 2.3.3) to check concentration and purity of samples. 
 
2.3.6 Polymerase chain reaction (PCR) 
 
PCR was used to optimize primer sets (Table 2.3) and to rule out primer-dimerisation 
before their use in quantitative Real-Time PCR (qRT-PCR). PCR reaction mixtures were 
prepared as follows:  
 
Forward primer (10 µM)                      1 µl 
Reverse primer (10 µM)                       1 µl 
cDNA sample                                       1 µl 
Reaction buffer (10X)                       2.5 µl 
dNTP (10 mM)                                     2 µl 
MgCl2 (25 mM)                                1.5 µl 
Taq Polymerase                               0.25 µl 
RNase free water                           15.75 µl 
Final volume                                       25 µl 
 
The mixture was then placed into an MJ Mini thermal cycler with hot-lid (Bio-Rad, 
CA, USA). Samples were then subjected to the following cycling conditions:  
 
Denature                                             95°C             5 min 
Cycling           Denature                      95°C           15 sec 
Annealing               55-60°C           30 sec 
Extension                     72°C           15 sec 
Extension                     72°C            5 min 
Hold                               4°C         Forever 
 
 
 
40 cycles 
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2.3.7 Quantitative Real-Time PCR (qRT-PCR) 
 
Target gene Primer sequence Product  
size 
Annealing  
temp 
eNOS For: 5’-GCTTGAGACCCTCAGTCAGG-3’ 
Rev: 5’-GGTCTCCAGTCTTGAGCTGG-3’ 
300 bp 61.4oC 
KLF2 For: 5’-GCACGCACACAGGTGAGAA-3’ 
Rev: 5’-ACCAGTCACATTTGGGAGG-3’ 
200 bp 57oC 
S18 For: 5’-CAGCCACCCGAGATTGAGCA-3' 
Rev: 5’ -TAGTAGCGACGGGCGGTGTG-3' 
250 bp 62oC 
GAPDH For: 5’-GAGTCAACGGATTTGGTCGT-3’ 
Rev: 5’-TTGATTTTGGAGGGATCTCG-3’ 
238 bp 56oC 
TM 
(Chen et Hsu, 
2006) 
For: 5’-ACCTTCCTCAATGCCAGTCAG-3’ 
Rev 5’-GCCGTCGCCGTTCAGTAG-3’ 
107 bp 60oC 
 
Table 2.4: Primer sequences, product size, and optimal annealing temperature used for both 
PCR and qRT-PCR. All primer sets were produced from human sequences and annealing 
temperatures varied, as they were specific to each primer set. GADPH and S18 act as 
endogenous housekeeping gene controls, which may be used to normalise all experimental 
data. During primer optimization, a negative control with no reverse transcriptase (RT) and 
template controls (i.e., no cDNA) was also run with each primer to rule out any cDNA 
contamination of mRNA samples.  
 
Following optimisation of primers (Table 2.4) by routine PCR, they were 
subsequently employed in qRT-PCR. This technique follows the general principle of RT-PCR 
with amplified DNA quantified in real-time as it accumulates in the reaction. The reaction 
uses SYBR green, a dye that fluoresces only when bound to the minor groove of double 
stranded DNA. A laser then reads this fluorescence at the end of every cycle and the amount 
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of cDNA product formed during the PCR cycles can be quantified and graphically visualised 
in real time.  
To normalise the optical system involved in real-time analysis, ROX, a passive dye, is 
incorporated into the SYBR mastermix. This is achieved by the reporter dye’s (SYBR) signal 
being measured against the passive reference dye (ROX) signal to normalise for non-PCR-
related fluorescence fluctuations occurring from well to well. The threshold cycle represents 
the refraction cycle number at which a positive amplification reaction was measured and was 
set at 10 times the standard deviation of the mean baseline emission calculated for PCR cycles 
3 to 15. The results were analysed according to the Comparative CT method (ΔΔCT) as 
described by (Livak and Schmittgen, 2001). An Applied Biosystems 7900HT Fast real-time 
PCR system was used for qPCR. Each reaction was set up in triplicate as shown below: 
 
Forward primer (10 µM)                          1.0 µl 
Reverse primer (10 µM)                           1.0 µl 
cDNA                                                       2.0 µl 
SYBR Green                                          11.5 µl 
RNase free water                                      9.5 µl 
Total volume                         24 µl 
 
 
Samples were then subjected to an initial denaturation step of 95°C for 10 min 
followed by 40 cycles of 95°C for 15 sec and a primer-specific temperature of between 55-
60°C for 1 min. Data were collected during the annealing step. Quantification of cDNA target 
was normalised for differences across experiments/samples using endogenous S18/GAPDH 
housekeeper controls as active reference genes.  
Routinely, melt curve analysis was carried out to ensure single product formation and 
to rule out possible contamination of product by non-specific binding and primer dimerisation. 
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Samples from both RT-PCR and qRT-PCR reactions were then visualized on 1% agarose gels 
as described below. 
 
2.3.8 Agarose gel electrophoresis 
 
Agarose gels were prepared by boiling 1 g of agarose in 100 ml of 1X TAE buffer (40 
mM Tris-Acetate pH 8.2, 1 mM EDTA) to make a 1% gel. After adequate cooling (~60°C), 
10 µl of SYBR Safe (Invitrogen, The Netherlands) was added to the gel, mixed by swirling 
and then poured into a casting rig. A comb was inserted for formation of wells. The gel was 
allowed to cool and polymerise before filling the chamber with 1X TAE and removing the 
comb.  
As the 10X buffer in the RT-PCR reaction already contained a loading and tracking 
dye 15 ml of RT-PCR product was loaded directly to the gel. A 1 Kb or 100 bp DNA ladder 
was also added to one well as a molecular weight marker for reference. The gel was run at 
constant voltage (5 V/cm, usually 100 V) for 1 to 2 hrs. Samples were then visualised using 
the transilluminator settings on a G:BOX (Syngene, UK). Images could then be saved for later 
densitometric analysis. 
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2.4 Immunodetection techniques 
 
2.4.1 Western Blotting 
 
2.4.1.1 Preparation of whole cell lysates 
 
After strain experiments, confluent HAECs were harvested from 6-well Bioflex® 
plates for analysis by cell lysis via the radioimmunoprecipitation assay protocol (Alcaraz et 
al., 1990). On ice, culture media was removed by aspiration and then cells were washed three 
times in chilled PBS. Following complete aspiration of PBS, cells were harvested using a cell 
scraper in radioimmunoprecipitation assay (RIPA) lysis buffer (64 mM HEPES pH 7.5, 192 
mM NaCL, 1.28% w/v Triton X-100, 0.64% w/v sodium deoxycholate, 0.128% w/v sodium 
dodecyl sulfate SDS, supplemented with 0.5 M sodium fluoride, 0.5 M EDTA pH 8.0, 0.1 M 
sodium phosphate, 10 mM sodium orthovanadate, and 1X protease and phosphatase inhibitor 
cocktail) and transferred into a pre-chilled micro-centrifuge tube. Continuous lysate rotation 
was applied for 1hr at 4°C, prior to lysate clarification by centrifugation at 10,000 for 20 min 
at 4°C to sediment any triton-insoluble material. Clarified lysates were subsequently aliquoted 
into fresh tubes and were either stored at -80°C for future analysis or immediately subjected to 
a BCA assay and used for Western blot. 
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2.4.1.2 Bicinchoninic acid (BCA) assay 
 
The BCA assay is a biochemical assay used to quantify the amount of protein in 
solution (Smith et al., 1985). In this assay, Cu2+ reacts with protein under alkaline conditions 
to produce Cu+, which in-turn reacts with BCA to produce a coloured product. Two separate 
reagents were supplied in the commercial kit (Thermo Fisher Scientific); (A) an alkaline 
bicarbonate solution and; (B) a copper sulfate solution. 1 part solution B is mixed with 49 
parts solution A. 200 µl of this mixture is then added to 10 µl of protein lysate or BSA 
standards (standard curve in the range 0-2 mg/ml). The 96-well plate is incubated at 37oC for 
30 minutes and the absorbance read at 562 nm using a Bio-TEK® ELx800 microtitre plate 
reader. The intensity of the coloured reaction product is a direct function of protein amount 
that can be determined by comparing its absorbance value to a BSA standard curve. 
 
2.4.1.3 Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was carried out on HAECs using 10% polyacrylamide gels as described 
by (Laemmli, 1970). Gels were prepared as outlined below in Table 2.5. SDS-PAGE was 
performed using the Mini-PROTEAN Tetra Cell® system (BioRad, CA, USA). The resolving 
gel was poured first, overlaid with distilled water and allowed to polymerize for 20 min. The 
distilled water was removed and the stacking gel was poured over the resolving gel, a comb 
inserted and the gel allowed to polymerize for 15 min. Combs, clamps and gaskets were then 
removed and the gel plates inserted into the electrophoresis chamber. The chamber is then 
filled with the reservoir buffer (25 mM tris, 192 mM glycine, 0.1% SDS, pH 8.3).  
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Component Resolving gel (10%) Stacking gel (5%) 
1.5M Tris-HCL, ph 8.8 1.5 ml  
0.5M Tris-HCL, ph 6.8  750 µl  
40% acrylamide stock 1.5 ml 375 µl 
Distilled water 3 ml 1.85 ml 
10% w/v SDS 60 µl 30 µl 
10% w/v ammonium persulphate 30 µl 15 µl 
TEMED 7 µl 7 µl 
Final volume 6.097 ml 3.027 ml 
 
Table 2.5: SDS-PAGE gel formations: Resolving gel buffer and stacking gel buffers have a 
pH of 8.8 and 6.8, respectively. 
 
Protein concentration of each sample was determined by BCA assay to allow for equal 
protein loading/well. 6X loading buffer (6 g SDS, 30 ml glycerol, 3 ml β mercaptoethanol, 
0.06 g bromophenol blue and 17 ml 1.5 M Tris-HCL, made up to final volume of 50 ml, pH 
6.8) was added to volume - adjusted samples (final volume of sample was 30 µl), which were 
then boiled at 95oC for 5 min and immediately placed on ice. Samples were then loaded onto 
the gel into the appropriate lanes with 3 µl Precision Plus® protein molecular weight marker 
(BioRad). Both samples and protein markers were separated electrophoretically at 100V for 
120 min.  
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2.4.1.4 Electrotransfer to nitrocellulose membrane  
 
The wet or tank transfer method (Towbin et al., 1979) was utilized for electrotransfer 
of proteins to a nitrocellulose membrane. This was accomplished using a Mini PROTEAN® 
Trans Blot Module (BioRad) according to the manufacturer’s instructions. Following 
electrophoresis, the gel was removed and soaked for 10 min in transfer buffer (25 mM tris pH 
8.3, 192 mM glycine, 20% methanol and 0.1% w/v SDS) to remove any SDS complexes that 
might be bound to the gel. Nitrocellulose membrane and Whatmann filter paper were cut to 
the same size as the gel and also soaked in transfer buffer for 5 min. Following the gel and 
membrane pre-soakings, the transfer cassette accompanying the Mini-PROTEAN® 
electrophoresis system (BioRad, CA, USA) was assembled as in Fig 2.8. Once assembled, the 
cassette was checked to be free of air bubbles by rolling a 15 ml test tube over the cassette 
while submerged in transfer buffer to remove any residual bubbles. The cassette was then 
placed in the Trans Blot Module with the correct orientation and subjected to 100 V for 2 hrs 
at room temperature or 40 V overnight at 4oC.  
 
2.4.1.5 Ponceau S staining 
 
Following transfer completion, membranes were soaked in Ponceau S solution for 3 
min with constant agitation to visually confirm uniform transfer of protein. Ponceau S is a 
negative stain, which binds to positively charged amino acid groups of protein. Transferred 
proteins were detected as red bands on a white background. The stain was subsequently 
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removed by gentle washing in dH2O until all the stain has been washed away. The membrane 
was then used for immunological probing. 
 
 
 
Figure 2.8: Wet transfer cassette assembly used to transfer electrophoresed proteins from an 
SDS-PAGE gel to the nitrocellulose membrane. The black coloured side is assembled face 
down, overlaid with a fibre pad, filter paper, resolved gel, nitrocellulose membrane, filter 
paper, and fibre pad, and sealed using the cassette clamp. 
 
2.4.1.6 Immunoblotting and chemiluminescence band detection 
 
Following removal of the Ponceau stain, membranes were blocked for 60 min in 
blocking solution (5% w/v milk in TBS, 10 mM Tris pH 8.0, 150 mM NaCl) and then 
incubated overnight at 4oC with primary antibody (Table 2.6) and gentle agitation. Following 
completion of primary incubations, membranes were washed 3 times for 10 min (30 min in 
total) in wash buffer. Membranes were subsequently incubated with the appropriate secondary 
antibody in TBST (5% milk w/v) for 2 hr with gentle agitation at room temperature. 
Membranes were then washed again using the same conditions described above. 
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Luminata™ Crescendo Western HRP Substrate (Millpore, MA USA) was the 
chemiluminescent substrate used for detection of horseradish peroxidise (HRP)-conjugated 
secondary antibodies. Resulting immunoblots were scanned and densitometric analysis was 
performed using NIH Image v1.61 software to obtain relative comparisons between bands. 
 
1o Ab Species 1o dilution 2o Ab 2o dilution 
GAPDH polyclonal 
(Santa Cruz) 
Rabbit 
monoclonal 
IgG 
1 µg/ml Anti-rabbit-HRP 
conjugated 
1:3000 
TM (Abcam) Mouse 
polyclonal IgG 
10 µg/ml Anti-mouse HRP-
conjugated  
1:3000 
TM (Acris) Rabbit 
polyclonal IgG 
1 µg/ml Anti-rabbit-HRP 
conjugated 
1:3000 
 
Table 2.6: Optimized primary and secondary antibody dilutions for proteins monitored by 
Western blots. 
 
2.4.1.7 Coomassie gel staining 
 
Coomassie gel staining was routinely used to visualise protein bands on an SDS-
PAGE gel. This is a useful technique to ensure that the transfer method worked as expected. 
In brief, the SDS-PAGE gel was treated with filtered (0.25 µM) coomassie solution whilst 
rocking for approximately 4 hrs. The gel was then de-stained, whilst rocking, in a methanol: 
acetic acid (50:50) solution until the protein bands appeared clear and distinct with no 
background staining, changing the de-stain solution regularly. 
 
 
 83 
2.4.2 ELISA 
 
2.4.2.1 ELISA analysis 
 
The enzyme linked immunosorbent assay (ELISA) is used for the detection and 
quantification of cellular proteins and proteins secreted by activated cells in culture into the 
tissue culture media. A protein-specific capture antibody is immobilized onto a high protein 
binding capacity ELISA plate which enables the capture of the target protein (Fig 2.9). The 
captured protein is detected by a biotinylated antibody, which recognizes a distinct epitope. 
The sandwiched target protein is then quantified using a colourimetric reaction based on 
activity of avidin-horseradish peroxidase (bound to the biotinylated secondary antibody) on a 
specific soluble substrate. The coloured end product is read by a spectrophotometer. All 
ELISA’s outlined below were sandwich-based immunoassays and were carried out according 
to manufacturer’s instructions. 
 
 
Figure 2.9: Principles of sandwich-based ELISA immunoassays. 
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2.4.2.2 Thrombomodulin Human ELISA Kit 
 
The Thrombomodulin Human ELISA Kit (Abcam, MA USA) was used for the 
determination of thrombomodulin protein released into culture media. This assay has the 
ability to recognize both natural and recombinant thrombomodulin variants. 
 
2.4.2.3 Human Thrombomodulin/BDCA-3 DuoSet® ELISA 
 
The Human Thrombomodulin/BDCA-3 DuoSet® ELISA kit (R&D Systems, MN 
USA) contains the basic components necessary for the development of sandwich ELISA to 
measure both natural and recombinant human thrombomodulin in cell culture supernatants 
and lysates. The protocol followed was provided by the manufacturer and each step is 
followed by a wash/aspiration step as described in the manual (not including before the 
addition of the stop solution). Media supernatants and cell culture lysates were harvested for 
ELISA analysis from each well of all 6-well Bioflex® plates.  
F96 maxisorp Nunc-Immuno 96-well plates (Bio-Sciences Ltd, Ireland) were coated 
with 50 µl of the capture antibody per well and incubated overnight at room temperature. The 
plate was then blocked by adding 150 µl of Reagent Diluent to each well and incubated for 1 
hour at room temperature. Cell culture lysates were diluted 1:20 in 25% FCS in 1X PBS 
before addition to ELISA. Subsequently, 50 µl of the sample (undiluted media supernatants or 
diluted cell lysates) or TM standard were added to each well in duplicate and incubated for 2 
hours at room temperature. The standards range from 31.25 to 2000 pg/ml of human 
thrombomodulin. 50 µl of the detection antibody was added to each well and then incubated 
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for 2 hours at room temperature. Following this, 50 µl of streptavidin-HRP was dispensed to 
each well and incubated for 20 minutes at room temperature in the dark. 50 µl of substrate 
solution was added to each well and incubated for 20 minutes at room temperature in the dark. 
With the addition of 25 µl of stop solution to each well, the reaction was terminated and the 
plate read using at both plate reader at both 570 and 450 nm. Wave correction is used to 
subtract the readings at 570 nm from 450 nm (corrects for optical imperfections in the plate). 
The reaction generates a coloured product, which is a direct function of the total measured TM 
concentration (media samples or cell lysates) that can be determined by comparing its 
absorbance value to a standard curve. 
 
2.4.2.4 Multiplex ELISA 
 
Multi-Array® Technology (Meso Scale Discovery, MD USA) is a multiplex 
immunoassay system that enables the measurement of biomarkers using 
electrochemiluminescent detection. In an MSD® assay, specific capture antibodies for the 
analytes are coated in arrays in each well of a 96-well carbon electrode plate surface. The 
detection system uses patented SULFO-TAG™ labels, which emit light upon electrochemical 
stimulation initiated at the electrode surfaces of the Multi-Spot® plates. The electrical 
stimulation is decoupled from the output signal, which is light, to generate assays with 
minimal background. MSD labels, which are stable and non-radioactive, can be conveniently 
conjugated to biological molecules. Additionally, only labels near the electrode surface are 
detected, enabling non-washed assays.  
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The MSD assays only require minimal sample volume as compared to a traditional 
ELISA (which is limited by its inability to measure more than one analyte). With an MSD 
assay, four different biomarkers can be analyzed simultaneously using as little as 10-25 µl of 
sample. These assays have high sensitivity, up to five logs of linear dynamic range, and 
excellent performance in complex biological matrices. This allows the measurement of native 
levels of biomarkers in normal and diseased samples without multiple dilutions. In order to 
investigate the effect of elevated cyclic strain on vascular and proinflammatory biomarkers, 
we used two custom-made plates; a human proinflammatory panel (measuring IFN-γ, IL-1β, 
IL-6 and TNF-α) and a human vascular injury panel (measuring sICAM-3, E-selectin, P-
selectin and TM). 
 
2.4.2.4.1 Human ProInflammatory-I Ultra-Sensitive 96-Well Multi-Spot® 
Plate 
  
The Human ProInflammatory I 4-Plex Assay detects proinflammatory targets in a 
sandwich immunoassay format (Meso Scale Discovery, MD USA). This assay consists of a 
plate, which is pre-coated with four capture antibodies on spatially distinct spots specific for 
IFN-γ, IL-1β, IL-6 and TNF-α (Fig 2.10).   
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Figure 2.10: Human ProInflammatory I 4-Plex Multi-Spot® Plate.  
 
Firstly, the plate was blocked by dispensing 25 µl of the diluent into each well and 
then incubating for 30 minutes with vigorous shaking (9-98 rpm) at room temperature. The 
sample, either media supernatant or cell lysate, was diluted 1:2 with Endothelial Cell Growth 
Media MV. 25 µl of each calibrator and diluted sample is added to each well in triplicate and 
duplicate respectively. The calibrators used a range from 0.61 to 10,000 pg/ml and contain 
labelled detection antibodies for anti-IFN-γ, anti-IL-1β, anti-IL-6 and anti-TNF-α, labelled 
with an electrochemiluminescent compound, MSD SULFO-TAG™. The plate was then 
incubated for 2 hours with vigorous shaking (9-98 rcf) at room temperature. Analytes in the 
samples bind to capture antibodies immobilized on the working electrode surface. 
Subsequently, 25 µl of the detection antibody was added to each well and left to incubate for 2 
hours with vigorous shaking at room temperature. Target analytes subsequently bound to the 
labelled detection antibodies to complete the sandwich. 150 µl of MSD read buffer was added 
to each well, which provides the necessary chemical environment for 
electrochemiluminscence. The plate was loaded onto the MSD SECTOR® instrument where a 
voltage applied to the plate electrodes caused the labels bound to the electrode surface to emit 
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light. The instrument measured the intensity of emitted light to give a quantitative measure of 
IFN- γ, IL-1β, IL-6 and TNF-α present in the sample. 
 
2.4.2.4.2 Human Vascular Injury I 96-Well Multi-Spot® Plate 
  
The Human Vascular Injury I 4-plex ELISA detects soluble intercellular adhesion 
molecule-3 (sICAM-3), E-selectin, P-selectin and thrombomodulin (TM) (Fig 2.11) in a 
sandwich immunoassay format (Meso Scale Discovery, MD USA).  This immunoassay is 
conducted in the same manner as the Human ProInflammatory Multi-Spot® plate as already 
described above. 
 
 
 
Figure 2.11: Human Vascular Injury I 96-well Multi-Spot® Plate. 
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2.4.3 Immunocytochemistry  
 
Immunocytochemical techniques, as previously described by Groarke et al., were 
employed to visually monitor the expression and/or subcellular localization of 
thrombomodulin (Groake, et al. 2001). Firstly, cell culture media was aspirated from the dish. 
HAECs were washed 3 times in PBS and fixed with 3.7% (v/v) formaldehyde for 20 minutes. 
Cells were subsequently washed in PBS 3 times; at this point samples could be stored in PBS 
for up to 2 days at 4°C. Cells were then blocked for 30 min in PBS containing 5% (w/v) BSA 
solution. After blocking, cells were washed 3 times in PBS and then incubated with a 50 µl 
solution of Thrombomodulin primary antibody (Table 2.7) for 1 hour at room temperature or 
on ice (Abcam, MA, USA; Acris Antibodies, Germany). Again cells were washed 3 times in 
PBS after which, they were incubated with 1:1000 Alexa Fluor 488 anti-rabbit (TM) or anti-
mouse secondary antibody in 5% BSA for 1 hour in the dark at room temperature. Again cells 
were washed 3 times in PBS after which, nuclear DAPI staining was performed by incubating 
cells with propidium iodide (PI) for 3 min. Samples were then washed for a final time and 
mounting medium was added to the cells. Samples were visualised by standard fluorescent 
microscopy (Nikon Eclipse Ti, Tokyo, Japan). 
 
Primary antibody/stain Dilution 
PI 1:2000 
TM (Abcam) 1:50 
TM (Acris) 1:50 
 
Table 2.7: Optimized primary and secondary antibody dilutions for proteins monitored by 
immunocytochemistry. 
 90 
2.5 Statistical analysis 
 
Results are expressed as mean±sem. Unless otherwise indicated, all experiments were 
conducted in triplicate (n=3). Statistical comparisons between controls versus treated groups 
were made by ANOVA in conjugation with a Dunnett’s post-hoc test for multiple 
comparisons. A Student’ s unpaired t-test was employed for pairwise comparisons. A value 
of P ≤ 0.05 was considered significant. 
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Chapter 3: 
Investigation of the effects of cyclic 
strain on the expression and release 
of thrombomodulin 
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3.1 Introduction 
 
The primary aim of this project was to characterize an in vitro endothelial cell model 
focusing on the effects of elevated cyclic strain on macrovascular endothelial phenotype with 
respect to TM expression and release. Cyclic strain, the rhythmic distension of the blood 
vessel wall in time with the cardiac cycle, was to be applied to human aortic endothelial cells 
(HAECs) using a FlexerCell® Tension Plus™ FX-4000T™ System (Dunn Labortechnik 
GmBH, Germany) in conjugation with Pronectin®-coated Bioflex® plates. It has been well 
documented that when cyclic strain is pathologically elevated, vascular complications may 
result (i.e., vein graft rejection, hypertension) (Goch et al., 2009; Weiß et al., 2009). Cyclic 
strain induces both short- and long-term changes in cell signalling, protein synthesis, protein 
secretion/degradation, rate of cell division and energy metabolism (Chien, 2007). In addition, 
cyclic strain up-regulates the production of adhesion molecules and pro-inflammatory 
cytokines in endothelial cells (Sasmoto et al., 2005). HAECs are ideal for this model as large 
arteries are the most susceptible location for strain- and shear-based hemodynamic injury, as 
well as being translationally relevant to human CVD. Basic studies were carried out initially 
in bovine aortic endothelial cells (BAECs) due to their rapid doubling time and ease of use. 
This allowed techniques to be optimized and validated before proceeding to work with 
HAECs.  
Initially, to ensure that our results were not due to excessively compromised cell 
viability following strain treatments, a number of cell viability assessments were conducted. 
In characterising this hemodynamic model, we were subsequently interested in assessing the 
range of inflammatory damage that could be elicited in endothelial cells by elevated levels of 
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cyclic strain. Following this, our goal was to focus in on one relatively unstudied but 
physiologically crucial target, thrombomodulin (TM), in order to define more clearly how it 
was responding to cyclic strain in vitro. TM is a cell membrane protein predominantly known 
for its involvement in the coagulation cascade (Cines et al., 1998; Pearson, 1999). 
Additionally, TM has beneficial antifibrinolytic and anti-inflammatory outcomes for the 
vessel wall (Conway, 2012), which would indicate the importance of TM to vascular 
homeostasis. The impact of cyclic strain on the expression/release of TM has received very 
little attention within in vitro models, highlighting the importance of understanding how strain 
regulates this physiologically and therapeutically relevant molecule. In this chapter, dose-, 
time- and cyclic frequency-dependency studies were conducted to investigate how cyclic 
strain mediates TM expression and release levels in HAECs. We also extended these studies 
to include another highly relevant biomechanical force, namely shear stress, to determine if it 
regulates TM in the same manner as cyclic strain. Initially, importance basic endothelial 
characterisation was performed.  
 
3.2 Results 
 
3.2.1 Characterisation of endothelial cells 
 
3.2.1.1 Endothelial cell markers 
 
Endothelial cells have specific biomarkers such as von Willebrand factor (vWF) and 
endothelial nitric oxide synthase (eNOS) that can be identified and measured to guarantee the 
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validity of the commercially-sourced HAECs. vWF and eNOS mRNA was detected in 
HAECs  by RT-PCR (Fig 3.1). 
 
3.2.1.2 Endothelial cell morphology 
 
HAECs were grown to confluency and monitored daily by phase-contrast microscopy 
for characteristic growth patterns and typical “cobblestone” shaped morphology. Using the 
orbital flow system, low shear stress (10 dynes.cm2, 24 hrs) was applied to HAECs, which 
realign in the direction of flow (Fig 3.2). 
 
3.2.2 Viability studies 
 
Viability studies on HAECs prior to treatment with cyclic strain were carried out using 
a range of methods to ensure that there were sufficient viable cells available for each 
experiment. Further viability checks were done post-strain experimentation for both 
normalisation purposes and to determine if cell viability was significantly affected by the 
strain treatment. Viability assessments were performed using; 
 
(i) The Vybrant™ apoptosis flow cytometry (FACs) assay was carried out post-cyclic 
strain (2.5% vs 12.5% for 24 hrs). R1, R2, R3 and R4 represent total, live, necrotic and 
apoptotic cells, respectively (Fig 3.3E). Since the four images are nearly identical, it is 
clear that the 12.5% cyclic strain treatment does not significantly reduce cell viability. 
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This quantitatively illustrates the strain-dependent change in HAEC viability (Fig 
3.3F). 
(ii) Trypan blue was also used to measure the viability status of cells in each Bioflex® 
well after treatment with cyclic strain (2.5% vs 12.5% for 24 hrs). As before, virtually 
no difference was observed in cell viability between the 2.5% and 12.5% treatments 
with cyclic strain (Fig 3.4A). 
(iii) The ADAM™ cell counter was used routinely to measure cell number and viability 
after every cyclic strain experiment. The graphs (Fig 3.4B and C) show that cell 
viability is nearly identical after two different 24 hrs cyclic strain ranges were applied 
(2.5% vs 12.5% and 0% - 7.5%). 
 
3.2.3 Effect of elevated cyclic strain on biomarker levels in HAECs  
 
Multiplex ELISA technology was employed to analyse levels of multiple cellular 
targets in both HAEC lysates and media supernatants. Samples were harvested from 
individual Bioflex® wells after treatment with low (2.5%) and high (12.5%) cyclic strain for 
24 hrs at 60 cycles/min (routine frequency used throughout thesis). This ELISA measured 
levels of established pro-inflammatory and vascular injury markers using custom multiplex 
ELISA MSD® panels. For control studies, untreated cells were also compared to thrombin-
treated cells (1.0 U/ml for 24 hrs). 
The MSD® pro-inflammatory injury panel measured the concentration of four 
biomarkers; Interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour 
necrosis factor-α (TNF-α). We observed no difference in IFN-γ concentration in media yet it 
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was significantly decreased in cell lysates after 12.5% cyclic strain (Fig 3.5). Moreover, there 
was no significant change in IL-1β levels in either media or cell lysates following 12.5% 
cyclic strain (Fig 3.6). IL-6 was notably up-regulated in both media and cell lysates after 
treatment with 12.5% cyclic strain (Fig 3.7). TNF-α was down-regulated in cell lysates but 
increased slightly in media following 12.5% cyclic strain (Fig 3.8).  
The MSD® vascular injury panel quantified the concentration of four injury 
biomarkers; soluble intercellular adhesion molecule-3 (siCAM-3), E-selectin, P-selectin and 
thrombomodulin (TM). There was no significant difference in siCAM-3 concentration in 
media but a considerable decrease in cell lysates after 12.5% cyclic strain (Fig 3.9). A small 
increase was observed in E-selectin levels in media with a significant decrease in cell lysates 
following 12.5% strain (Fig 3.10). No significant changes were detected in the concentrations 
of P-selectin in media or cell lysates post 12.5% strain (Fig 3.11). Finally, TM levels were 
significantly up-regulated in media in parallel with a reduction in cellular lysates following 
12.5% cyclic strain (Fig 3.12) Given the pathophysiological significance of TM, and the very 
limited in vitro data of TM with respect to cyclic strain, this target was selected for a further 
detailed study as the main focus of this thesis. These results are summarised in Table 3.1. 
Thrombin (a pro-inflammatory molecule that also binds to TM) was employed as a 
control for treating cells and monitoring biomarker levels with both the Pro-Inflammatory and 
Vascular Injury MSD® panels. The Pro-Inflammatory Injury panel shows no significant 
difference in cytokine concentration between the thrombin-treated and untreated samples in 
media, although slight to moderate increases in cellular levels of cytokine expression were 
noted (particularly for IL-6) (Fig 3.13A-B). The Vascular Injury panel shows that thrombin-
treated media samples have reduced release of both E-selectin and P-selectin. Moreover, TM 
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was the only biomarker that was significantly up-regulated intracellularly in thrombin-treated 
HAECs (Fig 3.13C-D).  
 
3.2.4 Constitutive expression and release of TM in “static” HAECs 
 
 For the remainder of the thesis, specific focus will be placed on the vascular injury 
target, TM. Initially, we wanted to confirm both expression and constitutive release of TM in 
static HAECs. Fluorescent and confocal imaging of TM imunnoreactivity was carried out to 
visualise constitutive cellular distribution of TM in HAECs under static conditions (Fig 3.14). 
Samples were visualised by standard fluorescent microscopy (Nikon Eclipse Ti, Tokyo, 
Japan) and confocal microscopy (Zeiss Axioskop FS, USA). TM mRNA expression was 
confirmed in static HAECs using standard RT-PCR (Fig 3.15A). TM protein expression was 
also confirmed in HAECs by Western blotting (Fig 3.15B). Time-dependent constitutive 
release of TM was observed between 24 – 72 hrs in HAECs (Fig 3.15C). For all subsequent 
experiments monitoring TM release from HAECs, the TM/BCDA-3 Duoset ELISA (R&D 
Systems, MN USA) was employed (Fig 3.15D).   
 
3.2.5 Effect of cyclic strain on TM expression levels in HAECs 
 
To further investigate this, a number of experiments were conducted with respect to 
different doses and frequencies of cyclic strain on HAECs in vitro. Dose-response studies 
were carried out on HAECs to examine the effect of cyclic strain on TM protein and mRNA 
expression levels. For protein expression studies, three Bioflex® wells were harvested and 
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pooled per sample after varying levels of cyclic strain (0%, 2.5% and 7.5%) were applied and 
then analysed by Western blotting (Fig 3.16). It can be noted that 7.5% was used as the upper 
level of strain for all subsequent experiments as the higher strain levels of up to 12.5% 
frequently caused significant cellular detachment from the Bioflex® membrane during stretch 
experiments (i.e., due to over-stretching of the membrane). 7.5% cyclic strain is still quite 
elevated for the endothelium in vivo but causes less cell detachment from the membrane. For 
technical ease, the control strain condition was selected as 0% (as opposed to 2.5%), which 
allows us to model the effect of cyclic strain on TM dynamics in endothelial cells (i.e. 0% 
versus 7.5%), as opposed to modeling a particular pathology manifesting elevated strain (i.e. 
2.5% normal versus 7.5% elevated). In agreement with the MSD® multi-plex ELISA result, 
the Western blots showed an almost 75% down regulation in TM cellular expression in 
response to cyclic strain. 
Next, cellular TM levels in response to changes in cyclic strain dose and frequency 
were monitored using ELISA. A similar downward trend in cellular TM levels was confirmed 
in response to cyclic strain treatment (Fig 3.17A). Frequency-response studies were also 
carried out in HAECs to examine the effect on TM protein expression of varying the strain 
frequency (30 – 120 cycles/min) whilst maintaining the amplitude (7.5%). Relative to the 
physiological norm of 60 cycles/min TM expression was slightly decreased following 
elevation of strain frequency to 120 cycles/minute (Fig 3.17B).  
Finally, for mRNA studies, two Bioflex® wells were harvested and pooled per sample 
following cyclic strain (0% and 7.5%), and analysed using qRT-PCR with a 7900HT Fast 
real-time PCR system (Applied Biosystems, CA USA) (Fig 3.18). A decrease in TM mRNA 
levels of approximately 40% was observed after 7.5% cyclic strain. 
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3.2.6 Effect of cyclic strain on TM release from HAECs 
 
Cyclic strain-dependent TM release from HAECs into media was measured following 
dose-, time- and frequency-dependent cyclic strain studies. Media samples were harvested 
from individual wells for the TM assay of 6 replicates per plate. In response to increasing 
cyclic strain (0-12.5%), TM release was elevated in a dose-dependent manner (by almost 8-
fold) with no significant difference in release observed between 7.5% and 12.5% cyclic strain 
(Fig 3.19A). Moreover, when HAECs were exposed to 7.5% cyclic strain over a 48hr period, 
significant TM release was not observed until between 12 - 24 hrs, with levels increasing 
significantly up to 48 hrs (Fig 3.19B). Finally, in response to changing cyclic strain frequency 
from physiological level (60 cycles/min) to lower (30 cycles/min) or higher levels (120 
cycles/min) whilst maintaining the amplitude (7.5%) of cyclic strain, we observed a very 
significant increase in TM release at elevated frequency (Fig 3.19C).  
 
3.2.7 Effect of laminar shear stress on TM expression and release 
 
Shear stress, the atheroprotective frictional force of the blood acting tangentially on 
the endothelium, was also briefly investigated as part of this study. Laminar shear stress (0 
versus 10 dynes/cm2, 0 - 48 hrs) was applied to HAECs, after which cells were harvested for 
either TM mRNA analysis or cell culture media for monitoring TM release.  
TM mRNA levels were increased almost two-fold in response to physiological levels 
of shear stress (Fig 3.20A). TM release was also strongly up-regulated by shear stress, with 
TM release apparent after just 3-6 hrs of shear (Fig 3.20B). 
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3.3 Table and Figures 
 
Biomarker Cell Function Media Cell Lysates 
Interferon-γ (IFN-γ) Innate and adaptive immunity − ↓ 
Interleukin-1β (IL-1β) Inflammatory response − − 
Interleukin-6 (IL-6) Acute phase response ↑ ↑ 
Tumour necrosis factor-α 
(TNF- α) 
Acute phase response ↑ ↓ 
Soluble intercellular 
adhesion molecular-3 
(siCAM-3) 
Cell adhesion − ↓ 
E-selectin Recruitment of leukocytes − ↓ 
P-selectin Recruitment of leukocytes − − 
Thrombomodulin (TM) Activates Protein C, 
inflammation and fibrinolysis 
↑ ↓ 
 
Table 3.1: The effects of elevated levels of cyclic strain (12.5%) on the expression of each 
biomarker measured both in total cell lysates and cell media. The symbols used represent the 
following; ↑, ↓ and − denotes up-regulation, down-regulation and no effect, respectively.    
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Figure 3.1: Characterisation of HAECs. (A) Shows the presence of the endothelial-specific 
marker vWF, in HAECs as detected by RT-PCR. (B) Shows the presence of endothelial-
specific marker, eNOS, in HAECs as detected by RT-PCR. Blots are representative of 3 
replicates. 
 
 
 
Figure 3.2: Endothelial cell morphological alterations in response to shear stress compared to 
static control cells. HAECs were sheared using the ibidi system. White arrow indicates the 
direction of the shear flow. Images are representative.  
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Figure 3.3: Vybrant™ Apoptosis FACs Assay. Cell viability was measured after treatment 
with either 2.5% (A - B) or 12.5% (C - D) cyclic strain for 24 hrs. (E) Gated events of 
viability assay. (F) Average values of cell viability per strain group (n=2). Key: R2, live cells; 
R3, necrotic cells; R4, apoptotic cells. 
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Figure 3.4: Trypan blue and ADAM™ cell counter viability studies. Trypan blue and the 
ADAM™ cell counter was used to analyse cell viability post-treatment with cyclic strain for 
24 hrs. (A) Illustrates the percentage of viable cells post-treatment with either 2.5% or 12.5% 
cyclic strain for 24 hrs (n=6). (B) Employs the ADAM™ cell counter to assess the viability of 
the HAECs post-strain with 2.5% vs 12.5% strain for 24 hrs (n=6). (C) Employs the ADAM™ 
cell counter to assess cell viability from 0 – 7.5% strain (n=6). 
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Figure 3.5: IFN-γ biomarker data. IFN-γ standard curve from ELISA is shown in (A). IFN-γ 
concentration (pg/ml) was measured in media supernatants (B) and cell lysates (C) that were 
previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (*P≤0.05 versus 2.5% 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). 
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Figure 3.6: IL-1β biomarker data. IL-1β standard curve from ELISA is shown in (A). IL-1β 
concentration (pg/ml) was measured in media supernatants (B) and cell lysates (C) that were 
previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (n=6).      
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Figure 3.7: IL-6 biomarker data. IL-6 standard curve from ELISA is shown in (A). IL-6 
concentration (pg/ml) was measured in media supernatants (B) and cell lysates (C) that were 
previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (*P≤0.05 versus 2.5% 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).       
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Figure 3.8: TNF-α biomarker data. TNF-α standard curve from ELISA is shown in (A). TNF-
α concentration (pg/ml) was measured in media supernatants (B) and cell lysates (C) that 
were previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (*P≤0.05 versus 
2.5% determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).       
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Figure 3.9: siCAM-3 biomarker data. siCAM-3 standard curve from ELISA is shown in (A). 
siCAM-3 concentration (ng/ml) was measured in media supernatants (B) and cell lysates (C) 
which were previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (*P≤0.05 
versus 2.5% determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).              
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Figure 3.10 E-selectin biomarker data. E-selectin standard curve from ELISA is shown in 
(A). E-selectin concentration (ng/ml) was measured in media supernatants (B) and cell lysates 
(C) that were previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (*P≤0.05 
versus 2.5% determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).             
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Figure 3.11: P-selectin biomarker data. P-selectin standard curve from ELISA is shown in 
(A). P-selectin concentration (ng/ml) was measured in media supernatants (B) and cell lysates 
(C) that were previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs (n=6).     
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Figure 3.12: Thrombomodulin (TM) biomarker data. TM standard curve from ELISA is 
shown in (A). TM concentration (ng/ml) was measured in media supernatants (B) and cell 
lysates (C) that were previously treated with either 2.5% or 12.5% cyclic strain for 24 hrs 
(*P≤0.05 versus 2.5% determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).        
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Figure 3.13: Thrombin-treated and untreated controls for the Pro-Inflammatory Injury and 
Vascular Injury Panels. Cell lysates (A and D) and media supernatants (B and D) were 
harvested from HAECs either untreated (UT) or treated with thrombin (1.0 U/ml for 24 hrs) 
and then measured for cytokine and vascular target levels (n=1).  
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Figure 3.14: Fluorescent and confocal imaging of TM immunoreactivity in static HAECs. 
(A) TM is visualised (in green) along the cellular membrane. Propidium iodide, used for 
nuclear staining (in red). Intercellular TM is also shown. (B) Confocal imaging of TM 
immunoreactivity in static HAECs. TM is visualised (in green) both intracellularly and along 
the cellular membrane. All images are representative. 
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Figure 3.15: Constitutive expression and release of TM in static HAECs. (A) TM mRNA 
expression was measured by RT-PCR. Blots are representative of 3 replicates. (B) TM protein 
expression was observed by Western blotting. Blots are representative of 3 replicates. (C) 
Time-dependent release of TM from static HAECs into culture media was measured at 
different time points up to 72 hrs. (*P≤0.05 and ***P≤0.001 versus 0% determined using 1-
way ANOVA and post-hoc Dunnett’s test, n=6). (D) TM standard curve for the Duoset TM 
ELISA (R&D Systems, MN USA).  
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Figure 3.16: Dose-dependent effect of cyclic strain on cellular TM protein levels as 
monitored by Western blotting. Following application of cyclic strain (0%, 2.5% and 7.5% for 
24 hrs) to HAECs, cell lysates were harvested and monitored for changes in both TM and 
GAPDH protein expression by Western blotting. The histogram illustrates scanning 
densitometry carried out on the Western blots to quantitate the fold change of TM relative to 
GADPH  (i.e., relative TM expression) (*P≤0.05 versus 0% determined using 1-way ANOVA 
and post-hoc Dunnett’s test). Blots are representative of 3 replicates.  
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Figure 3.17: Dose- and frequency-dependent effects of cyclic strain on cellular TM protein 
levels in HAECs as monitored by ELISA. (A) Following application of cyclic strain (0% and 
7.5% at 60 cycles/min for 24 hrs) to HAECs, cell lysates (typically diluted 1:20) were 
harvested and monitored for changes in TM protein expression by Duoset ELISA (*P≤0.05 
versus 0% determined using 1-way ANOVA and post-hoc Dunnett’s test, n=57). (B) TM was 
measured in cellular lysates after 7.5% cyclic strain at frequencies of 30, 60 and 120 cycles 
per minute (*P≤0.05 versus 60 cycles/min determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=6). (C) The Duoset TM ELISA (designed primarily for measuring TM 
release into cell culture media) was validated to measure TM in cell lysates by preparing 
different dilutions of cellular lysates in 1X PBS (with 25% FCS) and subsequently measuring 
TM levels (n=3).  
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Figure 3.18: Effect of cyclic strain on TM mRNA levels in HAECs as monitored by qRT-
PCR. (A) Following application of cyclic strain (0% and 7.5% for 24 hrs) to HAECs, mRNA 
samples were harvested and monitored for TM and S18 (endogenous control) expression by 
qRT-PCR (*P≤0.05 versus 0% determined using 1-way ANOVA and post-hoc Dunnett’s test, 
n=16). (B) Primers for TM and S18 were initially optimized using standard PCR and then 
visualized on an agarose gel. Blots are representative of 3 replicates. (C) Melt curve analysis 
was carried out on the TM primers to determine their specificity. 
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Figure 3.19: Dose-, time- and frequency-dependent effects of cyclic strain on TM release. 
(A) Different doses of cyclic strain, 0%-12.5% for 24 hrs were applied to HAECs and TM 
release into media was subsequently measured by ELISA (*P≤0.05 versus 0%, δP≤0.05 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (B) TM release was also 
measured at different time points up to 48 hrs during the application of cyclic strain (0% and 
7.5%) (*P≤0.05 versus 0 hrs, δP≤0.05 determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=6). (C) The effect of cyclic strain frequency (7.5% strain at 30, 60, 120 
cycles/min) on TM release from HAECs was measured by ELISA (*P≤0.05 versus 60 
cycles/min determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6).  
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Figure 3.20: Shear stress regulates TM expression and release. HAECs were exposed to shear 
stress (0-10 dynes/cm2, 0-48 hrs) and monitored for TM mRNA expression and TM release. 
(A) Shear stress-dependent up-regulation of TM mRNA levels (*P≤0.05 versus 0 dynes/cm2 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=9). (B) Time-dependent 
increase in TM release in response to shear stress (*P≤0.05 versus 0 hrs, δP≤0.05 determined 
using 1-way ANOVA and post-hoc Dunnett’s test, n=6).  
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3.4 Discussion 
  
 One of the main objectives for this project was to further understand how elevated 
cyclic strain impacts vascular injury biomarkers including thrombomodulin (TM) in 
endothelial cells. Cyclic strain is a biomechanical force that contributes to endothelial 
homeostasis and vascular health (Cheng et al., 2001). Thus, when cyclic strain becomes 
dysregulated, endothelial dysfunction leading to cardiovascular diseases such as 
atherosclerosis and hypertension may result (Hahn and Schwartz, 2009). TM has evident 
physiological importance to the endothelial cell, indicated by its functions in coagulation, 
inflammation and fibrinolysis (Martin et al., 2013). There is a shortage of studies (and 
particularly in vitro studies) investigating the effects of cyclic strain on TM expression and 
release. This lack of information on TM regulation by this potent hemodynamic force has 
therefore framed the resultant thesis.  
Our initial MSD® Multiplex ELISA study identified a profile of pro-inflammatory and 
vascular injury molecules that were responsive to elevated cyclic strain. We looked at a range 
of pro-inflammatory cytokines, as they are known to play an imperative role in the formation 
and development of atherosclerotic lesions. We found that elevated cyclic strain reduced 
cellular expression of IFN-γ but had no effect on release. There were no available studies on 
IFN-γ, a dimerized soluble cytokine involved in innate and adaptive immunity 
(Theofilopoulos et al., 2001) in relation to cyclic strain for comparison. Subsequently, we 
observed that elevated strain had no effect on IL-1β expression or release. This was in 
agreement with an earlier study showing that IL-1β expression or release was not affected 
following 24 hrs cyclic strain (15.1%) (Okada et al., 1998). Next, we showed IL-6, a pro-
inflammatory cytokine, was up-regulated in cell lysates and media following elevated cyclic 
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strain indicating the pro-inflammatory nature of this stimulus on endothelial cells. This is not 
surprising as IL-6 expression has already been reported to be increased following cyclic strain 
in smooth muscle cells (Zampetaki et al., 2005). Additionally, increased plasma concentration 
of IL-6 was observed in subjects with high blood pressure, which also concurs with our result 
(Chae et al., 2001). TNF-α, another cytokine involved in systemic inflammation was shown to 
be increased in media and decreased in cell lysates following cyclic strain. This is in contrast 
with an earlier study where its levels were not affected after elevated cyclic strain in 
endothelial cells isolated from human umbilical veins (Okada et al., 1998).  
We also examined a range of known vascular injury markers in relation to elevated 
cyclic strain. Firstly, we found that siCAM-3 levels were decreased in cell lysates with no 
change noted in media, following elevated cyclic strain. siCAM-3 has not been linked to 
cyclic strain in the literature in respect to either expression or release making this result 
difficult to interpret. It is noteworthy however that siCAM-1, a member of the same cell 
adhesion family, has been reported to be up-regulated in the plasma of men with increased 
blood pressure (Chae et al., 2001). Subsequently, we went on to investigate the effect cyclic 
strain had on E-selectin and P-selectin, which are involved in the recruitment of leukocytes. 
We found that elevated cyclic strain had no significant effect on P-selectin levels in either 
media or cell lysates, whereas E-selectin was decreased in cell lysates with no change in 
media following cyclic strain. This is in contrast with an earlier study showing E-selectin 
substantially up-regulated after strain when compared to control cells under static conditions 
(Yun et al., 1999). This group used a “supraphysiological” level of 25% maximal strain at 30 
cycles/min for 24 hrs, which renders this result somewhat questionable.  
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Of particular interest were the observations in relation to TM, a known injury marker 
for endothelial cells. Intracellular protein levels for TM were found to be significantly down-
regulated by high cyclic strain, whilst its release from HAECs was increased (Martin et al., 
2013). Further studies involving Western blotting and qRT-PCR both confirmed the dose-
dependent reduction of TM protein and mRNA expression levels following elevated cyclic 
strain of HAECs. Moreover, further ELISA studies using a single-plex Duoset ELISA 
demonstrated how TM release/shedding was increased in response to cyclic strain in a dose-, 
frequency- and time-dependent manner. The increased release and reduced expression of TM 
would indicate that the endothelial cells are “losing” TM which would mean the endothelium 
would exhibit decreased anti-coagulant and anti-inflammatory properties (i.e., leading to a 
more pro-inflammatory and pro-coagulant endothelium). Conversely, the increased release of 
TM could be cardioprotective for the endothelium, as functional efficacy has been attributed 
to circulating sTM variants (Lin et al., 2008; Lopes et al., 2002). The assortment of viability 
studies employed concludes that the elevated strain conditions were not excessively 
detrimental to HAEC viability. 
The current literature has contradicting reports on the regulation of TM by cyclic 
strain, the repetitive mechanical deformation of the vessel wall as it rhythmically distends and 
relaxes within the cardiac cycle. Consistent with our in vitro results demonstrating reduced 
TM expression levels induced by cyclic strain, substantially decreased in vivo mRNA and 
protein TM expression in response to outward vessel wall distension was previously reported 
in vein grafts using a rabbit autologous vein graft model (Sperry et al., 2003). Importantly, 
this group also claimed that wall tension was a more important regulator of TM gene 
expression than shear stress, which they demonstrated by ligating the distal carotid artery to 
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alter blood flow and pressure-induced vessel wall distension. Two somewhat older paired 
reports disagree with this aforementioned vein graft study; by using ex vivo human saphenous 
vein segments inside an external flow circuit, they describe how exposure of vein grafts to 
arterial flow significantly reduced endothelial TM expression in a cyclic strain-independent 
manner (Golledge et al., 1999; Gosling et al., 1999). One justification for this contradiction in 
results may perhaps be due to the insufficient external stenting used in the earlier studies 
(Golledge et al., 1999; Gosling et al., 1999) to prevent any cyclic strain influences, with up to 
7±2% pulsatile expansion still possible with external polytetrafluoroethylene (PTFE) stents. 
Another reason for this difference may be because that the later (Sperry et al., 2003) and 
earlier (Golledge et al., 1999; Gosling et al., 1999) studies represent chronic (weeks) versus 
acute (45-90 mins) observations, respectively. A further additional study using ex vivo vein 
graft and in vitro vascular cell culture models persuasively demonstrate that cyclic strain-
dependent induction (10% stretch at 1Hz for 16 hours) and release of transforming growth 
factor-β1 (TGF-β1) within the medial smooth muscle cell layer of the vessel could decrease 
endothelial TM expression in a paracrine manner (Kapur et al., 2011). Using a pan-
neutralizing TGF-β1 antibody (1D11), this group succeeded in blocking TM down-regulation, 
thereby conserving levels of activated protein C and decreasing thrombus formation in a 
rabbit vein graft model. A lone report that contradicted these studies (and indeed other studies 
including our own results) demonstrated a sustained increase in TM protein expression in 
HUVEC cultures after application of 21% (but not 15%) cyclic strain, with a role for NO 
signalling mechanisms strongly implicated (Chen et al., 2008). These authors suggest that the 
prolonged increase in protein expression may putatively be attributed to NO-mediated 
stabilization of TM protein via S-nitrosylation as the TM promoter activity was not induced 
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by cyclic strain of HUVECs. However, there is no further data to back-up these observations 
and taking into account the supra-physiological levels of strain applied, the significance of 
this study remains uncertain. Finally, a 2.6 fold down-regulation of TM expression in human 
aortic smooth muscle cells (HASMCs) following 4% equibiaxial cyclic strain for 24 hrs was 
reported (Feng et al., 1999). Again, the physiological relevance of this result is also open to 
debate, as SMCs do not express TM protein or mRNA within the vessel wall in vivo.  
The previous studies emphasise the limitation of cell culture models in addressing the 
regulatory impact of cyclic strain on TM expression. In fact, this thesis is the first time TM 
expression and release has been shown to be negatively mediated by cyclic strain in an in 
vitro model, observations that are consistent with in vivo and ex vivo studies. Almost all the ex 
vivo and in vivo work mentioned above concur with our observations that TM expression is 
reduced in endothelial cells following elevated cyclic strain treatment, apart from the 
debatable studies by Chen et al. in 2008.  
We also examined the effect of varying the frequency of cyclic strain, whilst 
maintaining the same amplitude (7.5%), on TM expression and release from HAECs. 
Endothelial cells are typically exposed to elevated frequencies of cyclic strain due to long-
term increased blood pressure, intense exercise, and also sustained stress and anxiety 
(Laughlin et al., 2008). Evidently, permanent exposure to elevated blood pressure is 
detrimental to the endothelium whilst short-term increases (e.g., physical activity) in cyclic 
strain frequency have beneficial effects for the arterial endothelial cell, allowing it to sustain a 
normal phenotype (Hambrecht et al., 2003). To date, there are no reports on the impact of 
elevated strain frequency on either TM expression or release in endothelial cells, which would 
again highlight the deficiency of in vitro data regarding cyclic strain-dependent regulation of 
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TM. Relative to the physiological level of 60 cycles/min, we found that TM expression was 
only slightly decreased following 120 cycles/minute at the same 7.5% amplitude, although 
TM release was very substantially elevated. The reduction in TM protein expression 
combined with the elevated release of TM suggests that elevated strain amplitude (7.5%) and 
frequency (120 cycles/min) may have a profoundly deleterious effect on the endothelium 
thrombogenicity in the long term. Moreover, it also suggests that released TM (sTM) may be 
a novel biomarker for elevated blood pressure and endothelial dysfunction in general, 
possibly acting as an “SOS” signal for damaged endothelial cells to communicate with 
adjacent healthy cells.  
Our data also demonstrates how TM expression and release from HAECs is up-
regulated by elevated laminar shear stress, a hemodynamic component of blood flow known 
to convey an atheroprotective phenotype to the endothelium (Traub and Berk, 1998). TM has 
a shear stress response element (-GAGACC-) within its promoter region, which would partly 
explain the sensitivity of TM expression to laminar shear stress. We found that TM mRNA 
expression is increased by shear stress, which is in accordance with the current literature 
(Malek et al., 1994; Takada et al., 1994). The majority of studies show that shear stress is a 
positive regulator of TM expression, which is not surprising when one considers the anti-
coagulant and anti-thrombotic properties of TM. Shear-dependent up-regulation of TM 
expression under both acute and chronic treatment paradigms has been observed in a wide 
range of models including a mouse transverse aortic constriction model of flow-dependent 
remodelling (Li et al., 2007), HUVECs (Takada et al., 1994; Bergh et al., 2009; Wu et al., 
2011), human abdominal aortic endothelial cells (HAAECs) (Rossi et al., 2011), human 
retinal microvascular endothelial cells (Ishibazawa et al., 2011), and also in primate 
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peripheral blood-derived endothelial outgrowth cells (Ensley et al., 2012). Shear stress has 
also been reported to offset the down-regulatory influence of TNF-α treatment on TM 
expression in HUVECs (Jun et al., 2009). In contrast to these studies (and our own 
observations), endothelial TM expression showed a mild transient increase followed by a 
(reversible) decrease to just 16% of baseline levels within 9 hrs of flow onset in BAECs 
(Malek et al., 1994). However, this observation should be regarded with caution due to both 
the volume of studies reporting the opposite effect and the authors use of BAECs (as opposed 
to human/primate/mouse models). 
In addition to expression, it is interesting to note that shear stress was also found to 
up-regulate TM release in a temporal manner. Indeed, shear was a significantly more potent 
stimulus for TM release, with higher amounts of sTM (i.e., soluble/release TM) measured in 
media when compared to cyclic strain. By contrast, cyclic strain causes a reduction of 
expression whilst temporally (and moderately) up-regulating release of TM. Although the 
reasons for this difference are unknown, it is possible to speculate. Levels of shear stress used 
in this study (up to 10 dynes/cm2) are considered healthy and atheroprotective for the 
endothelium whereas elevated strain (7.5%) is potentially patho-physiological. The increased 
TM release following shear stress may be having cardioprotective functions in the 
endothelium in vivo, thus helping to maintain homeostasis. In addition, it is important to note 
that the endothelium is not losing TM in this circumstance as cellular expression of TM is 
increased by healthy levels of shear. Elevated cyclic strain on the other hand is decreasing 
TM expression whilst increasing release so the endothelium would become more susceptible 
to endothelial dysfunction. Long-term elevated levels of strain may consequently be a 
contributor to the initiation of CVD. This may explain the elevated production of TM under 
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shear stress and the reduced production of TM under cyclic strain. Moreover, both 
haemodynamic stimuli are almost certainly eliciting distinct signalling pathways mediating 
expression and release of TM. Both shear and strain may also differentially activate 
transcription factors known to modulate TM expression (e.g., KLF-2). With this in mind, we 
next decided to examine the signalling pathway(s) putatively mediating the cyclic strain 
effects on TM. We also decided to examine how elevated cyclic strain impacts TM release in 
both the absence and presence of other inflammatory/atherogenic mediators.  
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Chapter 4: 
Investigation into the signalling 
mechanisms underlying cyclic strain-
mediated thrombomodulin 
expression and release 
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4.1 Introduction 
 
The previous chapter dealt with characterising the impact of cyclic strain on TM 
expression and release in HAECs. So far, we have observed that TM release is increased and 
cellular expression is reduced in response to elevated levels of cyclic strain. In this chapter, 
we extend our investigations by exploring the molecular mechanisms putatively involved in 
mediating the strain-induced modulation of TM expression and release from endothelial cells, 
which is as yet poorly defined in the literature.  
In Section 4.2.1, we first looked at the effect that inflammatory mediators such as 
tumour necrosis factor-α (TNF-α), oxidized low density lipoprotein (ox-LDL) and elevated 
glucose have on TM expression and release from HAECs in the both absence and presence of 
cyclic strain (as inflammatory events in vivo usually involve a combination of humoral and 
biomechanical events, again an area relatively unexplored in the literature).  It is widely 
accepted that TNF-α, a pro-inflammatory cytokine, is a negative regulator of TM expression 
(Bergh et al., 2009; Boehme et al., 1996; Grey et al., 1998; Lin et al., 2011; Soff et al., 1991). 
Oxidation of low density lipoprotein (LDL) is thought to play a crucial role in plaque 
development during atherosclerosis (Cominacini et al., 2000). It has also been reported that 
ox-LDL down-regulates TM expression (Ishii et al., 2003), yet there are no studies measuring 
how these inflammatory mediators impact TM release when combined with elevated cyclic 
strain. Hyperglycemia (i.e., toxic high glucose levels typically observed during type-2 
diabetes) is another established cause of endothelial dysfunction during metabolic syndrome 
(Nakagami et al., 2005), yet there is nothing reported about how glucose may affect either TM 
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expression or release from the endothelium. As such, we also included this in our 
investigations.  
In Section 4.2.2, we look at known signaling pathways activated by cyclic strain in an 
effort to identify the signaling mechanism(s) mediating the effects of strain on TM dynamics. 
GM6001, a generic inhibitor of matrix metalloproteinases, was employed to ablate 
matrix metalloproteinase (MMP) activity. MMPs are known to be up-regulated by cyclic 
strain (Cummins et al., 2007; Hasaneen et al., 2005) and have previously been shown to 
mediate lysophosphatidic acid (LPA)-induced TM lectin-like domain shedding (Wu et al., 
2008). We also utilised a specific serine protease inhibitor, 3,4-dichloroisoisocoumarin (DCI). 
Whilst there is no study thus far linking serine proteases to TM protein expression, they have 
been shown to specifically cleave TM (Cheng et al., 2011). Additionally, rhomboids, a family 
of intramembrane proteases sensitive to DCI inhibition, were previously reported to cleave 
TM from the membrane (Lohi et al., 2004) facilitating its release into media.  
Another signaling component examined was endothelial nitric oxide synthase (eNOS) 
as it is up-regulated by cyclic strain in BAECs (Awolesi et al., 1995). eNOS, as its name 
suggests, produces nitric oxide (NO) in blood vessels which regulates vascular tone by 
inhibiting smooth muscle contraction and platelet aggregation (Vanhoutte PM, 2009). L-
NAME (L-NG-Nitroarginine methyl ester) was therefore employed to inhibit eNOS in strain 
experiments in order to observe its influence on TM expression and release from HAECs. 
Similarly, NSC23766 was employed to block Rac1 GTPase, a member of the Rho protein 
family. An earlier study showed that pravastatin could regulate TM expression in HAECs by 
inhibiting the activation of Rac1/Cdc42 and NFкB (Lin et al., 2007). Furthermore, cyclic 
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mechanical strain is known to be partly transduced via activation of Rac1 GTPase (Kumar et 
al., 2004). However, nothing in the literature associates Rac1 with TM release.  
The putative role of NADPH oxidase (a superoxide-generating enzyme) was also 
investigated in our model because of its known mechano-sensitivity to cyclic strain (Cheng et 
al., 2001; Howard et al., 1997; Matsushita et al., 2001). There are no reports of a direct link 
between NADPH oxidase activation and TM regulation. Apocynin and superoxide dismutase 
(SOD) were therefore incorporated into strain experiments to selectively block NADPH 
oxidase activation and to degrade reactive oxygen species (ROS), respectively.  
We also explored a number of kinase cascades; Protein tyrosine kinase (PTK), 
phosphoinositide 3-kinase (PI3K) and mitogen activated protein kinases (MAPKs) - p38 and 
Erk-1/2. A previous study has reported that the activation of PI3K/Akt causes a reduction in 
TM expression in a non-small cell lung cancer (NCLC) A549 cell line (Liu et al., 2010). In 
addition, it was shown in vivo using transgenic mice that MAP kinase pathways were 
dampened by the lectin-like domain of TM (Conway et al., 2002). Cyclic strain also elicits 
regulatory effects via various kinase cascades including protein tyrosine kinase (Yano et al., 
1996), PI3K (Han et al., 2010), MAPK p38 (Shyu et al., 2010) and Erk-1/2 (Cheng et al., 
2001). However, there is no study directly investigating the link between these kinases and 
the cyclic strain-mediated regulation of TM expression or release from endothelial cells. 
Finally, we investigated integrins, heterodimeric mechanotransduction receptors 
known to be activated by strain (Wilson et al., 1995). In this regard, we employed a cyclic 
RGD peptide inhibitor into strain experiments to observe any integrin involvement in our TM 
model.  
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4.2 Results 
 
4.2.1 Inflammatory mediators 
 
HAECs were subjected to a range of atherogenic inflammatory conditions and the 
impact on TM expression (mRNA and protein) and release into cell culture media were 
assessed in the absence and presence of cyclic strain (7.5% equibiaxial, 60 cycles per min). 
Post-experiment, cells were harvested for total cellular protein (Western blotting), mRNA 
(qRT-PCR), and media (ELISA) for TM analysis. The inflammatory mediators and conditions 
employed are listed below;  
i. TNF-α: 0 versus 10 ng/ml (protein expression) or 0 - 100 ng/ml (mRNA analysis and 
TM release) for 24 hrs  
ii. ox-LDL: 0 - 50 µg/ml (mRNA analysis and TM release) for 24 hrs 
iii. Glucose: 5 - 30 mM (mRNA analysis and TM release) for 24 hrs 
The reagent concentrations for each condition were chosen to best imitate the in vivo 
situation. For example, the ox-LDL experiment employed 0, 10 and 50 µg/ml of ox-LDL with 
10 µg/ml being normal and 50 µg/ml being high normal - early atherogenic.  
In the first study, TNF-α moderately decreased TM protein and mRNA expression in 
static HAECs (Fig 4.1A-B) whilst having no effect on TM release from static HAECs. TNF-α 
was seen to potentiate the strain-mediated induction of TM release from HAECs at 100 ng/ml 
(Fig 4.1C).  
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With respect to ox-LDL treatment, TM mRNA expression exhibits a statistically 
insignificant increase (at 10 µg/ml) followed by a significant decrease at higher oxLDL 
concentrations (50 µg/ml) (Fig 4.2A). Moreover, ox-LDL had no significant effect on TM 
release when used on static HAECs, but was seen to strongly potentiate cyclic strain-induced 
TM release at concentrations up to 50 µg/ml (Fig 4.2B).  
With respect to glucose levels, TM mRNA expression was initially increased 
(statistically insignificant) after 15 mM glucose application followed by a return to baseline 
conditions after 30 mM in static HAECs (Fig 4.3A). Elevated glucose levels (15 - 30 mM) 
had no significant effect on TM protein expression in static endothelial cells (Fig 4.3B). 
Finally, elevated glucose (15 – 30 mM) was found to strongly reduce cyclic strain-induced 
TM release (Fig 4.3C). Table 4.1 summarises the results from this study.  
 
4.2.2 Signalling components 
 
 Pharmacological inhibitors were chosen to selectively attenuate a range of different 
signalling components that were known to be strain-sensitive and putatively associated with 
strain-dependent changes in gene expression and cell function. Inhibitors towards a range of 
different signalling pathways were incubated with HAECs in the presence and absence of 
cyclic strain (7.5% equibiaxial, 60 cycles per min for 24 hrs). Post-treatment, cells were 
harvested for total cellular protein and cell culture media for TM analyses. The signalling 
components employed for the TM expression and release studies are listed below;  
i. GM6001, a broad-spectrum inhibitor of MMPs (e.g., MMP-1, 2, 3, 8, and 9) (25 µM 
for 24 hrs).  
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ii. 3,4-dichloroisocoumarin (DCI), serine protease and rhomboid inhibitor (10 µM for 24 
hrs).  
iii. L-NAME, an eNOS inhibitor (1 mM for 24 hrs).  
iv. NSC23766, a Rac1 inhibitor (50 µM for 24 hrs).  
v. Apocynin, a selective NADPH oxidase inhibitor (10 µM for 24 hrs).  
vi. SOD, superoxide radical scavenger (100 U/ml for 24 hrs). 
vii. PI3K-α inhibitor (2 µM for 24 hrs). 
viii. PD98059, Erk1/2 inhibitor (10 µM for 24 hrs). 
ix. PD169316, p38 inhibitor (10 µM for 24 hrs). 
x. Genistein, protein tyrosine kinase inhibitor (50 µM for 24 hrs). 
xi. Cyclic RGD peptide, integrin inhibitor (130 µM for 24 hrs).  
 
4.2.2.1 Impact of signal pathway blockade on TM cellular expression 
 
 The TM BDCA-3 Duoset ELISA was routinely used to monitor TM protein levels in 
HAECs for these signalling studies. These results are outlined between Fig 4.4 and 4.6. 
Firstly, application of genistein or PD169316 to block protein tyrosine kinase or p38, 
respectively, significantly reversed the cyclic strain-mediated reduction in TM cellular 
expression (Fig 4.6A-B). Application of either NSC23766 (Fig 4.4B) or PI3Kα (Fig 4.6D) did 
not exhibit a statistically significant effect on the strain-induced reduction in TM protein 
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levels. Lastly, experiments using either L-NAME (Fig 4.4A), apocynin (Fig 4.5A), SOD (Fig 
4.5B) or PD98059 (Fig 4.6C) unfortunately lacked any clear statistical relevance (unknown 
reasons). The results are summarised in Table 4.2.  
 
4.2.2.2 Impact of signal pathway blockade on TM release 
 
This section investigated the impact that blockade of signalling components may have 
on cyclic strain-mediated TM release. These results are outlined between Fig 4.7 and 4.11. 
Firstly, application of GM6001 to inhibit MMPs moderately decreased (statistically 
significant) the cyclic strain-mediated increase in TM release (Fig 4.7A). Conversely, 
blockade of rhomboids with DCI had the opposite effect by moderately increasing the strain-
induced TM release (Fig 4.7B). We also observed a strong decrease in cyclic strain-induced 
TM release following the addition of SOD to inhibit ROS (Fig 4.10B), although inhibition of 
NADPH oxidase using apocynin did not have an effect on the elevated TM release (Fig 
4.10A). Interestingly, we observed a very significant increase in TM release under both static 
and strained conditions following the addition of cyclic RGD peptide (to inhibit ανβ3 
integrin), whilst PD169316 (for p38 inhibition) increased TM release under strain conditions 
(Fig 4.8 and 4.11B). Finally, the addition of either L-NAME (Fig 4.9A), NSC23766 (Fig 
4.9B), genistein (Fig 4.11A), PD98059 (Fig 4.11C) or PI3K-α inhibitor (Fig 4.11D) had no 
statistically significant effect on the cyclic strain-induced increase of TM release from 
HAECs. Details of the signaling components tested are summarised in Table 4.2. 
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4.3 Tables and Figures 
 
Inflammatory 
component 
Conc. Used TM mRNA  
expression 
TM protein  
expression 
         TM release 
    - CS             + CS 
TNF-α 0-100 ng/ml             ↓ ↓ NE ↑ (100 
ng/ml) 
Ox-LDL 0-50 µg/ml             ↓ ND NE ↑ (10-50 
µg/ml) 
Glucose 5-30 mM           NE NE NE ↓ (15-30 
mM) 
 
 
Table 4.1: Inflammatory conditions tested in the absence or presence of cyclic strain. Details 
of the inflammatory components tested. The symbols used represent the following; ↑, 
significant increase; ↓, significant decrease; +/-CS, in the absence or presence of cyclic strain; 
ND, not determined; NE, no effect. 
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Target Inhibitor Conc. Thrombomodulin 
      Expression             Release  
MMPs GM6001 10 µM ND ↓ 
Integrin ανβ3 Cyclic RGD 
integrin inhibitor 
130 µM ND ↑ 
Rhomboids DCI 10 µM ND ↑ 
eNOS L-NAME 1mM NE NE 
Rac1 NSC23766 50 µM NE NE 
NADPH oxidase Apocynin 10 µM NE NE 
ROS SOD 100 U/ml NE ↓ 
Erk 1/2 PD98059 10 µM NE NE 
p38 PD169316 10 µM ↑ ↑ 
PI3K PI3K-α In. 2 µM NE NE 
Protein Tyr 
Kinase 
Genistein 2 µM ↑ NE 
 
Table 4.2: Signalling components tested in the absence or presence of cyclic strain for effect 
on strain-induced changes in TM expression and release. The symbols used represent the 
following; ↑, significant increase; ↓, significant decrease; ND, not determined; NE, no effect. 
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Figure 4.1: Effect of TNF-α on TM expression and release. Static HAECs were initially 
exposed to TNF-α (0 – 100 ng/ml for 24 hrs) and monitored for TM expression and release. 
(A) TNF-α-dependent reduction in TM mRNA levels (n=3). Histogram represents fold 
change in relative levels of TM mRNA normalized to untreated control (S18 primers). (B) 
TNF-α-dependent reduction in TM protein levels. Histogram represents fold change in 
relative levels of TM protein normalized to untreated control (GAPDH) (*P≤0.05 versus 0 
ng/ml determined using 1-way ANOVA and post-hoc Dunnett’s test). Blots are representative 
of 3 replicates. (C) TM release following TNF-α treatment in the absence and presence of 
cyclic strain (*P≤0.05 versus unstrained 0 ng/ml; δP≤0.05; εP≤0.05 determined using 1-way 
ANOVA and post-hoc Dunnett’s test, n=6).  
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Figure 4.2: Effect of ox-LDL on TM expression and release. Static HAECs were initially 
exposed to ox-LDL (0 – 50 µg/ml for 24 hrs) and monitored for TM expression and release. 
(A) ox-LDL-dependent reduction in TM mRNA levels. Histogram represents fold change in 
relative levels of TM mRNA normalized to untreated controls (S18 primers) (*P≤0.05 versus 
0 µg/ml determined using 1-way ANOVA and post-hoc Dunnett’s test, n=3). (B) TM release 
following ox-LDL treatment in the absence and presence of cyclic strain (*P≤0.05 versus 
unstrained 0 µg/ml; δP≤0.05; εP≤0.05 determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=3). 
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Figure 4.3: Effect of glucose on TM expression and release. Static HAECs were initially 
exposed to glucose (5 – 30 mM for 24 hrs) and monitored for TM expression and release. (A) 
Glucose-dependent regulation in TM mRNA levels. Histogram represents fold change in 
relative levels of TM mRNA normalized to untreated control (S18 primers) (n=3). (B) 
Glucose-dependent regulation of TM protein levels (n=3). (C) TM release following glucose 
treatment in the absence and presence of cyclic strain (*P≤0.05, **P≤0.01 versus unstrained 5 
mM determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). 
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Figure 4.4: Effect of L-NAME and NSC23766 on cyclic strain-dependent TM protein 
expression. HAECs were pre-incubated with the relevant inhibitor for 30 mins before 
undergoing 7.5% cyclic strain for 24 hrs. (A) Effect of 1 mM L-NAME (n=12). (B) Effect of 
50 µM NSC23766 (*P≤0.05 versus unstrained 0 µM determined using 1-way ANOVA and 
post-hoc Dunnett’s test, n=9).  
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Figure 4.5: Effect of apocynin and SOD on cyclic strain-dependent TM protein expression. 
HAECs were pre-incubated with the relevant inhibitor for 30 mins before undergoing 7.5% 
cyclic strain for 24 hrs. (A) Effect of 10 µM apocynin (n=3). (B) Effect of 100 U/ml SOD 
(n=9).  
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Figure 4.6: Effect of Genistein, PD169316, PD98059 and PI3Kα inhibitor on cyclic strain-
dependent TM protein expression. HAECs were pre-incubated with the relevant inhibitor for 
30 mins before undergoing 7.5% cyclic strain for 24 hrs. (A) Effect of 50 µM Genistein 
(*P≤0.05 versus unstrained 0 µM, δP≤0.05 determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=3). (B) Effect of 10 µM PD169316 (*P≤0.05 versus unstrained 0 µM, 
δP≤0.05 determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (C) Effect of 10 
µM PD98059 (n=9). (D) Effect of 2 µM PI3Kα inhibitor (*P≤0.05 versus unstrained 0 µM 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=9). 
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Figure 4.7: Effect of GM6001 and DCI on cyclic strain-induced TM release. HAECs were 
pre-incubated with the relevant inhibitor for 30 mins before undergoing 7.5% cyclic strain 
treatment for 24 hrs.  (A) Effect of 25 µM GM6001 (*P≤0.05 versus unstrained 0 µM, 
δP≤0.05 determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (B) Effect of 10 
µM DCI (*P≤0.05 versus unstrained 0 µM determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=3). 
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Figure 4.8: Effect of cyclic RGD peptide inhibitor on cyclic strain-induced TM release. 
HAECs were pre-incubated with the inhibitor for 30 mins before undergoing 7.5% cyclic 
strain treatment for 24 hrs. Effect of 130 µM cyclic RGD peptide inhibitor (*P≤0.05 versus 
unstrained 0 µM determined using 1-way ANOVA and post-hoc Dunnett’s test, n=3). 
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Figure 4.9: Effect of L-NAME and NSC23766 on cyclic strain-induced TM release. HAECs 
were pre-incubated with the relevant inhibitor for 30 mins before undergoing 7.5% cyclic 
strain treatment for 24 hrs.  (A) Effect of 1 mM L-NAME (*P≤0.05 versus unstrained 0 mM 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (B) Effect of 50 µM 
NSC23766 (n=3). 
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Figure 4.10: Effect of apocynin and SOD on cyclic strain-induced TM release. HAECs were 
pre-incubated with the relevant inhibitor for 30 mins before undergoing 7.5% cyclic strain 
treatment for 24 hrs. (A) Effect of 10 µM apocynin (*P≤0.05 versus unstrained 0 µM 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (B) Effect of 100 U/ml 
SOD (*P≤0.05 versus unstrained 0 U/ml determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=3). 
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Figure 4.11: Effect of Genistein, PD169316, PD98059 and PI3Kα inhibitor on cyclic strain-
induced TM release. HAECs were pre-incubated with the relevant inhibitor for 30 mins 
before undergoing 7.5% cyclic strain treatment for 24 hrs. (A) Effect of 50 µM Genistein 
(*P≤0.05 versus unstrained 0 µM determined using 1-way ANOVA and post-hoc Dunnett’s 
test, n=3). (B) Effect of 10 µM PD169316 (*P≤0.05 versus unstrained 0 µM, δP≤0.05 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=3). (C) Effect of 10 µM 
PD98059 (*P≤0.05 versus unstrained 0 µM determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=6). (D) Effect of 2 µM PI3Kα inhibitor (*P≤0.05 versus unstrained 0 µM 
determined using 1-way ANOVA and post-hoc Dunnett’s test, n=3). 
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4.4 Discussion 
 
The results from this chapter give a more detailed insight into the molecular signalling 
mechanisms putatively regulating the cyclic strain-induced change in TM expression and 
release from HAECs. Section 4.2.1 describes the impact of different inflammatory mediators 
under static and strain conditions. Atherogenic conditions typically involve “multiple” 
vascular parameters such as abnormal strain and shear levels, high oxLDL, high glucose, and 
increased levels of pro-inflammatory cytokines. We therefore decided to investigate these 
stimuli both in isolation and in combination with elevated strain to identify possible 
synergistic effects on the expression and release of TM from HAECs.  
Firstly, we looked at the effect that TNF-α, a pro-inflammatory cytokine, would have 
on TM expression in HAECs. We were not surprised to observe a TNF-α-mediated reduction 
of TM protein and mRNA expression in static HAECs. This is in agreement with the literature 
(Bergh et al., 2009; Grey et al., 1998) as TNF-α has previously been shown to down-regulate 
TM expression/release in monocytes (Lin et al., 2011) via suppression of TM transcription 
and TM protein internalization with subsequent degradation. Subsequently, we investigated 
the effect TNF-α would have on TM release in HAECs in the presence and absence of cyclic 
strain. Interestingly, TNF-α had no significant effect on TM release in static HAECs (i.e., 
unstrained) but an “additive” effect at high concentrations (100 ng/ml) in the presence of 
7.5% cyclic strain. There is nothing reported in the literature about the combined effect of 
cyclic strain and TNF-α on TM release, making this a relatively novel observation. It has been 
shown that TNF-α stimulation of endothelial/neutrophil co-cultures causes TM release from 
static endothelial cells, possibly explaining the TNF-α induced increase in serum TM levels 
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observed in diseases associated with elevated inflammatory signalling (Boehme et al., 1996). 
The same group observed that incubation of endothelial cell monocultures with TNF-α (i.e., 
without neutrophils) had no effect on TM release, which also agrees with our observations. 
These two observations of reduced TM expression and increased TM release following 
incubation with high concentrations of TNF-α are typical of an inflammatory stimulus. 
The second inflammatory mediator we looked at in this context was ox-LDL. We first 
observed the effect ox-LDL had on TM mRNA expression in HAECs. We found that ox-LDL 
reduced TM mRNA expression in static HAECs at 50 µg/ml. This result was consistent with 
the literature as ox-LDL has previously been shown to down-regulate TM mRNA expression 
in HUVECs (Ishii et al., 1996). This group suggested that the decrease in mRNA expression 
was caused by an inhibition of TM transcription, likely explaining our result. Next, we looked 
at the effect ox-LDL had on TM release in the presence and absence of cyclic strain in 
HAECs. We observed that ox-LDL had little or no effect on TM release at 10 µg/ml in static 
HAECs but clearly potentiated TM release dose-dependently in the presence of 7.5% cyclic 
strain. Again, to our knowledge there are no reports investigating the effect that oxLDL has 
on TM release either in static or strained cells. Interestingly, ox-LDL produces free radicals 
which are cytotoxic to endothelial cells (Cominacini et al., 2000) and may stimulate TM 
release. This possibility and others (e.g., ox-LDL interaction with endothelial plasma 
membrane dynamics and vesicular production under strain) remains to be investigated as 
possible mechanisms. Based on these observations, we can conclude that atherogenic 
mediators such as TNF-α and ox-LDL may potentiate endothelial dysfunction stemming from 
elevated cyclic strain, leading to reduced production of TM and enhanced release by either 
cleavage or shedding into the circulation. 
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Next, we observed the effect that glucose, present at high levels in hyperglycemia and 
diabetes mellitus, would have on TM regulatory dynamics in HAECs. Firstly, we looked at 
the effect glucose would have on TM mRNA expression in static HAECs. We observed a 
slight (but insignificant) increase of TM mRNA expression at 15 mM glucose that returns to 
baseline levels at 30 mM. This is in contrast with an earlier study that reported an up-
regulation of TM mRNA expression in static HAECs following incubation with 30 mM 
glucose for 4-6 hours (Wang et al., 2012). The difference in results may be due to different 
incubation times (i.e., 6 hours versus 24 hours) and perhaps glucose has an acute short-term 
effect on the cells but returns to homeostatic status following 24 hours. We next investigated 
the effect glucose would have on TM protein expression (as monitored by ELISA). We noted 
a small but non-significant increase in TM cellular expression after incubation with 30 mM 
glucose in static HAECs. These observations somewhat agree with the previous study (Wang 
et al., 2012) which reported a 9% increase in TM protein expression in static HAECs 
following 30 mM glucose application for 4 – 6 hours. We subsequently investigated the effect 
glucose had on TM release in HAECs in the presence and absence of cyclic strain. We 
observed a small, but non-significant increase in TM release at 30 mM glucose in static 
HAECs. Intriguingly, TM release was significantly reduced at 15 and 30 mM glucose in the 
presence of 7.5% cyclic strain. There is an absence of in vitro studies documenting this 
response but there is some clinical data available. Increased soluble TM antigen levels were 
reported in the serum and urine of streptozotocin-induced diabetes model rats (Nakano et al., 
2000). High levels of TM have also been reported in the serum of diabetic patients (Aso et al., 
2000), likely reflecting an impairment of renal clearance of TM from the blood. Our own 
results in static cells indicate that elevated glucose (30 mM) can significantly enhance TM 
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release, consistent with these in vivo observations. Elevated soluble TM levels are associated 
with hypercoagulability and enhanced fibrinolysis in patients with type 2 diabetes (Aso et al., 
2000), although cardioprotective effects cannot be ruled out. In this regard, the reduction of 
TM release observed following a combination of elevated glucose with strain in our studies 
may reflect a reduction in cardioprotection in diabetes with combined hypertension (a feature 
of advanced metabolic syndrome and diabetes).  
In conclusion, our data to this point suggests that atherogenic conditions may involve 
multiple inflammatory mediators in combination to impact endothelial homeostasis and TM 
levels. We observed that TNF-α reduced TM expression in static HAECs but additively 
potentiated TM release in HAECs undergoing 7.5% cyclic strain. Similar to TNF-α, ox-LDL 
decreased TM mRNA expression in static HAECs whilst significantly increasing TM release 
in HAECs following 7.5% strain. We also found that glucose had no effect on TM expression 
in static HAECs and attenuated release in HAECs undergoing 7.5% cyclic strain. This area 
warrants further investigation possibly by combining these three different humoral conditions 
with elevated cyclic strain to help better replicate the actual in vivo situation. 
The following section (4.2.2) describes how selective blockade of key signalling 
components may affect the cyclic strain-dependent change in TM expression and/or release. 
In the first portion of this section (4.2.2.1), we investigate the effect of inhibiting these 
signalling components on the cyclic strain-mediated reduction in TM cellular expression. 
Specifically, we found that the addition of either genistein or PD169316 to block Protein 
Tyrosine Kinase (PTK) and p38, respectively, significantly reversed the cyclic strain-
mediated reduction in TM cellular expression (Fig 4.12). Other inhibitors tested either showed 
no effect (NSC23766) or indeed data were generally insignificant. This may be because the 
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pharmacological inhibitors employed had off target effects, elicited some level of cytotoxicity 
or interfered with the mechanism of the ELISA.  
 
 
 
Figure 4.12: Signalling components affecting the cyclic strain-mediated TM cellular 
expression pathway. Cyclic strain activates PTK and p38 MAPK to dampen TM cellular 
expression (top diagram). Inhibition of PTK or p38 MAPK significantly reverses the cyclic 
strain-reduction in TM protein expression (lower diagram). Key: COOH, carboxylic acid; CS, 
chondroitin sulphate; MAPK, mitogen-activated protein kinase; NH2, amine group; O, 
oxygen; PTK, protein tyrosine kinase; TM, thrombomodulin.   
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As mentioned above, the addition of genistein, a PTK inhibitor, significantly reversed 
the typical cyclic strain-mediated reduction in TM protein expression in HAECs. This is 
consistent with earlier work reporting the strain sensitivity of PTK (Cheng et al., 2002). The 
addition of genistein has previously been shown to reduce the strain-dependent induction of 
MMP-2 cellular expression in BAECs (Von Offenberg Sweeney et al., 2004), indicating a 
role for PKT in the mechanotransduction of strain (Fig 4.12). Similarly, cyclic strain has 
previously been shown to stimulate monocyte chemotactic protein-1 (MCP-1) mRNA 
expression in smooth muscle cells through tyrosine kinase activation (Jiang et al., 1999). Due 
to the crucial involvement of PTK in many signal transduction cascades, it was therefore not 
unexpected that it had a significant effect in our TM model. 
Additionally, we explored MAPK p38 by utilising PD169316 in our strain model. We 
determined that the addition of PD169316 significantly reversed the usual cyclic strain-
dependent decrease in TM cellular expression in HAECs (Fig 4.12). p38 is known to be 
activated by stress stimuli and in response to various cytokines, thus mediating cellular 
activities including apoptosis and inflammation (Noel et al., 2008). Moreover, p38 is known 
to be sensitive to cyclic strain in BAECs (Von Offenberg Sweeney et al., 2004) and smooth 
muscle cells (Li et al., 2000). In addition, p38 is involved in mediating the strain-induced 
expression of endothelin-1 in BAECs (Cheng et al., 2001). To our knowledge, this is the first 
instance in which the strain-dependent modulation of TM expression has been linked to PTK 
and p38 MAPK activation (note: whether these components are working in a linear fashion or 
via separate pathways remains to be determined however).  
Also worth mentioning is the effect of NSC23766, a Rac1 inhibitor. In the presence of 
strain, NSC23766 failed to reverse the strain-dependent down-regulation in TM protein levels 
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in HAECs, suggesting lack of involvement of Rac1 in these events. Previously, pravastatin 
was shown to up-regulate TM expression in TNF-α treated HAECs by inhibiting the 
activation of Rac1/Cdc42 and NFкB (Lin et al., 2007). This is significant as TNF-α normally 
has a down-regulatory effect on TM expression. Additionally, elevated strain was shown to 
stimulate IL-6 expression via a Rac1 signalling pathway in smooth muscle cells (Zampetaki et 
al., 2005). Given the pivotal role of Rac1 in the regulation of the cellular cytoskeleton in 
response to various stimuli (including strain), its lack of involvement in the 
mechanoregulation of TM expression was surprising.   
In the second part of this section (4.2.2.2), we examined the outcome of blocking 
specific signalling components (as described above) on cyclic strain-induced TM release from 
HAECs. We observed a significant decrease in cyclic strain-induced TM release following the 
addition of GM6001 and SOD to specifically inhibit MMPs and to scavenge ROS, 
respectively (Fig 4.13). In addition, we noted a slight increase in cyclic strain-mediated TM 
release following addition of DCI and PD169316, and a very significant increase in both static 
and strain-mediated TM release with cyclic RGD peptide inhibitor. Results with other 
inhibitors were non-significant or had no effect. Additionally, it is important to note that we 
observed a lot of variation in the fold decrease in TM expression or increase in TM release in 
response to 7.5% cyclic strain. We have addressed this issue in the Appendix in Figure B.  
Numerous publications have focused on the proteolytic cleavage of endothelial TM to 
yield a soluble released TM variant (sTM). sTM has been detected in many biological fluids 
including serum (Oida et al., 1990), urine (Jackson et al., 1994) and synovial fluid (Conway 
and Nowakowski, 1993). This proteolytic cleavage has been attributed to a number of 
causative elements including leukocyte-derived lysosomal proteases (Abe et al., 1994), 
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neutrophil-derived enzymes (Matsuyama et al., 2008), MMPs (Wu et al., 2008), cysteine 
proteases (Inomata et al., 2009) and serine proteases (Lohi et al., 2004). In this respect, we 
initially concentrated on the role MMPs and rhomboids play in relation to cyclic strain-
mediated TM release. In this regard, GM6001 was incorporated into our strain experiments in 
order to inhibit a broad range of MMPs. MMPs were investigated based on their sensitivity to 
cyclic strain (Cummins et al., 2007; Hasaneen et al., 2005), and on an earlier report indicating 
that LPA-induced TM lectin-like domain shedding is MMP-dependent in HUVECs (Wu et 
al., 2008). Lysophosphatidic acid (LPA) is a bioactive lipid mediator present in biological 
fluids during endothelial damage or injury that can trigger MMP-dependent TM shedding. 
This may contribute to the exposure of its EGF-like domain for EGF receptor (EGFR) 
binding, thus inducing subsequent cell proliferation and possibly mediating LPA-induced 
EGFR transactivation. Interestingly, the lectin-like domain has anti-inflammatory properties 
by inhibiting NF-қB activation and mitogen-activated protein kinase (MAPK) pathways. DCI 
was also included in our strain model to investigate rhomboids. It has been reported that a 
rhomboid-like serine protease, RHBDL2, specifically cleaves TM at the transmembrane 
domain for the release of soluble TM (Cheng et al., 2011). Conversely, another group 
observed the same affect but stated that this was not mutually exclusive as most 
thrombomodulin transmembrane domains (TMDs) are not rhomboid substrates (Lohi et al., 
2004). We observed that the blockade of MMPs with GM6001 appeared to cause a slight 
decrease in the cyclic strain-induced TM release (Fig 4.13). By contrast, inhibition of 
rhomboids with DCI resulted in a slight increase in the cyclic strain mediated TM release. 
Based on these observations, we concluded that a small proportion of TM release is caused by 
proteolytic cleavage via MMPs (~10% following correction for baseline effects), whilst 
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rhomboids may be putatively involved in “slowing down” TM release (i.e., inhibition with 
DCI is enhancing release). However, the remainder of released sTM following strain may 
possibly be attributed to a different release mechanism (i.e., vesicular), which will be 
discussed further on.  
Cyclic strain induces oxidative stress, which produces reactive oxygen species (ROS) 
in endothelial cells (Howard et al., 1997; Matsushita et al., 2001). This subsequently regulates 
gene expression, migration, proliferation, release and apoptosis (Cheng et al., 1996; Cheng et 
al., 2001; Hannafin et al., 2006; Kou et al., 2009; Lin et al., 2010). NADPH oxidase, a ROS 
producer, is implicated in atherosclerosis and vascular remodelling (Matsushita et al., 2001).  
NADPH oxidase was not shown in our studies to mediate cyclic strain-induced TM release 
(i.e., using apocynin), even though NADPH oxidase – derived ROS have previously been 
linked to strain-mediated MMP-2 upregulation in vascular smooth muscle cells (Grote et al., 
2003) and other endothelial pathways. SOD was therefore included into our strain 
experiments to scavenge strain-induced superoxide (ROS) production from other cellular 
sources. We reported a significant decrease in cyclic strain-induced TM release with SOD 
(Fig 4.13), contrasting sharply with the lack of effect of apocynin. It is apparent therefore that 
ROS has a role in cyclic strain-induced TM release but from an NADPH oxidase-independent 
source. This would indicate the involvement of a strain-inducible ROS-source other than 
NADPH oxidase (e.g., xanthine oxidase). As mentioned already, elevated cyclic strain leads 
to the production of ROS (Howards et al., 1997), which is associated with hypertension (Chae 
et al., 2001; Goch et al., 2009). ROS have the ability to target and modify MAPK proteins and 
PTKs (Paravicini and Touyz, 2006), both of which we have already shown to affect cyclic 
strain-mediated TM cellular expression. Additionally, ROS may be working in tandem with 
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MMPs to stimulate proteolytic release of TM due to their ability to promote MMP-2 release in 
vascular smooth muscle cells (Grote et al., 2003). This question requires further answers 
however before the mechanism can be fully described.  
 
 
Figure 4.13: Signalling components affecting the cyclic strain-mediated TM release pathway. 
Cyclic strain activates MMPs and ROS to induce in-part TM release (top diagram). Inhibition 
of MMPs or ROS significantly reversed the cyclic strain-increase in TM release (lower 
diagram). Key: MMP, matrix metalloproteinase; TM, thrombomodulin; ROS, reactive oxygen 
species.   
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We next looked at integrins, transmembrane receptors known to be cyclic strain-
sensitive mechanotransducers (Wilson et al., 1995; Yano et al., 1997). They mediate crucial 
endothelial cell functions such as migration and tube formation in response to hemodynamic 
forces (Thodeti et al., 2009; Von Offenberg Sweeney et al., 2005). To our knowledge, there is 
a complete absence of in vitro data documenting a role for integrins in regulating cyclic 
strain-mediated TM release. Integrins were previously shown to regulate cyclic strain-induced 
IL-6 secretion in HUVECs (Sasmoto et al., 2005) among other markers. We employed cyclic 
RGD peptide inhibitor to specifically block integrin ανβ3 in our strain experiments. 
Interestingly, TM release was further increased very significantly under both static and strain 
conditions following inhibition of this integrin. This suggests that integrins “slow down” the 
release of TM under both basal and cyclic strain conditions (i.e., inhibition enhances release), 
which may reflect their typical “outside-in” signalling capacities (Hannafin et al., 2006). This 
possibly reveals the status of the endothelial cell to the extracellular environment as elevated 
sTM is a well-known injury marker for cardiovascular disorders (Thorand et al., 2007; Urban 
et al., 2005; Wu et al., 2003). Furthermore, integrin-mediated shedding of procoagulant 
microparticles from unstimulated platelets was reported (Cauwenberghs et al., 2006) which 
points to a possible role for microvesicles in cyclic strain-induced TM release. This study 
contrasts with our observations which may indicate that the response we are observing may be 
an endothelial-cell specific one.  
Finally, we did not observe an effect on strain-induced TM release after the addition of 
NSC23766, genistein, PD169316 or L-NAME to inhibit rac1, PTK, MAPK p38 and eNOS, 
respectively. We investigated Rac1 due to its sensitivity to cyclic strain (Kumar et al., 2004) 
and its link to TM expression (Lin et al., 2007) but nothing has previously been reported in 
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relation to TM release. Interestingly, Rac1 was previously shown to regulate the release of 
Weibel-Palade Bodies in HAECs (Yang et al., 2004) so it was surprising that Rac1 had no 
role in the cyclic strain-mediated TM release. Similarly, PTK and MAPK p38, both strain-
sensitive kinases (Cheng et al., 2002; Lin et al., 2000; Von Offenberg Sweeney et al., 2004) 
had no effect on this strain-driven event. This is despite the fact that these proteins 
significantly reversed the cyclic strain-induced reduction of TM protein expression (Section 
4.2.2.1). Taken together, these results indicate that TM expression and release likely engage 
different signalling pathways.  
In summary, the first portion of this chapter demonstrated that many inflammatory 
mediators work together to regulate endothelial homeostasis and TM dynamics. TNF-α 
potentiated TM release in HAECs undergoing 7.5% cyclic strain, which may reflect its ability 
to activate NF-κB and MAPK pathways (Anrather et al., 1997; Li et al., 2005). Similarly to 
TNF-α, ox-LDL reduced TM mRNA expression in static HAECs possibly due to decreased 
TM transcription (Ishii et al., 1996; Ishii et al., 2003). Ox-LDL also potentiated TM release in 
HAECs undergoing cyclic strain although, like TNF-α, the cellular mechanisms involved are 
unknown at present. Lastly, we observed that glucose had no significant effect on TM 
expression in static HAECs despite reports suggesting the opposite in the literature (Wang et 
al., 2012). We also found that the addition of glucose (30 mM) enhances TM release in statics 
HAECs. This is consistent with the in vivo literature, as elevated levels of TM have been 
reported in the serum of patients with type 2 diabetes (Aso et al., 2000). Additionally, TM 
release was attenuated when elevated glucose (30 mM) was combined with strain, which may 
suggest a decrease in cardioprotection. This observation is somewhat consistent with a second 
clinical study showing that levels of soluble TM were inversely correlated with the risk of 
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developing type 2 diabetes (Thorand et al., 2007). However, contradictory data has been 
reported on sTM levels (whether they are increased or decreased) and type-2 diabetes.  This 
area warrants further investigation possibly by combining these three different humoral 
conditions with elevated cyclic strain to help better replicate the actual in vivo situation. 
Additionally, this would address the possible degree of commonality between these 
interlinked pathways (i.e., ox-LDL, TNF-α and glucose may operate through similar 
pathways) that these inflammatory mediators act on.  
The second portion of this chapter identifies the signalling components involved in 
cyclic strain-mediated TM regulation. We found that inhibition of PTK and p38 MAPK 
increased cyclic strain-mediated TM expression (i.e., reverses the typical strain-dependent 
response). In respect to these two proteins, this result was not unexpected due to their strain-
sensitivity (Cheng et al., 2002) and their involvement in many signal transduction pathways 
(Noel et al., 2008; Von Offenberg Sweeney et al., 2004). Subsequently, we focused on cyclic 
strain-induced TM release. Firstly, we observed that inhibition of MMPs decreased cyclic 
strain-induced TM release (i.e., reverses the typical strain-dependent response). This was not 
unexpected as MMPs are known to be strain-sensitive and implicated in atherosclerosis and 
hypertension (Cummins et al., 2007).  We also observed that NADPH oxidase-independent 
ROS plays a role in cyclic strain-induced TM release (e.g., xanthine oxidase), which was not 
surprising as the endothelium typically experiences oxidative stress (i.e., high levels of ROS) 
during CVD (Howard et al., 1997; Matsushita et al., 2001). ROS has previously been reported 
to target MAPK proteins and PTKs (Paravicini and Touyz, 2006), which also have a 
significant effect on cyclic strain-mediated TM cellular expression. We also found that 
inhibition of integrin ανβ3 causes an additional increase in TM release in both static and 
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strained HAECs, suggesting that integrins serve as a cellular “brake” for the release of TM, 
and may explain elevated TM release in pathophysiological situations wherein integrin 
function is compromised (e.g., atherosclerosis). Thus, a small proportion of TM release during 
strain is triggered by proteolytic cleavage by MMPs (~10% corrected for baseline effects), 
whilst the remainder of TM release may possibly proceed through a vesicular pathway (i.e., 
on microparticles or exosomes), which will be the focus of Chapter 5.   
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Chapter 5: 
Further studies on the dynamics of 
cyclic strain-mediated TM “release” 
from HAECs 
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5.1 Introduction 
 
In the previous chapter, we investigated the role of inflammatory mediators (e.g., 
TNF-α) and signaling components (e.g., p38) on cyclic strain-induced TM expression and 
release. For Chapter 5, we subsequently decided to focus on TM release, as it is very poorly 
understood in the literature, whilst soluble TM (sTM) is now widely regarded as a significant 
injury biomarker for endothelial dysfunction (Boehme et al., 1996). Indeed, elevated levels of 
sTM have been reported in the plasma of patients with atherosclerosis (Pawlak et al., 2010; 
Taylan et al., 2012), cardioembolic stroke (Dharmasaroja et al., 2012), obesity (Urban et al., 
2005), Lupus erythomatosus-associated metabolic syndrome (Mok et al., 2010), pre-eclampsia 
(Rousseau et al., 2009), sepsis-associated disseminated intravascular coagulation (DIC) (Lin 
et al., 2008), and severe acute respiratory syndrome (SARS) (Liu et al., 2005). Interestingly, 
the beneficial effects of soluble TM have also been reported in human clinical trials (Saito et 
al., 2007) with the development of ART-123 (thrombomodulin alpha, RecomodulinTM), a 
recombinant human soluble TM shown to be extremely effective in the rapid resolution of 
DIC. Given the consistent release of TM (dose- and time-dependently) from HAECs by cyclic 
strain, and considering that only a proportion (~30%) appears to be attributable to proteolytic 
release, we hypothesize that cellular microvesicles (MVs) may represent a possible vehicle for 
a proportion of strain-dependent TM release in this model.  
 MVs (Section 5.2.1) (Fig 5.1) are shed from the endothelium in response to cell 
activation or apoptosis and are emerging as novel biomarkers with the potential to regulate 
inflammation and immunological processes (reviewed in more detail in Leroyer et al., 2010). 
Due to the fact that we have shown that elevated levels of cyclic strain stimulate TM release, 
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we suspect that it may in fact be causing MV shedding. Although there is nothing reported in 
the literature that directly links cyclic strain with MVs, it has been shown that TM activity on 
both monocytes and monocyte-derived microparticles is increased after treatment with 
lipopolysaccahride (LPS) (Satta, 1997).  
 
 
 
Figure 5.1: Cellular microvesicle (MV). MVs are shed from the plasma membrane of 
activated cells. They store membrane and cytoplasmic proteins implicating them in a wide 
range of vital functions. Key; MHC, major histocompatibility complex; GPI, 
glycosylphosphatidylinositol (Hugel, 2005).   
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 Of the secreted membrane vesicles from endothelial cells, exosomes and 
microparticles (MPs) remain the most commonly studied (Azevedo et al., 2007; Vlassov et 
al., 2012). These differ by size, with exosomes measuring 30-100 nm (Théry et al., 2009) and 
MPs 100–1000 nm (Distler et al., 2005). Our aim in this chapter was to clarify whether TM 
released into the media (aka sTM) was present on a microvesicular structure such as a 
microparticle or an exosome. We therefore carried out a series of centrifugation experiments 
(Fig 5.3) to isolate MVs putatively released into media following strain of HAECs, with 
subsequent analysis of MV-associated TM levels by ELISA and Western blotting. A Total 
Exosome Isolation Kit was also employed for these studies. 
Soluble “released” thrombomodulin (sTM), a molecular marker for assessing 
endothelial cell injury, has been reported to vary in size between 55 kDa to 105 kDa (Ishii and 
Majerus, 1985; Salem et al., 1984) although its precise functional role in release is the subject 
of much speculation. To date, sTM has been detected in biological fluids ranging from serum 
(Oida et al., 1990) and urine (Jackson et al., 1994) to synovial fluid (Conway and 
Nowakowski, 1993). High levels of sTM typically signify endothelial dysfunction, thus acting 
as a biomarker for the same. The difference in molecular weight (MW) for sTM may be 
explained by it’s release mechanism from the membrane and subsequent processing within 
the extracellular environment. For example, it has been reported that cellular TM can be 
cleaved by proteases to release low MW sTM variants (Lohi et al., 2004; Wu et al., 2008). 
Others have suggested microparticle (and exosome) involvement in sTM release, which 
would suggest up to full size TM (Bouchama et al., 2008; Ogura et al., 2004). We therefore, 
decided to measure the MW of the sTM released by cyclic strain in vitro from HAECs. Post-
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strain, we harvested cell lysates and concentrated cell culture media with Amicon® Ultra-2 
centrifugal filter devices for MW analysis of sTM by Western blotting.   
 Due to the elevated presence of released sTM linked to endothelial injury and 
dysfunction in numerous vascular disorders (Aso et al., 2000; Blann et al., 1997; 
Dharmasaroja et al., 2012), it is logical to presume that this released entity may have a 
functional role within the vasculature in vivo. We therefore decided to investigate in this 
chapter whether the TM released via cyclic strain had functional activity. Methods used to 
measure TM “functionality” in vitro are limited however, with the most common being to 
measure protein C (PC) activation. In this regard, one group has developed a novel technique 
to quantitate sTM activity in vitro using a human activated protein C (APC) antibody-based 
ELISA in order to back-calculate levels of sTM (Carnemolla et al., 2012). Interestingly, one 
of the most well known roles of TM is the inhibition of coagulation by neutralization of 
thrombin. Our lab has therefore designed a novel assay based on thrombin neutralization by 
sTM in cell culture media (i.e., neutralization of thrombin’s ability to induce permeabilization 
in reporter human aortic endothelial cell cultures). This assay was subsequently employed in 
this chapter to monitor the functional efficacy of released TM following static and strain 
conditions.    
The ability of cyclic strain-conditioned media to elicit TM release in “static” reporter 
HAECs was also conducted as the final aspect of this chapter. This was performed in order to 
assess the “paracrine” impact of strain on TM release from endothelial cells. Interestingly, an 
earlier study showed that a cyclic strain-induced paracrine release of TGF-β(1) elicited a 
downregulation in TM expression in vein grafts (Kapur et al., 2011), although the signalling 
pathway used was unknown. Using a pan-neutralizing TGF-β1 antibody (1D11), these authors 
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were able to block TM down-regulation, preserve levels of activated protein C, and reduce 
thrombus formation in a rabbit vein graft model. In our study, we harvested endothelial 
“conditioned” media from static and strained cells, incubated it with static reporter HAECs, 
and subsequently measured the changes in TM release from these reporter cells as an index of 
paracrine regulation.  
 
5.2 Results 
 
5.2.1 Microvesicle (MV) analysis 
  
 HAECs were subjected to 0% and 7.5% equibiaxial cyclic strain (60 cycles per min 
for 24 hrs). Post-experiment, cell culture serum-free media was harvested from each Bioflex 
well and processed for MVs by centrifugation before being analysed for TM by ELISA 
(protocol illustrated in Fig 5.2). Centrifugation conditions obtained from previous literature 
(Nieuwland et al., 1997; Théry et al., 2009).  
 In a preliminary experiment (Fig 5.3A), we measured the TM concentrations in the 
cell culture serum–free media; before (Pre-Spin) and after (Super) centrifugation at 14,400 rcf 
for 20 mins, as well as in the pellets. We observed that a small proportion of TM release was 
microvesicular (i.e., detected in the pellets) in unstrained HAECs, with slightly more TM 
detected in the pellet after 7.5% cyclic strain. Subsequently, the experiment was repeated with 
spin conditions increased to 20,000 rcf for 40 mins (Fig 5.3B) in an attempt to enhance MV 
enrichment in the pellet fraction. Similar results were obtained.  
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Interestingly, when we repeated this study in BAECs (Fig 5.4) where cell culture 
serum-free media was centrifuged at 14,400 rcf for 20 mins, we did not see a significant 
induction of TM release in response to strain, nor any slight increase in pellet-enriched TM in 
response to strain.  
We subsequently compared the effectiveness of both microvesicle spin conditions 
using the “same” batch of HAEC serum-free media; 14,400 (spin A) vs 20,000 rcf (spin B) 
for 20 vs 40 mins, respectively (Fig 5.4A). Increasing spin speed and time was seen to 
decrease TM concentration in supernatants (Fig 5.5A). 
 MVs can be subdivided into exosomes and microparticles (MPs) based on size. With a 
view to further clarifying whether TM released post-cyclic strain is present on MPs or 
exosomes, we isolated exosomes using Total Exosome Isolation® (Invitrogen, The 
Netherlands) reagent from the cell culture serum-free media following static and strain 
conditions (protocol described in more detail in Fig 5.6). Total TM levels (pg) were measured 
in pre-spin media, supernatants and pellets (containing the enriched exosomes) by ELISA (Fig 
5.7). A high level of TM was observed in the static pellets with strain stimulating significantly 
more release of TM into the pellet fraction.  
 
5.2.2 Molecular size of sTM 
 
 To further investigate the molecular size of soluble TM (sTM) released into the media 
from HAECs, cell culture serum-free media was concentrated using Amicon® Ultra-2 
centrifugal filter devices, determined for protein concentration with a BCA assay and 
subsequently, analysed for TM cellular expression by Western blotting  (Fig 5.8). TM variants 
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were observed in cellular lysates at molecular weights ranging from 35-100 kDa. sTM 
variants were also detected in cell culture serum-free media faintly at 100 kDa and very 
strongly at 35 kDa.  
 
 
5.2.3 Functional efficacy of sTM 
 
 HAECs were subjected to cyclic strain (0% and 7.5% for 24 hrs). Cell culture serum-
free media was harvested post-treatment and concentrated using Amicon® Ultra-2 centrifugal 
filter devices and measured for protein via BCA assay. Conditioned serum-free medias 
(spiked with either vehicle buffer or thrombin, the latter a known permeability agent for 
endothelial cells) was incubated with reporter HAEC monolayers in transwell insert plates 
and the effects on HAEC barrier integrity monitored by a FITC-dextran permeability assay 
(Fig 5.9). We found that the sTM released into the cell culture serum-free media by cyclic 
strain had increased functional activity manifested as an increased ability to attenuate 
thrombin-induced permeability (presumably via sTM binding of thrombin).  
 
5.2.4 Paracrine release of TM 
 
 In order to determine if cyclic strain of endothelial cells can elicit TM release in a 
“paracrine” manner, we conducted a series of conditioned media experiments. Serum-free 
media was taken from pre-strained endothelial cells (0% and 7.5% for 24 hrs) and incubated 
with static “reporter” HAECs for 24 hrs, after which we measured for TM release. When 
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basally released TM was taken into account, we noted that cyclic strain could induce media 
conditioning leading to paracrine induction of TM release in HAECs (Fig 5.10A).  
Additionally, a time-dependent study was also carried out to identify the earliest time-
point at which a paracrine-induced release of TM may be observed. In this regard, serum-free 
media was harvested from pre-strained endothelial cells (0% and 7.5%, 0-24 hrs) and 
incubated with static HAEC reporter cultures for 24 hrs, after which we measured for TM 
release via ELISA (Fig 5.10B). Under cyclic strain conditions, a significant sharp increase in 
paracrine TM release is apparent after 12 hrs.  
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5.3 Table and Figures 
 
 
 
Figure 5.2: The steps involved in processing microvesicles (MVs) from cell culture media 
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Figure 5.3: Microvesicles and TM release. HAECs were exposed to cyclic strain (0% - 7.5% 
for 24 hrs) and monitored for TM levels in the pre-spin media, post-spin supernatant and 
pellet. (A) HAEC media centrifuged at 14,400 rcf for 20 mins (normalised for total pg) 
(δP≤0.05; *P≤0.05 versus 0% Pre-Spin determined using 1-way ANOVA and post-hoc 
Dunnett’s test, n=6). (B) HAEC media centrifuged at 20,000 rcf for 40 mins (normalised for 
total pg) (δP≤0.05; *P≤0.05 versus 0% Pre-Spin determined using 1-way ANOVA and post-
hoc Dunnett’s test, n=6). Key: Super, supernatant. 
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Figure 5.4: Microvesicle and TM release from BAECs. BAECs were exposed to cyclic strain 
(0% - 7.5% for 24 hrs) and then monitored for TM release in the pre-spin media, supernatants 
and pellet. BAEC media was centrifuged at 14,400 rcf 20 min (normalised for total pg) 
(*P≤0.05 versus 0% Pre-Spin determined using 1-way ANOVA and post-hoc Dunnett’s test, 
n=6). Key: Super, supernatant.  
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Figure 5.5: Impact of increasing centrifugation conditions. (A) HAECs were exposed to 
cyclic strain (0% - 7.5% for 24 hrs) and then monitored for TM concentration in the pre-spin 
media, post-spin supernatant and pellet following centrifugation of the same batch of HAEC-
conditioned media at 14,400 and 20,000 rcf for 20 and 40 mins, respectively. (δP≤0.05; 
*P≤0.05 versus 0% Pre-Spin determined using 1-way ANOVA and post-hoc Dunnett’s test, 
n=6). (B) The percentage decrease in sTM concentration in strain-conditioned media 
following both consecutive spins. Key: Super, supernatant. 
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Figure 5.6: The steps involved in enriching exosomes from cell culture media. 
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Figure 5.7: Exosome enrichment. HAECs were exposed to cyclic strain (0% - 7.5% for 24 
hrs) and TM levels (normalised for total pg) were measured in the pre-spin media, supernatant 
and pellet (containing the enriched exosomes) via ELISA. (δP≤0.05; *P≤0.05 versus 0% Pre-
spin Spin determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). Key: Super, 
supernatant.  
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Figure 5.8: Detection of TM in cell lysates and media supernatants. HAECs were exposed to 
cyclic strain (0% and 7.5%, for 24 hrs). Media supernatants were concentrated using Amicon® 
Ultra-2 centrifugal filter devices and then monitored alongside cell lysates for TM by Western 
blotting (30 µg/ml of protein per lane) (n=1). Key: L, lysates; M, media.  
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Figure 5.9: Functional efficacy of sTM. HAECs were exposed to cyclic strain (0% and 7.5%, 
for 24 hrs) with subsequent measurement of transendothelial permeability. Media 
supernatants containing sTM (harvested from static and strained HAECs) were concentrated 
using Amicon® Ultra-2 Centrifugal Filter Devices and then “spiked” with either buffer vehicle 
or thrombin (1 U/ml). Medias were then incubated into the abluminal space of transwell 
assays to monitor effects of permeabilization by thrombin. (A) Line graphs showing the fold-
change in % trans-endothelial exchange of FITC-Dextran over 3 hrs (n=2). (B) Histogram 
showing the difference in permeability at the 120 min-time point (n=2). Note: control media 
are unconditioned media. 
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Figure 5.10: Paracrine TM release. (A) HAECs were pre-exposed to cyclic strain (0% - 7.5% 
for 24 hrs) and conditioned media harvested and incubated with static HAEC reporter cultures 
for 24 hrs. Media supernatants from reporter cultures were monitored for TM release via 
ELISA (δP≤0.05 determined using 1-way ANOVA and post-hoc Dunnett’s test, n=6). (B) 
HAECs were pre-exposed to cyclic strain (0% vs 7.5%) and conditioned (strained) media 
supernatants were taken at varying time-points (0-24 hrs). This conditioned media was then 
incubated with static HAEC reporter cultures for 24 hrs and then measured for TM release via 
ELISA (δP≤0.05 determined using 1-way ANOVA and post-hoc Dunnett’s test, n=3). Key: 
CM, conditioned media.  
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5.4 Discussion 
 
This chapter further investigates the mechanisms associated with cyclic strain-induced 
TM release from HAECs. We started by investigating the possibility that TM release from 
HAECs in response to cyclic strain may proceed via a microvesicular vehicle, namely 
microparticles and/or exosomes. In this regard, we detected sTM on an enriched exosome 
fraction, which was increased in response to chronic cyclic strain.  Endothelial MVs are 
complex vesicular structures shed from activated or apoptotic endothelial cells (Leroyer et al., 
2010) and have roles in coagulation, inflammation, endothelial function, and angiogenesis. 
TM has in fact previously been linked to microvesicles as increased TM activity was shown 
on both monocytes and monocyte-derived microparticles following treatment with LPS (Satta 
et al., 1997). Additionally, endothelial MPs and sTM were found to be elevated in the plasma 
of patients with severe systemic inflammatory response syndrome (SIRS) (Ogura et al., 2004). 
In Chapter 4, we established that TM released after elevated cyclic strain is in part due to 
proteolysis by MMPs (~10%) but the remainder presumably advances through other pathways 
possibly including microparticles or exosomes. In section 5.2.1, we carried out a range of 
centrifugation experiments to enrich MVs within HAEC conditioned media taken from static 
and strained cells. Firstly, we centrifuged media at 14,400 rcf for 20 mins and analysed for 
TM via ELISA. We observed a significant decrease in TM levels from “pre-spin” media to 
supernatant fractions, within subsequent observation of TM in the pellet fraction. Moreover, 
the TM within the pellet fraction increased slightly (albeit significantly) in response to strain. 
Similar observations were made when we increased the centrifugation conditions to improve 
the microvesicle enrichment process. Interestingly, we did not observe a significant induction 
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of TM release in response to strain. When we employed BAECs (although we did observe a 
proportion of TM enrichment into the pellet fraction – equal for both static and strained 
BAECs). This may reflect a species issue between HAECs and BAECs and warrants further 
investigation. The lack of suitability of the human ELISA kit for the bovine cells may also be 
at issue here.  
Taken together, these results point to a putative microvesicular involvement in TM 
release following elevated cyclic strain of HAECs an observation not shown in the literature 
to date. It is worth noting however that mechanical strain was shown to stimulate 
microparticle formation in human pulmonary endothelial cells (Vion et al., 2013). 
Interestingly, this group used a similar centrifugation protocol (20,000 rcf for 30 mins) as our 
study and our data is consistent with their findings. Following high levels of cyclic strain, TM 
may utilise MVs as an escape pathway into the circulation to act as a biomarker for 
endothelial dysfunction and/or a ‘SOS’ signal to communicate with adjacent healthy 
endothelial cells.   
 We next considered that the centrifugation procedure employed may only be allowing 
enrichment of a small proportion of the microvesicular complement in conditioned media, and 
may in fact not be sufficiently enriching for exosomes. MVs are small membrane-enclosed 
sacs (size varying from 50 nm to 1000 nm) that are sub-characterised into exosomes, 
circulating MVs or microparticles (MPs) (Azevedo et al., 2007). These two entities differ in 
size with MPs measuring 100 to 1000 nm2 and exosomes, 50 -100 nm2-sized structures 
(György et al., 2011).  We subsequently enriched for exosomes from HAEC media using a 
Total Exosome Isolation® kit. TM was subsequently measured in pre-spin media, supernatant 
and pellet (containing the enriched exosomes) by ELISA. Whilst we did not observe a 
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substantial difference between TM levels in the pre-spin media and supernatants (which may 
be down to reagent interference with the ELISA) , we found enrichment in TM levels in the 
pellet fraction, with moderately higher amounts of TM detected following 7.5% cyclic strain. 
This presumably indicates that a moderate proportion of sTM released post-strain may be 
present on exosomes.  Again, this is the first time that the presence of released sTM on 
exosomes has been reported, and again warrants further investigation with the use of 
exosomal markers. A recent study showed that the release of MVs expressing an exosome 
marker tumor susceptibility gene (Tsg 101) decreased TM cellular expression in static 
HUVECs (Aharon et al., 2008). This led to increased endothelial thrombogenicity as well as a 
disruption in endothelial integrity and is somewhat consistent with our findings. Although the 
biological roles of exosomes are not clearly understood, we can speculate as to its subsequent 
function in this context. Exosomes are thought to function as “intercellular messengers” 
between adjacent cells, and in this capacity may be capable of delivering TM to other 
endothelial beds to help regulate vessel wall homeostasis during inflammation of the 
endothelium (Vlassov et al., 2012). Whilst the function of sTM in vivo has yet to be clarified 
(with opinion divided between damage biomarkers and functional efficacy), the size of the 
sTM variants has been shown to vary, and so we sought to examine this in the next portion of 
this chapter. Whilst microparticles are known to be regulated by shear stress (Vion et al., 
2013), there is an absence of literature showing that exosomes are strain-sensitive. Vion and 
co-workers established that sustained atheroprone low shear stress induces microparticle 
release from endothelial cells through activation of Rho kinases and Erk1/2 pathways, 
whereas atheroprotective high shear stress restricts microparticle release in an NO-dependent 
manner. This contrasts with our findings wherein we demonstrated increased release of TM in 
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response to shear stress (although did not investigate the release mechanism, barring any 
further conclusions).  
 sTM has been reported to vary in size between 55 kDa – 105 kDa (Blann and 
Taberner, 1995; Ikegami et al., 1998; Ishii and Majerus, 1985; Salem et al., 1984; Takahashi 
et al., 1995) which may reflect the method of release from the membrane. The literature has 
mainly attributed this to proteolysis induced by leukocyte-derived lysosomal proteases (Abe 
et al., 1994), neutrophil-derived enzymes (Matsuyama et al., 2008), MMPs (Wu et al., 2008), 
cysteine proteases (Inomata et al., 2009) and rhomboids (Cheng et al., 2011; Lohi et al., 
2004). Yet when we inhibited rhomboids using DCI (Fig 4.7, Chapter 4) we observed a slight 
but non-significant increase in the cyclic strain mediated TM release, which suggests that 
rhomboids may actually be involved indirectly in “slowing down” TM release (possibly via 
cleavage of a signalling component). Interestingly however, we found that a moderate 
percentage of TM release may be due to proteolytic cleavage via MMPs (~30%). To address 
this we concentrated HAEC media to analyse sTM via Western blotting alongside cellular 
lysates. We detected full length TM and fragments in the cell lysates (possibly due to cellular 
turnover or antibody non-specificity). In media, we identified a strong low molecular weight 
fragment and faint full length bands for TM. This may be due to a combination of proteolysis 
and MV involvement. Moreover, we cannot discount further proteolysis following full length 
release on MVs. This suggests that both the entire cellular TM molecule and a smaller 
fragment of TM are released following cyclic strain. Unfortunately, there is an absence of 
publications documenting biomechanical force-mediated release of sTM.  
 So far, we have established that TM is released following elevated cyclic strain, and so 
we were interested to determine if sTM had any functional activity. Techniques to measure 
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the activity of TM in vitro typically involve protein C activation (PC) assays (Carnemolla et 
al., 2012), which can be expensive and have long incubation times with the substrate. This led 
us to develop a TM functional efficacy assay based on the ability of TM to bind thrombin 
(and in terms of assay read-out, prevent it from causing HAEC permeabilization). Thrombin 
typically compromises the barrier integrity in endothelial cells (Adams and Huntington, 2006) 
so we employed concentrated HAEC media (presumably containing sTM) to neutralize 
thrombin permeabilization in a HAEC reporter transwell permeability assay using FITC-
dextran labels. In this experiment, we found that the sTM in the media had the ability to 
inhibit thrombin activity (at 1 U/ml) with 7.5% strain-conditioned media having the maximal 
effect. As this media has an elevated level of released sTM, we concluded that the sTM is 
functional. The reason for this elevated release of sTM post-strain is still not clear although 
we propose, based on our observations, it may have the ability to bind thrombin to regulate 
both coagulation and fibrinolysis in vivo. It is worth noting that numerous clinical 
observations of CVD patients (e.g., sepsis, lupus, SARS) have reported increased levels of 
sTM in patient plasma, which may have a functional role in the vasculature (Aso et al., 2000; 
Ho et al., 2003; Ikegami et al., 1998; Liu et al., 2005; Ogawa et al., 2012).  
The issue of “paracrine” TM release by cyclic strain was also considered in this 
chapter. In this regard, we conducted a range of conditioned media experiments involving 
incubation of static “reporter” HAECs with conditioned media harvested from HAECs 
maintained for 24 hrs under static and strain conditions. TM release from reporter HAECs 
was subsequently measured by ELISA. The addition of the strain-conditioned media to 
reporter HAECs was clearly seen to induce further TM release. Probing further into the 
dynamics of this event, we noted that a minimum of 12 hrs of conditioning by strain was 
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required to stimulate this paracrine release event. This strain-dependent “paracrine” effect of 
conditioned media has not previously been shown with respect to TM regulation within the 
endothelium, and constitutes relatively novel findings. Interestingly, another group reported 
that a strain-induced paracrine release of TGF-β(1) induced a reduction in TM expression in 
vein grafts (Kapur et al., 2011). Interestingly, it was shown that exposure of HUVECs to 
MVs, which include both microparticles and exosomes resulted in increased cell surface 
thrombogenicity with decreased levels of TM expression (Aharon et al., 2008). In this study, 
stimulation of a monocyte cell line by starvation or by endotoxin and calcium ionophore 
A23187 caused the release of MVs. These MVs were incubated with HUVECs for short (2-4 
hours) or long (20 hours) periods of time. MVs were shown to rapidly induce membrane 
blebbing following brief exposure (2-4 hours) whereas longer incubation (20 hours) times 
lead to further perturbation of the endothelial haemostatic balance. Although this group did 
not measure TM release, this still agrees with our observations in relation to this conditioned 
media study and coincides with our previous observations in relation to TM expression. We 
hypothesize that cyclic strain-mediated TM release may be a chronic response happening in 
vivo with sTM variants stimulating a cascade of further TM release. Whether the sTM 
fragments stimulate this ‘extra’ release via MMP, ROS or exosomes remains to be 
determined. In conclusion, the purpose of this paracrine TM release may be for the benefit of 
the endothelial cell to regain homeostatic balance during an inflammatory challenge. Our 
confirmation of a degree of functional efficacy within the released sTM function would be 
consistent with this hypothesis. 
To summarise, we observed MV involvement in the release of TM from HAECs, 
including the elevated release in response to high cyclic strain. Using an exosome enrichment 
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protocol, our data suggest that approximately one third of the TM release occurs via the 
exosomal pathway (with the remainder of TM release putatively attributed to microparticles 
and proteolytic cleavage). We further detected multiple TM size variants in both lysates and 
media (ranging from 35-100 kDa), which would possibly indicate proteolytic processing of 
TM. Next, we determined that sTM released post-strain still retained a level of functional 
activity (manifested on the ability to bind thrombin). Finally, we noted that strain-conditioned 
HAEC media serves as a “paracrine” stimulus for TM release from reporter HAECs. The 
vasculoprotective properties of this released sTM that we have identified in vitro are mirrored 
in the rapid development of recombinant sTM-based therapeutics (Matsusaki et al., 2008; 
Nakashima et al., 1998; Omichi et al., 2010). For instance, ART-123 (thrombomodulin alpha, 
RecomodulinTM) was approved in 2008 for human therapy in Japan (Saito et al., 2007) to treat 
disseminated intravascular coagulation (DIC). This therapeutic consists of the TM 
extracellular domains 1-3, which are crucial for the anti-inflammatory and anti-coagulant 
actions of the molecule.  
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Chapter 6: 
Final Summary 
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6.1 Final Summary 
 
Thrombomodulin (TM) has crucial physiological importance within the vasculature as 
evidenced by its functions in coagulation, inflammation and fibrinolysis (Conway, 2011). The 
endothelium, a continuous monolayer of flattened endothelial cells, is vital for maintaining 
the homeostatic integrity of the blood vessel by virtue of its ability to adapt and respond to the 
ever-changing environment of the vasculature (Aird, 2007). The endothelial cell exists within 
a pressurized fluid environment in direct contact with the circulating blood and blood-borne 
components. This creates blood flow-associated hemodynamic forces, namely pulsatile shear 
stress and cyclic circumferential strain, which exert a profound biochemical influence on the 
blood vessel wall (Fig 6.1) (Ando and Yamamoto, 2011). The latter force, and indeed the 
focus of this thesis, namely cyclic strain, describes the repetitive circumferential stretching of 
the vessel wall in synchronization with the cardiac cycle (Chen et a., 2008).  
Cyclic strain contributes to endothelial homeostasis whilst aberrantly high and low 
levels are strongly associated with endothelial dysfunction (Cheng et al., 2001; Chen et al., 
2008; Cummins et al., 2007). Interestingly, there are limited studies (and particularly in vitro 
studies) investigating the effects of cyclic strain upon TM expression and release. The 
hypothesis for this project was therefore to further understand; how elevated cyclic strain 
impacts the regulation and function of thrombomodulin (TM) in human aortic endothelial 
cells. This lack of information on TM regulation by this potent hemodynamic force has 
therefore framed the resultant thesis.  
In Chapter 3, we employed an MSD® Multiplex ELISA to identify a profile of pro-
inflammatory and vascular injury biomarkers that were responsive to elevated cyclic strain. 
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The most interesting result from this study showed down-regulation of TM cellular expression 
in combination with an increase of TM release following elevated cyclic strain. Additional 
studies using Western blotting and qRT-PCR both confirmed the dose-dependent decrease of 
TM protein and mRNA expression levels subsequent to elevated cyclic strain of HAECs. 
Furthermore, ELISA studies using a single-plex Duoset ELISA showed how TM 
release/shedding was amplified in response to cyclic strain in a dose-, frequency- and time-
dependent manner. Moreover, we found that TM mRNA expression was also increased by 
shear stress, a hemodynamic component of blood flow known to convey an atheroprotective 
phenotype to the endothelium (Traub and Berk, 1998), an observation – quite opposite to that 
of cyclic strain. Additionally, shear stress up-regulated TM release in a temporal manner. 
These results suggest to us that cyclic strain and shear stress are most likely eliciting effects 
on TM regulation via different pathways.  
In Chapter 4, we examined how elevated cyclic strain affects TM release in the 
presence and absence of a range of inflammatory mediators. We found that TNF-α moderately 
reduced TM mRNA expression in static HAECs whilst potentiating TM release in HAECs in 
the presence of 7.5% strain. Interestingly, ox-LDL exhibited similar effects. We did not 
observe a significant effect of glucose application on TM expression in static HAECs 
although by contrast to TNF-α and ox-LDL, it attenuated TM release in HAECs undergoing 
7.5% cyclic strain. The second portion of this chapter endeavored to identify the cellular 
signalling components mediating the effects of cyclic strain on TM dynamics. Firstly, we 
focused on TM cellular expression. We found that inhibition of PTK and p38 MAPK reversed 
the down-regulatory effects of cyclic strain on TM expression, implying their mutual roles in 
this event. We also determined the role that various components may play in the cyclic strain-
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induced increase in TM release. In this regard, we observed that blockade of MMPs partially 
decreased cyclic strain-induced TM release as well as implicating a role for NADPH. 
Interestingly, inhibition of integrin (ανβ3) caused a very substantive increase in TM release 
under both static and strained conditions, suggesting that integrins may serve to “dampen” the 
induction of TM release by cyclic strain. 
In Chapter 5, we further investigated mechanisms associated with strain-induced TM 
“release” from HAECs. We presented data to support the notion that, in addition to 
proteolytic release, a considerable proportion of TM release from endothelial cells under static 
and strain conditions proceeds through an exosomal pathway. Furthermore, we determined the 
sTM released post-strain still retained a level of functional efficacy. Moreover, we observed 
that strain-conditioning of HAECs may leads to the release of humoral components (including 
sTM) that can elicit a paracrine release of TM from reporter HAECs.  
We have focused on TM release extensively in this thesis in-part due to its relevance 
to diagnostics and therapeutics. sTM is an established biomarker for a number of 
cardiovascular disorders (Liu et al., 2005; Ogawa et al., 2012). Moreover, the 
vasculoprotective properties of this released sTM are reflected in the rapid development of 
recombinant sTM-based therapeutics (Matsusaki et al., 2008; Omichi et al., 2010). The most 
successful therapeutic based on sTM so far is ART-123 (thrombomodulin alpha, 
RecomodulinTM). This was approved in 2008 for human therapy in Japan (Saito et al., 2007) 
to treat disseminated intravascular coagulation (DIC) and consists of the TM extracellular 
domains 1-3, which are crucial for the anti-inflammatory and anti-coagulant actions of the 
molecule. This therapeutic proves to be a safer and more effective inhibitor of the propagation 
of coagulation then the traditional low-dose heparin therapy (Nakashima et al., 1998). The 
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data in this thesis documents the functionality and composition of sTM following release, 
which adds to the growing field of MVs as diagnostic markers and therapeutic models. We 
have also greatly enhanced the knowledge on cyclic strain-associated disorders (i.e., 
hypertension). In addition, clinical studies using exosomal biomarkers could be based on this 
research.  
The studies conducted in this thesis reflect the first comprehensive attempt to evaluate 
cyclic strain-dependent regulation of TM in endothelial cells in vitro, an important aspect of 
the mechanistic understanding of in vivo findings and clinical approaches. Naturally, several 
questions remain unanswered and so further studies are warranted; 
i. The role of KLF2 in the transcriptional regulation of TM in HAECs by cyclic strain. 
This transcription factor is inhibited by a microRNA, miR-92a that then indirectly 
inhibits TM (Dekker et al., 2002; Ishibazawa et al., 2011). However, the relationship 
between KLF2 and cyclic strain is somewhat less investigated so there may be a 
possibility it indirectly regulates cyclic strain-induced TM dynamics. 
ii. ROS source and function. We identified a NADPH oxidase-independent role for ROS 
in cyclic strain-induced TM release. This would suggest that an alternative oxidase 
may be involved in this event  (e.g., xanthine oxidase).  
iii. Precise functions and efficacy of the released TM. This could involve further 
functional studies involving thrombin and Protein C assays. 
iv. Nature of release mechanism by exosomes and microparticles. We could employ 
FACs analysis to confirm known markers for these vesicles.  
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v. Identification of conditioned-media components mediating paracrine release. This 
could entail knock-out experiments (i.e., eliminating one component to identify the 
regulator).  
 
Biomechanical force TM expression TM release 
Shear stress 
 
↑ (Takada 1994; Bergh 
2009; Wu 2011) 
 
↑ (Martin et al., 2013) 
↑ (Martin et al., 
2013) 
Cyclic strain ↑ in vitro (Chen et al., 
2008) 
 
↓ in vivo vein grafts 
(Sperry et al., 2003) 
 
↓ in vitro (Martin et 
al., 2013) 
↑ (Martin et al., 
2013) 
 
Soluble TM (sTM) NA ↑ in DIC, 
hypertension (Lin 
et al., 2008; 
Lopes et al., 
2002) 
 
↓ in type-2 
diabetes, 
coronary heart 
disease (Thorand 
et al., 2007; Wu 
et al., 2003) 
 
 
Table 6.1: My contribution demonstrating the effect of hemodynamic forces on TM 
expression and release (shown in red). The symbols used represent the following; ↑, 
increased; ↓, decreased; +/-CS, in the absence or presence of cyclic strain; NA, not applicable. 
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These studies will no doubt contribute to a fuller understanding of these important 
vascular concepts and ultimately contribute to a greater mechanistic understanding of the role 
cyclic strain plays in vascular cell physiology and CVD. Ultimately, succeeding the 
completion of further in vitro studies we would like to measure sTM levels in human serum 
samples from patients with CVD (i.e., hypertension, DIC) and subsequently, test the 
functionality and composition of these released fragments. This could lead to the development 
of a new therapeutic for coagulation disorders. 
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Appendix 
 
 
 
 
 
 
! B!
BCA assay standard curve 
 
The bicinchoninic acid assay (BCA) assay is a biochemical assay for colorimetric 
detection and quantitation of total protein. In this method, protein reduces Cu+2 to Cu+1 under 
alkaline conditions, which in turn reacts with bicinchoninic acid to produce a complex 
(purple) that absorbs light at 562 nm. Results of standards and unknown samples are then 
graphed to calculate protein concentration (Fig A).  
 
 
 
Figure A: Typical standard curve for a BCA assay, with absorbance on the Y-axis and 
concentration on the X-axis. 
 
 
! C!
Unpublished results 
 
Baseline response from signalling component studies  
 
There is a lot of variation in the fold decrease in TM cellular expression and increase 
in TM release between 0% and 7.5% strain in the signalling component studies. To address 
this, we merged all baseline data from these experiments to show that there is a significant 
decrease in TM cellular expression  and increase in TM release following 7.5% cyclic strain 
(Fig B).  
 
 
 
Figure B: Effect of cyclic strain on TM expression and release. Baseline response data from 
signalling components studies showing effect of cyclic strain on (A) TM cellular expression 
and (B) TM release. (P≤0.0001 determined by unpaired Student’s t test). 
 
 
! D!
Further microvesicle analysis 
 
 To further investigate the molecular size of soluble TM (sTM) post-strain, cell culture 
media was concentrated using Amicon® Ultra-2 centrifugal filter devices, determined for 
protein concentration with a BCA assay and subsequently, analysed for TM cellular 
expression via Western blotting  (Fig B). TM was observed in cellular lysates at different 
molecular weights including 100 kDa. sTM was detected in cell culture media at 50, 60, 70 
and 100 kDa. This suggests that a portion of TM release may be on a microvesicle and 
another proportion may be due to proteolytic cleavage (e.g., by MMPs). 
 
 
 
Figure C: Detection of TM in cell lysates and media supernatants. HAECs were exposed to 
cyclic strain (0% and 7.5%, for 24 hrs). Media supernatants were concentrated using Amicon® 
Ultra-2 centrifugal filter devices and then monitored alongside cell lysates for TM by Western 
blotting. TM was detected in cell lysates at 100 kDa and in media supernatants at 50, 60, 70 
and 100 kDa. Key: L, lysates; M, media.  
 
 
! E!
Further conditioned media analysis 
 
Cell culture media was harvested from HAECs post-cyclic strain (0% and 7.5%, 0-48 
hrs), incubated with static “reporter” HAECs for 24 hrs and then cell lysates were harvested. 
TM cellular expression was subsequently measured via ELISA (Fig C). We observed a 
downward trend in TM cellular expression following incubation with conditioned “strained” 
media. Nevertheless, there was no substantial affect noted. 
 
 
 
Figure D: Conditioned media and TM cellular expression. HAECs were pre-exposed to 
cyclic strain (0% - 7.5% for 24 hrs) and cell culture media was harvested. Static “reporter” 
HAECs were incubated with this conditioned (strained) media for 24 hrs. Subsequently, cell 
lysates were harvested and measured for TM cellular expression by ELISA.  
! F!
KLF2 mRNA expression 
 
 As already mentioned in Chapter 1 (Section 1.2.3), TM levels are regulated by 
transcription factor Krüppel-like factor 2 (KLF2), which is shear stress sensitive (Kumar et 
al., 2009). This transcription factor is inhibited by a microRNA, miR-92a that then indirectly 
inhibits TM (Dekker et al., 2002; Ishibazawa et al., 2011). The relationship between KLF2 
and laminar flow has been studied extensively (Bonauer and Dimmeler, 2009; Dekker et al., 
2002; Irani, 2011; Ishibazawa et al., 2011; Gracia-Sancho et al., 2011; Wu et al., 2011) but 
cyclic strain is somewhat less investigated.  
Dose response studies were carried out on HAECs to examine the effect of cyclic 
strain on KLF2 mRNA expression levels. For mRNA studies, two wells were harvested per 
sample post-cyclic strain (0% and 7.5%) and then analysed using qPCR with a 7900HT Fast 
real-time PCR system (Applied Biosystems, CA USA) (Fig D). Firstly, primers designed to 
target KLF2 for PCR amplification and then visualized on an agarose gel to ensure correct 
band size. To determine the specificity of my primers, I carried out a melt curve analysis to 
generate a dissociation curve for my primers for KLF2. We found that KLF2 was increased 
dose-dependently in response to cyclic strain, which may potentially be related to TM 
regulation.     Further experiments, will provide statistical clarity and also, identify if KLF2 
indirectly regulates TM expression in HAECs. 
 
! G!
 
 
Figure E: Dose-dependent effect of cyclic strain on KLF2 mRNA expression. (A) Following 
application of cyclic strain (0% and 7.5% for 24 hrs) to HAECs, mRNA KLF2 expression was 
measured using qPCR (n=3). (B) The same samples were monitored for KLF2 expression by 
standard PCR and visualised on an agarose gel (n=3). (C) Melt curve analysis was carried out 
on the KLF2 primers to determine their specificity. 
 
 
 
 
 
 
 
 
! H!
Recipes 
 
Coomassie stain 
Coomassie Brilliant Blue R250  0.25g 
Methanol:dH2O (1:1 v/v)   90 ml 
Glacial Acetic acid    10ml  
Filter the Coomassie stain using a 0.25 µm filter 
 
Coomassie destain solution 
Methanol:Acetic acid mixed in a 50:50 ratio 
 
10X Phosphate buffered saline (PBS) 
NaCl      80 g 
Na2HPO4     14.5 g 
KH2PO4     2 g 
KCL      2 g 
pH adjusted to 7.3 with HCL and volume adjusted to 1 L with dH2O 
 
TBS-T 
1X TBS     1L  
Tween 20     1 ml 
 
 
! I!
1.28X RIPA Lysis buffer(50 mls) 
Hepes      0.7625 g (64 mM) 
NaCl      0.561 g (192 mM) 
20% Triton X-100 stock   3.2 ml (1.28% v/v) 
10% Sodium deoxycholate stock  3.2 ml (0.64% v/v) 
10% SDS stock    0.64 ml (0.128% v/v) 
Volume adjusted to 50 mls with dH2O and stored at 4oC 
 
1X RIPA (1 ml) 
Protease inhibitors (25X)   40 µl 
1.28X RIPA     780 µl 
0.5M sodium fluoride   20 µl 
0.5M EDTA (ph 8.0)    10 µl 
0.1M sodium phosphate   100 µl 
10mM sodium orthovanadate  100 µl  
 
1X Tris buffered saline (TBS) 
Tris base     6.1 g 
NaCL      8.8 g 
dH2O      800 ml 
pH adjusted to 7.5 with HCL and volume adjusted to 1 L 
